

**Supplementary Table 1. Details of Assessed Outcomes**

| <b>Instrument</b> | <b>Concept</b>             | <b>Recall period</b>      | <b>Score range</b>                         | <b>Directionality</b>                        |
|-------------------|----------------------------|---------------------------|--|--|
| WP-NRS            | Itch                       | Past 24 hours             | 0–10                                       | Higher scores indicate more severe itch      |
| DLQI              | QoL                        | Past 7 days               | 0–30                                       | Higher scores indicate lower QoL             |
| CDLQI             | QoL                        | Past 7 days               | 0–30                                       | Higher scores indicate lower QoL             |
| EASI              | AD severity                | At the time of evaluation | 0–72                                       | Higher scores indicate higher severity       |
| SCORAD            | AD severity                | At the time of evaluation | 0–103                                      | Higher scores indicate higher severity       |
| vIGA-AD           | AD severity                | At the time of evaluation | 0–4  | Higher scores indicate higher severity       |
| BSA               | Total affected body region | At the time of evaluation | 0–100%                                     | Higher scores indicate greater affected area |
| Sleep questions   | Sleep                      | Past 7 days               | Time measures; interference question (0–5) | Varies per question                          |
| 5-D Pruritus      | Itch                       | Past 2 weeks              | 5–25                                       | Higher scores indicate more severe itch      |
| POEM              | Eczema severity            | Past 7 days               | 0–28                                       | Higher scores indicate more severe eczema    |
| ADerm-SS TSS-7    | Symptoms                   | Past 24 hours             | 0–70                                       | Higher scores indicate more severe symptoms  |
| ADerm-SS TSS-11   | Symptoms                   | Past 24 hours             | 0–110                                      | Higher scores indicate more severe symptoms  |
| ADerm-SS TSS-7    | Skin Pain                  | Past 24 hours             | 0–10                                       | Higher scores indicate more severe pain      |
| ADerm-IS Sleep    | Sleep                      | Past 24 hours             | 0–30                                       | Higher scores indicate more impact           |
| ADerm-IS Daily    | Daily                      | Past 7 days               | 0–40                                       | Higher scores                                |

|  |                              |                              |        |  |
|--|------------------------------|------------------------------|--------|--|
| Activities                               | activities                   |                              |        | indicate more impact   |
| ADerm-IS Emotional State                 | Emotional state              | Past 7 days                  | 0–30   | Higher scores indicate more impact                                     |
| AD flare questionnaire                   | Flares                       | Past 6 months                | NA     | Higher number indicates more flares                                    |
| Inadequately controlled AD questionnaire | Treatment control            | At the time of questionnaire | 1–5    | Higher scores indicate better treatment control with current treatment |
| HADS Anxiety                             | Anxiety                      | Past 7 days                  | 0–21   | Higher scores indicate more anxiety                                    |
| HADS Depression                          | Depression                   | Past 7 days                  | 0–21   | Higher scores indicate more depression                                 |
| SF-12                                    | QoL (adults)                 | Past 4 weeks                 | 0–100  | Higher scores indicate a better health state                           |
| SF-10                                    | QoL (adolescents)            | Past 4 weeks                 | 0–100  | Higher scores indicate a better health state                           |
| WPAI Absenteeism                         | Absenteeism                  | Past 7 days                  | 0–100% | Higher scores indicate more time missed from work                      |
| WPAI Presenteeism                        | Presenteeism                 | Past 7 days                  | 0–100% | Higher scores indicate more impairment while working                   |
| WPAI Work Productivity                   | Work productivity impairment | Past 7 days                  | 0–100% | Higher scores indicate more work productivity loss                     |
| WPAI Activity Impairment                 | Activity impairment          | Past 7 days                  | 0–100% | Higher scores indicate more activity impairment                        |
| HCRU                                     | Healthcare visits            | Past 6 months                | NA     |  |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; CDLQI, Children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; HADS, Hospital Anxiety and Depression Scale; HCRU, health-care research utilization; POEM, Patient-

---

Oriented Eczema Measure; QoL, quality of life; SCORAD, SCORing Atopic Dermatitis; SF-10, Short Form-10 Health Survey; SF-12, Short Form-12 Health Survey; vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis; WP-NRS, Worst Pruritus Numeric Rating Scale; WPAI, Work Productivity and Activity Impairment.

**Supplementary Table 2. Non-atopic Comorbidities in Adults With AD per Geographic Cluster.**

| n (%)                                   | Cluster 1     | Cluster 2    | Cluster 3    | Cluster 4    | Cluster 5    | Cluster 6    | Cluster 7    | Cluster 8    | Cluster 9    | Cluster 10   | Cluster 11   | Cluster 12   |
|---|---------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Any                                     | 107<br>(53.5) | 69<br>(32.9) | 40<br>(33.9) | 26<br>(28.6) | 54<br>(52.4) | 22<br>(36.7) | 87<br>(55.4) | 14<br>(23.7) | 32<br>(34.0) | 73<br>(37.1) | 37<br>(35.9) | 16<br>(38.1) |
| Anxiety disorder                        | 40<br>(20.0)  | 12<br>(5.7)  | 14<br>(11.9) | 16<br>(17.6) | 23<br>(22.3) | 4<br>(6.7)   | 61<br>(38.9) | 4<br>(6.8)   | 2<br>(2.1)   | 34<br>(17.3) | 6<br>(5.8)   | 4<br>(9.5)   |
| Hypertension                            | 34<br>(17.0)  | 31<br>(14.8) | 15<br>(12.7) | 6<br>(6.6)   | 10<br>(9.7)  | 4<br>(6.7)   | 18<br>(11.5) | 1<br>(1.7)   | 15<br>(16.0) | 21<br>(10.7) | 18<br>(17.5) | 8<br>(19.0)  |
| Depression                              | 36<br>(18.0)  | 26<br>(12.4) | 5<br>(4.2)   | 9<br>(9.9)   | 25<br>(24.3) | 2<br>(3.3)   | 28<br>(17.8) | 5<br>(8.5)   | 9<br>(9.6)   | 14<br>(7.1)  | 13<br>(12.6) | 5<br>(11.9)  |
| Alopecia areata                         | 9<br>(4.5)    | 8<br>(3.8)   | 2<br>(1.7)   | 3<br>(3.3)   | 5<br>(4.9)   | 3<br>(5.0)   | 6<br>(3.8)   | 2<br>(3.4)   | 1<br>(1.1)   | 7<br>(3.6)   | 7<br>(6.8)   | 4<br>(9.5)   |
| Diabetes                                | 11<br>(5.5)   | 5<br>(2.4)   | 5<br>(4.2)   | 0            | 3<br>(2.9)   | 0            | 11<br>(7.0)  | 0            | 4<br>(4.3)   | 4<br>(2.0)   | 1<br>(1.0)   | 3<br>(7.1)   |
| Cancer/history of cancer                | 16<br>(8.0)   | 7<br>(3.3)   | 3<br>(2.5)   | 2<br>(2.2)   | 4<br>(3.9)   | 2<br>(3.3)   | 2<br>(1.3)   | 2<br>(3.4)   | 2<br>(2.1)   | 3<br>(1.5)   | 2<br>(1.9)   | 0            |
| Heart disease <sup>a</sup>              | 8<br>(4.0)    | 7<br>(3.3)   | 1<br>(0.8)   | 0            | 3<br>(2.9)   | 5<br>(8.3)   | 1<br>(0.6)   | 2<br>(3.4)   | 5<br>(5.3)   | 5<br>(2.5)   | 2<br>(1.9)   | 1<br>(2.4)   |
| ADHD                                    | 6<br>(3.0)    | 0            | 0            | 6<br>(6.6)   | 1<br>(1.0)   | 4<br>(6.7)   | 6<br>(3.8)   | 3<br>(5.1)   | 1<br>(1.1)   | 5<br>(2.5)   | 2<br>(1.9)   | 0            |
| Autoimmune disease <sup>b</sup>         | 6<br>(3.0)    | 3<br>(1.4)   | 2<br>(1.7)   | 0            | 0            | 1<br>(1.7)   | 1<br>(0.6)   | 4<br>(6.8)   | 0            | 3<br>(1.5)   | 4<br>(3.9)   | 2<br>(4.8)   |
| Obstructive sleep apnea                 | 10<br>(5.0)   | 5<br>(2.4)   | 0            | 0            | 1<br>(1.0)   | 1<br>(1.7)   | 4<br>(2.5)   | 0            | 2<br>(2.1)   | 1<br>(0.5)   | 0            | 1<br>(2.4)   |
| Osteoporosis                            | 8<br>(4.0)    | 1<br>(0.5)   | 2<br>(1.7)   | 1<br>(1.1)   | 3<br>(2.9)   | 0            | 1<br>(0.6)   | 0            | 1<br>(1.1)   | 3<br>(1.5)   | 2<br>(1.9)   | 3<br>(7.1)   |
| Inflammatory bowel disease <sup>c</sup> | 9<br>(4.5)    | 1<br>(0.5)   | 0            | 0            | 2<br>(1.9)   | 0            | 2<br>(1.3)   | 0            | 0            | 1<br>(0.5)   | 0            | 0            |
| Cerebrovascular accident <sup>d</sup>   | 3<br>(1.5)    | 3<br>(1.4)   | 1<br>(0.8)   | 0            | 1<br>(1.0)   | 1<br>(1.7)   | 0            | 0            | 1<br>(1.1)   | 0            | 1<br>(1.0)   | 1<br>(2.4)   |
| Vitiligo                                | 0             | 0            | 0            | 0            | 2<br>(1.9)   | 1<br>(1.7)   | 1<br>(0.6)   | 0            | 4<br>(4.3)   | 1<br>(0.5)   | 2<br>(1.9)   | 1<br>(2.4)   |

ADHD, Attention deficit hyperactivity disorder.



The analyzed clusters were (1) Canada (n=200), (2) Germany (n=210), (3) Italy (n=118), (4) Spain (n=91), (5) Australia and New Zealand (n=103), (6) China and Taiwan (n=60), (7) Brazil, Argentina, and Mexico (n=157), (8) Netherlands, Belgium, and Ireland (n=59), (9) Switzerland and Austria (n=94), (10) Greece, Israel, Turkey, and Portugal (n=197), (11) Hungary, Romania, the Czech Republic, Poland, and Slovakia (n=103), and (12) Saudi Arabia, Kuwait, and United Arab Emirates (n=42).

<sup>a</sup>Coronary artery disease, angina, myocardial infarction, and heart failure.

<sup>b</sup>Rheumatoid arthritis, lupus erythematosus, multiple sclerosis, and Sjögren's syndrome.

<sup>c</sup>Crohn's disease and ulcerative colitis.

<sup>d</sup>Stroke and transient ischemic attack.

**Supplementary Table 3.1. Baseline Patient Demographics and Characteristics in Argentina**

|  | <b>Adults*<br/>(n=52)</b> |
|--|---------------------------|
| Age, years, mean (SD)  | 34.4 (16.1)               |
| Male, n (%)  | 25 (48.1)                 |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.5 (4.8)                |
| Employed, n (%)  | 26 (50.0)                 |
| Duration of AD, years, mean (SD)                                   | 19.2 (10.5)               |
| Time from AD diagnosis to first therapy, years, mean (SD)          | 11.3 (7.9)                |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 14.1 (10.4)               |
| Continuous systemic therapy over previous 12 months, n (%)         | 15 (28.8)                 |
| Current therapy, n (%)   | 52 (100.0)                |
| Systemic monotherapy or in combination                             | 39 (75.0)                 |
| Dupilumab  | 7 (17.9)                  |
| Systemic corticosteroids   | 12 (30.8)                 |
| Methotrexate   | 20 (51.3)                 |
| Cyclosporine   | 9 (23.1)                  |
| Azathioprine   | 0                         |
| Mycophenolate  | 0                         |
| Systemic monotherapy   | 14 (26.9)                 |
| Topical monotherapy or in combination                              | 36 (69.2)                 |
| Topical monotherapy  | 2 (3.8)                   |
| TCS or TCI monotherapy   | 2 (3.8)                   |
| Previous systemic therapy, n (%)                                   | 52 (100.0)                |
| Systemic monotherapy or in combination                             | 32 (61.5)                 |
| Systemic monotherapy   | 6 (11.5)                  |
| Dupilumab, monotherapy or in combination                           | 0                         |
| Dupilumab monotherapy  | 0                         |
| Treatment prior to study enrollment, n (%)                         |                           |
| Topical therapy received as monotherapy                            | 38 (73.1)                 |
| Suboptimal response to topical monotherapy                         | 37 (71.2)                 |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

\*Only adult patients were included from Argentina.

**Supplementary Table 3.2. Physician-Reported and Patient-Reported Clinical Outcomes in Argentina**

|   | <b>Adults*<br/>(n=52)</b> |
|---|---------------------------|
| <b>Physician-reported outcomes</b>  |                           |
| EASI, mean (SD)   | 15.8 (12.0)               |
| EASI categories, n (%)  |                           |
| Clear (0)   | 2 (3.8)                   |
| Mild (0.1–5.9)  | 9 (17.3)                  |
| Moderate (6.0–22.9)   | 29 (55.8)                 |
| Severe (23.0–72.0)  | 12 (23.1)                 |
| SCORAD, mean (SD)   | 50.2 (22.1)               |
| SCORAD categories, n (%)  |                           |
| Mild (<25.0)  | 7 (13.5)                  |
| Moderate (25.0–50.0)  | 19 (36.5)                 |
| Severe (>50.0)  | 26 (50.0)                 |
| vIGA-AD, mean (SD)  | 2.8 (1.0)                 |
| Clear (0)   | 2 (3.8)                   |
| Almost clear (1)  | 4 (7.7)                   |
| Mild (2)  | 6 (11.5)                  |
| Moderate (3)  | 29 (55.8)                 |
| Severe (4)  | 11 (21.2)                 |
| BSA, % affected, mean (SD)  | 21.5 (18.7)               |
| Average hours of sleep per night in the past week, mean (SD)                | 6.0 (2.3)                 |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 38.3 (32.07)              |
| Sleep problems interfered with daily function over the past week, n (%)     |                           |
| I do not have sleep problems  | 2 (3.8)                   |
| Not at all  | 15 (28.8)                 |
| A little  | 13 (25.0)                 |
| Somewhat  | 10 (19.2)                 |
| Much  | 7 (13.5)                  |
| Very much   | 5 (9.6)                   |
| <b>Patient-reported outcomes</b>  |                           |
| 5D-Pruritus score, mean (SD)  | 16.0 (4.1)<br>n=49        |
| POEM, mean (SD)   | 16.1 (7.8)                |
| Total ADerm-IS, mean (SD)   | 39.0 (28.0)<br>n=51       |
| ADerm-IS Sleep domain, mean (SD)  | 12.3 (9.7)                |
| ADerm-SS TSS-7, mean (SD)   | 37.0 (19.5)               |
| ADerm-SS TSS-11, mean (SD)  | 50.5 (28.7)<br>n=49       |
| ADerm-SS Skin pain, mean (SD)   | 4.9 (3.5)                 |
| Number of flares in last 6 months, n (%)                                    |                           |

|   |                    |
|---|--------------------|
| 0   | 2 (3.8)            |
| 1–2   | 9 (17.3)           |
| 3–4   | 14 (26.9)          |
| 5–6   | 11 (21.2)          |
| >6  | 9 (17.3)           |
| Missing   | 7 (13.5)           |
| Number of flares in the last 6 months, mean (range) | 6.6 (0–50)<br>n=45 |
| Average duration of flares in last 6 months, n (%)  |                    |
| ≤2 days   | 7 (13.5)           |
| 3–7 days  | 14 (26.9)          |
| 8–14 days   | 8 (15.4)           |
| ≥15 days  | 15 (28.8)          |
| Missing   | 8 (15.4)           |
| Inadequately controlled AD, n (%)                   | 16 (30.8)          |
| SF-12 PCS, mean (SD)                                | 51.9 (8.1)         |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary; vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

\*Only adult patients were included from Argentina.

**Supplementary Table 3.3. Psychosocial-Economic Burden of AD in Argentina**

|   | <b>Adults*<br/>(n=52)</b> |
|---|---------------------------|
| HADS-A, mean (SD)   | 7.0 (4.1)                 |
| HADS-A $\geq 8$ , n (%)   | 20 (38.5)                 |
| HADS-D, mean (SD)   | 4.9 (4.3)                 |
| HADS-D $\geq 8$ , n (%)   | 11 (21.2)                 |
| SF-12 MCS, mean (SD)  | 43.6 (10.9)               |
| ADerm-IS Daily Activities, mean (SD)  | 12.9 (11.7)               |
| ADerm-IS Emotional State, mean (SD)   | 14.0 (10.5)               |
| WPAI-AD, Employed, n (%)  | 26 (50.0)                 |
| Absenteeism, %, mean (SD)   | 6.6 (12.3)<br>n=21        |
| Presenteeism, %, mean (SD)  | 27.5 (20.5)<br>n=24       |
| Overall work productivity impairment, %, mean (SD)  | 32.9 (22.8)<br>n=21       |
| Activity impairment, %, mean (SD)   | 33.9 (32.1)               |
| Hours missed from work, mean (SD)   | 1.6 (2.7)<br>n=22         |
| HCRU  |                           |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 9.2 (13.7)<br>n=42        |
| Out of pocket expenses  |                           |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 84.3 (84.3)<br>n=44       |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care resource utilization; SF-12 MCS, Short Form-12 Health Survey mental component summary; USD, United States dollars (2021); WPAI-AD, work activity; Work Productivity and Activity Impairment Atopic Dermatitis.

\*Only adult patients were included from Argentina.

**Supplementary Table 4.1. Baseline Patient Demographics and Characteristics in Australia**

|  | <b>Total population<br/>(n=72)</b> | <b>Adults<br/>(n=64)</b> | <b>Adolescents<br/>(n=8)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 33.5 (15.8)                        | 35.8 (15.3)              | 15.3 (1.4)                   |
| Male, n (%)  | 38 (52.8)                          | 33 (51.6)                | 5 (62.5)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.3 (4.7)                         | 25.9 (4.6)               | 20.8 (2.9)                   |
| Employed, n (%)  | 43 (59.7)                          | 42 (65.6)                | 1 (12.5)                     |
| Duration of AD, years, mean (SD)                                   | 27.6 (14.6)                        | 29.7 (14.1)              | 11.5 (4.8)                   |
| Time from AD diagnosis to first therapy, years, mean (SD)          | 17.5 (10.2)<br>n=8                 | 17.5 (10.2)<br>n=8       | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 24.5 (14.6)<br>n=38                | 24.8 (14.6)<br>n=37      | 11.7 (NA)<br>n=1             |
| Continuous systemic therapy over previous 12 months, n (%)         | 5 (6.9)                            | 5 (7.8)                  | 0                            |
| Current therapy, n (%)   | 62 (86.1)                          | 55 (85.9)                | 7 (87.5)                     |
| Systemic monotherapy or in combination                             | 11 (15.3)                          | 10 (15.6)                | 1 (12.5)                     |
| Dupilumab  | 5 (45.5)                           | 5 (50.0)                 | 0                            |
| Systemic corticosteroids   | 1 (9.1)                            | 0                        | 1 (100.0)                    |
| Methotrexate   | 1 (9.1)                            | 1 (10.0)                 | 0                            |
| Cyclosporine   | 4 (36.4)                           | 4 (40.0)                 | 0                            |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 1 (9.1)                            | 1 (10.0)                 | 0                            |
| Systemic monotherapy   | 1 (1.4)                            | 1 (1.6)                  | 0                            |
| Topical monotherapy or in combination                              | 58 (80.6)                          | 51 (79.7)                | 7 (87.5)                     |
| Topical monotherapy  | 33 (45.8)                          | 28 (43.8)                | 5 (62.5)                     |
| TCS or TCI monotherapy   | 23 (31.9)                          | 20 (31.3)                | 3 (37.5)                     |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 35 (48.6)                          | 34 (53.1)                | 1 (12.5)                     |
| Systemic monotherapy   | 2 (2.8)                            | 2 (3.1)                  | 0                            |
| Dupilumab, monotherapy or in combination                           | 1 (1.4)                            | 1 (1.6)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 69 (95.8)                          | 61 (95.3)                | 8 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 66 (91.7)                          | 59 (92.2)                | 7 (87.5)                     |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 4.2. Physician-Reported and Patient-Reported Clinical Outcomes in Australia**

|  | <b>Total<br/>population<br/>(n=72)</b> | <b>Adults<br/>(n=64)</b> | <b>Adolescents<br/>(n=8)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 21.3 (13.5)                            | 21.5 (13.7)              | 19.8 (12.8)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 3 (4.2)                                | 3 (4.7)                  | 0                            |
| Mild (0.1–5.9)   | 6 (8.3)                                | 6 (9.4)                  | 0                            |
| Moderate (6.0–22.9)  | 30 (41.7)                              | 24 (37.5)                | 6 (75.0)                     |
| Severe (23.0–72.0)   | 33 (45.8)                              | 31 (48.4)                | 2 (25.0)                     |
| SCORAD, mean (SD)  | 51.5 (21.6)<br>n=71                    | 50.6 (21.9)              | 59.3 (17.8)<br>n=7           |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 9 (12.5)                               | 9 (14.1)                 | 0                            |
| Moderate (25.0–50.0)   | 22 (30.6)                              | 20 (31.3)                | 2 (25.0)                     |
| Severe (>50.0)   | 40 (55.6)                              | 35 (54.7)                | 5 (62.5)                     |
| Missing  | 1 (1.4)                                | 0                        | 1 (12.5)                     |
| vIGA-AD, mean (SD)   | 3.0 (0.9)                              | 2.9 (1.0)                | 3.1 (0.6)                    |
| Clear (0)  | 3 (4.2)                                | 3 (4.7)                  | 0                            |
| Almost clear (1)   | 3 (4.2)                                | 3 (4.7)                  | 0                            |
| Mild (2)   | 6 (8.3)                                | 5 (7.8)                  | 1 (12.5)                     |
| Moderate (3)   | 42 (58.3)                              | 37 (57.8)                | 5 (62.5)                     |
| Severe (4)   | 18 (25.0)                              | 16 (25.0)                | 2 (25.0)                     |
| BSA, % affected, mean (SD)   | 35.9 (24.7)                            | 36.1 (25.0)              | 34.9 (23.3)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.5 (1.6)                              | 6.4 (1.6)                | 7.6 (1.2)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 39.7 (38.1)<br>n=71                    | 40.2 (38.4)<br>n=63      | 36.3 (37.7)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 2 (2.8)                                | 2 (3.1)                  | 0                            |
| Not at all   | 17 (23.6)                              | 13 (20.3)                | 4 (50.0)                     |
| A little   | 17 (23.6)                              | 15 (23.4)                | 2 (25.0)                     |
| Somewhat   | 16 (22.2)                              | 16 (25.0)                | 0                            |
| Much   | 10 (13.9)                              | 8 (12.5)                 | 2 (25.0)                     |
| Very much  | 10 (13.9)                              | 10 (15.6)                | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 16.8 (4.2)<br>n=64                     | 16.8 (4.1)<br>n=60       | 16.5 (5.6)<br>n=4            |
| POEM, mean (SD)  | 17.2 (8.7)<br>n=67                     | 17.3 (8.7)<br>n=63       | 15.8 (9.3)<br>n=4            |
| Total ADerm-IS, mean (SD)  | 44.6 (28.3)                            | 44.3 (28.2)              | 49.5 (33.6)                  |

|   |                     |                     |                    |
|---|---------------------|---------------------|--------------------|
|   | n=66                | n=62                | n=4                |
| ADerm-IS Sleep domain, mean (SD)                    | 14.0 (10.1)<br>n=67 | 14.0 (10.1)<br>n=63 | 15.0 (11.7)<br>n=4 |
| ADerm-SS TSS-7, mean (SD)                           | 35.1 (21.5)<br>n=66 | 35.1 (21.4)<br>n=62 | 34.5 (27.3)<br>n=4 |
| ADerm-SS TSS-11, mean (SD)                          | 52.0 (32.9)<br>n=66 | 51.8 (32.6)<br>n=62 | 55.5 (42.2)<br>n=4 |
| ADerm-SS Skin pain, mean (SD)                       | 4.5 (3.4)<br>n=66   | 4.4 (3.3)<br>n=62   | 5.3 (4.4)<br>n=4   |
| Number of flares in last 6 months, n (%)            |                     |                     |                    |
| 0   | 6 (8.3)             | 6 (9.4)             | 0                  |
| 1–2   | 11 (15.3)           | 11 (17.2)           | 0                  |
| 3–4   | 6 (8.3)             | 5 (7.8)             | 1 (12.5)           |
| 5–6   | 10 (13.9)           | 9 (14.1)            | 1 (12.5)           |
| >6  | 30 (41.7)           | 28 (43.8)           | 2 (25.0)           |
| Missing   | 9 (12.5)            | 5 (7.8)             | 4 (50.0)           |
| Number of flares in the last 6 months, mean (range) | 9.1 (0–30)<br>n=63  | 8.7 (0–30)<br>n=59  | 14.5 (3–30)<br>n=4 |
| Average duration of flares in last 6 months, n (%)  |                     |                     |                    |
| ≤2 days   | 12 (16.7)           | 12 (18.8)           | 0                  |
| 3–7 days  | 23 (31.9)           | 20 (31.3)           | 3 (37.5)           |
| 8–14 days   | 17 (23.6)           | 16 (25.0)           | 1 (12.5)           |
| ≥15 days  | 11 (15.3)           | 11 (17.2)           | 0                  |
| Missing   | 9 (12.5)            | 5 (7.8)             | 4 (50.0)           |
| Inadequately controlled AD, n (%)                   | 31 (43.1)           | 29 (45.3)           | 2 (25.0)           |
| SF-12 PCS, mean (SD)                                | NA                  | 50.7 (8.4)<br>n=62  | NA                 |
| SF-10 PHS, mean (SD)                                | NA                  | NA                  | 37.7 (16.8)        |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 4.3. Psychosocial-Economic Burden of AD in Australia**

|   | <b>Total<br/>population<br/>(n=72)</b> | <b>Adults<br/>(n=64)</b> | <b>Adolescents<br/>(n=8)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 7.6 (4.6)<br>n=67                      | 7.5 (4.7)<br>n=63        | 8.0 (2.9)<br>n=4             |
| HADS-A $\geq 8$ , n (%)   | 34 (47.2)                              | 32 (50.0)                | 2 (25.0)                     |
| HADS-D, mean (SD)   | 5.3 (4.2)<br>n=67                      | 5.4 (4.3)<br>n=63        | 3.3 (1.9)<br>n=4             |
| HADS-D $\geq 8$ , n (%)   | 21 (29.2)                              | 21 (32.8)                | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 42.8 (11.0)<br>n=62      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 48.2 (11.0)                  |
| ADerm-IS Daily Activities, mean (SD)  | 14.7 (11.7)<br>n=66                    | 14.7 (11.7)<br>n=62      | 15.5 (14.3)<br>n=4           |
| ADerm-IS Emotional State, mean (SD)   | 16.0 (10.2)<br>n=67                    | 15.8 (10.1)<br>n=63      | 19.0 (12.3)<br>n=4           |
| WPAI-AD, Employed, n (%)  | 43 (59.7)                              | 42 (65.6)                | 1 (12.5)                     |
| Absenteeism, %, mean (SD)   | 14.7 (26.4)<br>n=42                    | 12.6 (22.9)<br>n=41      | 100 (NA)<br>n=1              |
| Presenteeism, %, mean (SD)  | 36.1 (33.5)<br>n=41                    | 36.1 (33.5)<br>n=41      | 0                            |
| Overall work productivity impairment, %, mean (SD)  | 40.3 (35.7)<br>n=40                    | 40.3 (35.7)<br>n=40      | 0                            |
| Activity impairment, %, mean (SD)   | 43.9 (32.3)<br>n=67                    | 43.0 (32.1)<br>n=63      | 57.5 (36.9)<br>n=4           |
| Hours missed from work, mean (SD)   | 5.1 (9.0)<br>n=42                      | 4.3 (7.6)<br>n=41        | 36.0 (NA)<br>n=1             |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 2.8 (3.7)<br>n=60                      | 2.7 (3.8)<br>n=57        | 4.3 (2.5)<br>n=3             |
| <b>Out of pocket expenses</b>   |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 212.0 (241.7)<br>n=64                  | 198.2 (207.1)<br>n=60    | 417.7 (568.6)<br>n=4         |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 5.1. Baseline Patient Demographics and Characteristics in Austria**

|  | <b>Total population<br/>(n=41)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=2)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 39.8 (20.3)                        | 41.0 (20.0)              | 16.0 (1.4)                   |
| Male, n (%)  | 18 (43.9)                          | 18 (46.2)                | 0                            |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.2 (3.8)                         | 25.5 (3.7)               | 19.9 (1.0)                   |
| Employed, n (%)  | 26 (63.4)                          | 26 (66.7)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 25.4 (16.9)                        | 26.3 (16.9)              | 10.4 (7.0)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 15.0 (14.6)<br>n=4                 | 15.0 (14.6)<br>n=4       | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 19.4 (10.5)<br>n=14                | 19.4 (10.5)<br>n=14      | –                            |
| Continuous systemic therapy over previous 12 months, n (%)         | 5 (12.2)                           | 5 (12.8)                 | –                            |
| Current therapy, n (%)   | 41 (100.0)                         | 39 (100.0)               | 2 (100.0)                    |
| Systemic monotherapy or in combination                             | 17 (41.5)                          | 17 (43.6)                | 0                            |
| Dupilumab  | 9 (52.9)                           | 9 (52.9)                 | 0                            |
| Systemic corticosteroids   | 6 (35.3)                           | 6 (35.3)                 | 0                            |
| Methotrexate   | 2 (11.8)                           | 2 (11.8)                 | 0                            |
| Cyclosporine   | 2 (11.8)                           | 2 (11.8)                 | 0                            |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 2 (4.9)                            | 2 (5.1)                  | 0                            |
| Topical monotherapy or in combination                              | 38 (92.7)                          | 36 (92.3)                | 2 (100.0)                    |
| Topical monotherapy  | 19 (46.3)                          | 18 (46.2)                | 1 (50.0)                     |
| TCS or TCI monotherapy   | 13 (31.7)                          | 12 (30.8)                | 1 (50.0)                     |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 15 (36.6)                          | 15 (38.5)                | 0                            |
| Systemic monotherapy   | 2 (4.9)                            | 2 (5.1)                  | 0                            |
| Dupilumab, monotherapy or in combination                           | 2 (4.9)                            | 2 (5.1)                  | 0                            |
| Dupilumab monotherapy  | 1 (2.4)                            | 1 (2.6)                  | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 34 (82.9)                          | 33 (84.6)                | 1 (50.0)                     |
| Suboptimal response to topical monotherapy                         | 27 (65.9)                          | 26 (66.7)                | 1 (50.0)                     |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 5.2. Physician-Reported and Patient-Reported Clinical Outcomes in Austria**

|   | <b>Total<br/>population<br/>(n=41)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=2)</b> |
|---|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>  |  |                          |                              |
| EASI, mean (SD)   | 14.1 (13.3)                            | 13.6 (13.5)              | 22.7 (6.1)                   |
| EASI categories, n (%)  |  |                          |                              |
| Clear (0)   | 3 (7.3)                                | 3 (7.7)                  | 0                            |
| Mild (0.1–5.9)  | 9 (22.0)                               | 9 (23.1)                 | 0                            |
| Moderate (6.0–22.9)   | 22 (53.7)                              | 21 (53.8)                | 1 (50.0)                     |
| Severe (23.0–72.0)  | 7 (17.1)                               | 6 (15.4)                 | 1 (50.0)                     |
| SCORAD, mean (SD)   | 43.3 (23.3)                            | 42.6 (23.7)              | 57.4 (4.8)                   |
| SCORAD categories, n (%)  |  |                          |                              |
| Mild (<25.0)  | 10 (24.4)                              | 10 (25.6)                | 0                            |
| Moderate (25.0–50.0)  | 14 (34.1)                              | 14 (35.9)                | 0                            |
| Severe (>50.0)  | 17 (41.5)                              | 15 (38.5)                | 2 (100.0)                    |
| vIGA-AD, mean (SD)  | 2.5 (1.2)                              | 2.4 (1.2)                | 3.5 (0.7)                    |
| Clear (0)   | 3 (7.3)                                | 3 (7.7)                  | 0                            |
| Almost clear (1)  | 6 (14.6)                               | 6 (15.4)                 | 0                            |
| Mild (2)  | 8 (19.5)                               | 8 (20.5)                 | 0                            |
| Moderate (3)  | 17 (41.5)                              | 16 (41.0)                | 1 (50.0)                     |
| Severe (4)  | 7 (17.1)                               | 6 (15.4)                 | 1 (50.0)                     |
| BSA, % affected, mean (SD)  | 20.5 (20.9)                            | 20.4 (21.4)              | 22.5 (10.6)                  |
| Average hours of sleep per night in the past week, mean (SD)                | 7.0 (1.4)<br>n=40                      | 7.0 (1.4)<br>n=38        | 6.5 (2.1)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 25.7 (15.7)<br>n=40                    | 26.1 (16.0)<br>n=38      | 17.5 (3.5)                   |
| Sleep problems interfered with daily function over the past week, n (%)     |  |                          |                              |
| I do not have sleep problems  | 1 (2.4)                                | 1 (2.6)                  | 0                            |
| Not at all  | 14 (34.1)                              | 14 (35.9)                | 0                            |
| A little  | 11 (26.8)                              | 11 (28.2)                | 0                            |
| Somewhat  | 10 (24.4)                              | 9 (23.1)                 | 1 (50.0)                     |
| Much  | 2 (4.9)                                | 2 (5.1)                  | 0                            |
| Very much   | 3 (7.3)                                | 2 (5.1)                  | 1 (50.0)                     |
| <b>Patient-reported outcomes</b>  |  |                          |                              |
| 5D-Pruritus score, mean (SD)  | 14.5 (3.8)<br>n=39                     | 14.2 (3.7)<br>n=37       | 20.0 (1.4)                   |
| POEM, mean (SD)   | 14.0 (7.3)<br>n=39                     | 13.6 (7.3)<br>n=37       | 21.0 (2.8)                   |
| Total ADerm-IS, mean (SD)   | 25.8 (20.5)<br>n=39                    | 25.6 (20.7)<br>n=38      | 36.0 (NA)<br>n=1             |

|   |                    |                    |                  |
|---|--------------------|--------------------|------------------|
| ADerm-IS Sleep domain, mean (SD)                    | 8.1 (8.3)<br>n=40  | 7.5 (8.1)<br>n=38  | 19.5 (6.4)       |
| ADerm-SS TSS-7, mean (SD)                           | 24.8 (16.9)        | 23.5 (16.1)        | 50.0 (18.4)      |
| ADerm-SS TSS-11, mean (SD)                          | 35.2 (25.7)        | 33.2 (24.1)        | 75.0 (32.5)      |
| ADerm-SS Skin pain, mean (SD)                       | 3.1 (2.7)          | 2.9 (2.5)          | 8.0 (1.4)        |
| Number of flares in last 6 months, n (%)            |                    |                    |                  |
| 0   | 7 (17.1)           | 7 (17.9)           | 0                |
| 1–2   | 10 (24.4)          | 9 (23.1)           | 1 (50.0)         |
| 3–4   | 10 (24.4)          | 10 (25.6)          | 0                |
| 5–6   | 5 (12.2)           | 5 (12.8)           | 0                |
| >6  | 6 (14.6)           | 6 (15.4)           | 0                |
| Missing   | 3 (7.3)            | 2 (5.1)            | 1 (50.0)         |
| Number of flares in the last 6 months, mean (range) | 4.4 (0–40)<br>n=38 | 4.5 (0–40)<br>n=37 | 2.0 (2–2)<br>n=1 |
| Average duration of flares in last 6 months, n (%)  |                    |                    |                  |
| ≤2 days   | 9 (22.0)           | 9 (23.1)           | 0                |
| 3–7 days  | 5 (12.2)           | 5 (12.8)           | 0                |
| 8–14 days   | 17 (41.5)          | 16 (41.0)          | 1 (50.0)         |
| ≥15 days  | 8 (19.5)           | 7 (17.9)           | 1 (50.0)         |
| Missing   | 2 (4.9)            | 2 (5.1)            | 0                |
| Inadequately controlled AD, n (%)                   | 11 (26.8)          | 10 (25.6)          | 1 (50.0)         |
| SF-12 PCS, mean (SD)                                | NA                 | 52.8 (8.0)         | NA               |
| SF-10 PHS, mean (SD)                                | NA                 | NA                 | –                |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 5.3. Psychosocial-Economic Burden of AD in Austria**

|  | <b>Total<br/>population<br/>(n=41)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=2)</b> |
|--|--|--------------------------|------------------------------|
| HADS-A, mean (SD)  | 5.7 (3.8)                              | 5.6 (3.9)                | 7.5 (2.1)                    |
| HADS-A $\geq 8$ , n (%)  | 12 (29.3)                              | 11 (28.2)                | 1 (50.0)                     |
| HADS-D, mean (SD)  | 4.8 (3.4)                              | 4.5 (3.3)                | 9.0 (0.0)                    |
| HADS-D $\geq 8$ , n (%)  | 10 (24.4)                              | 8 (20.5)                 | 2 (100.0)                    |
| SF-12 MCS, mean (SD)   | NA                                     | 44.1 (11.5)              | NA                           |
| SF-10 PSS, mean (SD)   | NA                                     | NA                       | –                            |
| ADerm-IS Daily Activities, mean (SD)   | 11.4 (10.0)<br>n=40                    | 11.5 (10.1)              | 8.0 (NA)<br>n=1              |
| ADerm-IS Emotional State, mean (SD)  | 7.7 (6.6)                              | 7.1 (6.1)                | 19.0 (8.5)                   |
| WPAI-AD, Employed, n (%)   | 26 (63.4)                              | 26 (66.7)                | 0                            |
| Absenteeism, %, mean (SD)  | 5.2 (13.4)<br>n=23                     | 5.2 (13.4)<br>n=23       | NA                           |
| Presenteeism, %, mean (SD)   | 28.9 (23.9)                            | 28.9 (23.9)              | NA                           |
| Overall work productivity<br>impairment, %, mean (SD)  | 31.6 (25.8)<br>n=23                    | 31.6 (25.8)<br>n=23      | NA                           |
| Activity impairment, %, mean (SD)  | 31.0 (25.7)<br>n=40                    | 29.5 (24.5)<br>n=38      | 60.0 (42.4)                  |
| Hours missed from work, mean (SD)  | 2.5 (8.5)<br>n=23                      | 2.5 (8.5)<br>n=23        | NA                           |
| HCRU   |  |                          |                              |
| Number of healthcare or acute care<br>visits in previous 6 months, mean<br>(SD)                                    | 3.5 (5.4)<br>n=35                      | 3.7 (5.5)<br>n=33        | 1.0 (1.4)                    |
| Out of pocket expenses   |  |                          |                              |
| Total monthly healthcare-related<br>expenses and costs of everyday<br>necessities related to AD, USD, mean<br>(SD) | 168.2 (155.7)                          | 161.5 (149.3)            | 278.3 (290.9)                |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 6.1. Baseline Patient Demographics and Characteristics in Belgium**

|  | <b>Adults*<br/>(n=20)</b> |
|--|---------------------------|
| Age, years, mean (SD)  | 37.1 (13.6)               |
| Male, n (%)  | 13 (65.0)                 |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 24.5 (4.5)                |
| Employed, n (%)  | 15 (75.0)                 |
| Duration of AD, years, mean (SD)                                   | 30.7 (11.5)               |
| Time from AD diagnosis to first therapy, years mean (SD)           | 18.4 (18.0)<br>n=17       |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 22.4 (9.4)<br>n=14        |
| Continuous systemic therapy over previous 12 months, n (%)         | 8 (40.0)                  |
| Current therapy, n (%)   | 20 (100.0)                |
| Systemic monotherapy or in combination                             | 14 (70.0)                 |
| Dupilumab  | 7 (50.0)                  |
| Systemic corticosteroids   | 1 (7.1)                   |
| Methotrexate   | 1 (7.1)                   |
| Cyclosporine   | 5 (35.7)                  |
| Azathioprine   | 0                         |
| Mycophenolate  | 0                         |
| Systemic monotherapy   | 4 (20.0)                  |
| Topical monotherapy or in combination                              | 16 (80.0)                 |
| Topical monotherapy  | 2 (10.0)                  |
| TCS or TCI monotherapy   | 2 (10.0)                  |
| Previous systemic therapy, n (%)                                   |                           |
| Systemic monotherapy or in combination                             | 15 (75.0)                 |
| Systemic monotherapy   | 1 (5.0)                   |
| Dupilumab, monotherapy or in combination                           | 2 (10.0)                  |
| Dupilumab monotherapy  | 0                         |
| Treatment prior to study enrollment, n (%)                         |                           |
| Topical therapy received as monotherapy                            | 19 (95.0)                 |
| Suboptimal response to topical monotherapy                         | 19 (95.0)                 |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

\*Only adult patients were included from Belgium.

**Supplementary Table 6.2. Physician-Reported and Patient-Reported Clinical Outcomes in Belgium**

|   | <b>Adults*<br/>(n=20)</b> |
|---|---------------------------|
| <b>Physician-reported outcomes</b>  |                           |
| EASI, mean (SD)   | 14.6 (12.9)               |
| EASI categories, n (%)  |                           |
| Clear (0)   | 2 (10.0)                  |
| Mild (0.1–5.9)  | 4 (20.0)                  |
| Moderate (6.0–22.9)   | 8 (40.0)                  |
| Severe (23.0–72.0)  | 6 (30.0)                  |
| SCORAD, mean (SD)   | 41.3 (22.4)               |
| SCORAD categories, n (%)  |                           |
| Mild (<25.0)  | 6 (30.0)                  |
| Moderate (25.0–50.0)  | 5 (25.0)                  |
| Severe (>50.0)  | 9 (45.0)                  |
| vIGA-AD, mean (SD)  | 2.4 (1.3)                 |
| Clear (0)   | 2 (10.0)                  |
| Almost clear (1)  | 3 (15.0)                  |
| Mild (2)  | 5 (25.0)                  |
| Moderate (3)  | 5 (25.0)                  |
| Severe (4)  | 5 (25.0)                  |
| BSA, % affected, mean (SD)  | 21.4 (18.7)               |
| Average hours of sleep per night in the past week, mean (SD)                | 6.6 (1.8)                 |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 28.1 (26.7)               |
| Sleep problems interfered with daily function over the past week, n (%)     |                           |
| I do not have sleep problems  | 1 (5.0)                   |
| Not at all  | 11 (55.0)                 |
| A little  | 2 (10.0)                  |
| Somewhat  | 3 (15.0)                  |
| Much  | 2 (10.0)                  |
| Very much   | 1 (5.0)                   |
| <b>Patient-reported outcomes</b>  |                           |
| 5D-Pruritus score, mean (SD)  | 14.4 (5.1)                |
| POEM, mean (SD)   | 14.3 (9.1)                |
| Total ADerm-IS, mean (SD)   | 32.6 (27.2)               |
| ADerm-IS Sleep domain, mean (SD)  | 10.0 (10.2)               |
| ADerm-SS TSS-7, mean (SD)   | 26.1 (19.1)               |
| ADerm-SS TSS-11, mean (SD)  | 38.4 (29.7)               |
| ADerm-SS Skin pain, mean (SD)   | 3.2 (3.4)                 |
| Number of flares in last 6 months, n (%)                                    |                           |
| 0   | 4 (20.0)                  |
| 1–2   | 3 (15.0)                  |
| 3–4   | 8 (40.0)                  |

|   |                    |
|---|--------------------|
| 5–6   | 3 (15.0)           |
| >6  | 2 (10.0)           |
| Number of flares in the last 6 months, mean (range) | 3.5 (0–12)         |
| Average duration of flares in last 6 months, n (%)  |                    |
| ≤2 days   | 6 (30.0)           |
| 3–7 days  | 6 (30.0)           |
| 8–14 days   | 3 (15.0)           |
| ≥15 days  | 5 (25.0)           |
| Inadequately controlled AD, n (%)                   | 3 (15.0)           |
| SF-12 PCS, mean (SD)                                | 52.9 (5.6)<br>n=19 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary; vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

\*Only adult patients were included from Belgium.



**Supplementary Table 6.3. Psychosocial-Economic Burden of AD in Belgium**

|   | <b>Adults*<br/>(n=20)</b> |
|---|---------------------------|
| HADS-A, mean (SD)   | 5.9 (3.1)                 |
| HADS-A $\geq 8$ , n (%)   | 6 (30.0)                  |
| HADS-D, mean (SD)   | 2.0 (2.5)                 |
| HADS-D $\geq 8$ , n (%)   | 1 (5.0)                   |
| SF-12 MCS, mean (SD)  | 47.6 (9.5)<br>n=19        |
| ADerm-IS Daily Activities, mean (SD)  | 11.5 (10.5)               |
| ADerm-IS Emotional State, mean (SD)   | 11.2 (8.2)                |
| WPAI-AD, Employed, n (%)  | 15 (75.0)                 |
| Absenteeism, %, mean (SD)   | 0<br>n=13                 |
| Presenteeism, %, mean (SD)  | 23.9 (23.3)<br>n=13       |
| Overall work productivity impairment, %, mean (SD)  | 23.9 (23.3)<br>n=13       |
| Activity impairment, %, mean (SD)   | 27.5 (27.7)               |
| Hours missed from work, mean (SD)   | 0                         |
| HCRU  |                           |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 4.1 (3.7)<br>n=17         |
| Out of pocket expenses  |                           |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 96.8 (47.4)<br>n=15       |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care resource utilization; SF-12 MCS, Short Form-12 Health Survey mental component summary; USD, United States dollars (2021); WPAI-AD, work activity; Work Productivity and Activity Impairment Atopic Dermatitis.

\*Only adult patients were included in Belgium.

**Supplementary Table 7.1. Baseline Patient Demographics and Characteristics in Brazil**

|  | <b>Total population<br/>(n=56)</b> | <b>Adults<br/>(n=41)</b> | <b>Adolescents<br/>(n=15)</b> |
|--|------------------------------------|--------------------------|-------------------------------|
| Age, years, mean (SD)  | 27.5 (12.2)                        | 32.3 (10.9)              | 14.6 (1.7)                    |
| Male, n (%)  | 35 (62.5)                          | 25 (61.0)                | 10 (66.7)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 27.0 (5.2)                         | 28.1 (4.7)               | 24.1 (5.5)                    |
| Employed, n (%)  | 29 (51.8)                          | 25 (61.0)                | 4 (26.7)                      |
| Duration of AD, years, mean (SD)                                   | 17.2 (10.7)                        | 19.1 (11.8)              | 12.0 (3.8)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 6.9 (11.9)<br>n=14                 | 7.1 (14.3)<br>n=10       | 6.4 (2.7)<br>n=4              |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 9.4 (10.8)<br>n=41                 | 10.8 (12.3)<br>n=29      | 6.2 (4.9)<br>n=12             |
| Continuous systemic therapy over previous 12 months, n (%)         | 12 (21.4)                          | 7 (17.1)                 | 5 (33.3)                      |
| Current therapy, n (%)   | 56 (100.0)                         | 41 (100.0)               | 15 (100.0)                    |
| Systemic monotherapy or in combination                             | 32 (57.1)                          | 21 (51.2)                | 11 (73.3)                     |
| Dupilumab  | 12 (37.5)                          | 9 (42.9)                 | 3 (27.3)                      |
| Systemic corticosteroids   | 2 (6.3)                            | 2 (9.5)                  | 0                             |
| Methotrexate   | 15 (46.9)                          | 8 (38.1)                 | 7 (63.6)                      |
| Cyclosporine   | 3 (9.4)                            | 2 (9.5)                  | 1 (9.1)                       |
| Azathioprine   | 1 (3.1)                            | 1 (4.8)                  | 0                             |
| Mycophenolate  | 0                                  | 0                        | 0                             |
| Systemic monotherapy   | 4 (7.1)                            | 3 (7.3)                  | 1 (6.7)                       |
| Topical monotherapy or in combination                              | 47 (83.9)                          | 35 (85.4)                | 12 (80.0)                     |
| Topical monotherapy  | 7 (12.5)                           | 6 (14.6)                 | 1 (6.7)                       |
| TCS or TCI monotherapy   | 6 (10.7)                           | 5 (12.2)                 | 1 (6.7)                       |
| Previous systemic therapy, n (%)                                   |                                    |                          |                               |
| Systemic monotherapy or in combination                             | 24 (42.9)                          | 20 (48.8)                | 4 (26.7)                      |
| Systemic monotherapy   | 8 (14.3)                           | 7 (17.1)                 | 1 (6.7)                       |
| Dupilumab, monotherapy or in combination                           | 2 (3.6)                            | 1 (2.4)                  | 1 (6.7)                       |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                             |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                               |
| Topical therapy received as monotherapy                            | 49 (87.5)                          | 35 (85.4)                | 14 (93.3)                     |
| Suboptimal response to topical monotherapy                         | 45 (80.4)                          | 33 (80.5)                | 12 (80.0)                     |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 7.2. Physician-Reported and Patient-Reported Clinical Outcomes in Brazil**

|   | <b>Total<br/>population<br/>(n=56)</b> | <b>Adults<br/>(n=41)</b> | <b>Adolescents<br/>(n=15)</b> |
|---|--|--------------------------|-------------------------------|
| <b>Physician-reported outcomes</b>  |  |                          |                               |
| EASI, mean (SD)   | 14.2 (10.3)                            | 14.6 (10.0)              | 13.0 (11.1)                   |
| EASI categories, n (%)  |  |                          |                               |
| Clear (0)   | 4 (7.1)                                | 2 (4.9)                  | 2 (13.3)                      |
| Mild (0.1–5.9)  | 9 (16.1)                               | 5 (12.2)                 | 4 (26.7)                      |
| Moderate (6.0–22.9)   | 35 (62.5)                              | 29 (70.7)                | 6 (40.0)                      |
| Severe (23.0–72.0)  | 8 (14.3)                               | 5 (12.2)                 | 3 (20.0)                      |
| SCORAD, mean (SD)   | 43.8 (20.1)                            | 45.8 (18.8)              | 38.4 (23.3)                   |
| SCORAD categories, n (%)  |  |                          |                               |
| Mild (<25.0)  | 9 (16.1)                               | 5 (12.2)                 | 4 (26.7)                      |
| Moderate (25.0–50.0)  | 23 (41.1)                              | 18 (43.9)                | 5 (33.3)                      |
| Severe (>50.0)  | 24 (42.9)                              | 18 (43.9)                | 6 (40.0)                      |
| vIGA-AD, mean (SD)  | 2.5 (1.1)                              | 2.5 (1.0)                | 2.4 (1.4)                     |
| Clear (0)   | 3 (5.4)                                | 2 (4.9)                  | 1 (6.7)                       |
| Almost clear (1)  | 8 (14.3)                               | 4 (9.8)                  | 4 (26.7)                      |
| Mild (2)  | 11 (19.6)                              | 9 (22.0)                 | 2 (13.3)                      |
| Moderate (3)  | 26 (46.4)                              | 22 (53.7)                | 4 (26.7)                      |
| Severe (4)  | 8 (14.3)                               | 4 (9.8)                  | 4 (26.7)                      |
| BSA, % affected, mean (SD)  | 33.0 (23.6)                            | 34.8 (24.7)              | 28.2 (20.2)                   |
| Average hours of sleep per night in the past week, mean (SD)                | 6.8 (1.6)                              | 6.5 (1.5)                | 7.3 (1.6)                     |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 50.9 (74.1)                            | 50.4 (76.9)              | 52.2 (68.3)                   |
| Sleep problems interfered with daily function over the past week, n (%)     |  |                          |                               |
| I do not have sleep problems  | 4 (7.1)                                | 3 (7.3)                  | 1 (6.7)                       |
| Not at all  | 20 (35.7)                              | 12 (29.3)                | 8 (53.3)                      |
| A little  | 13 (23.2)                              | 9 (22.0)                 | 4 (26.7)                      |
| Somewhat  | 8 (14.3)                               | 8 (19.5)                 | 0                             |
| Much  | 5 (8.9)                                | 5 (12.2)                 | 0                             |
| Very much   | 6 (10.7)                               | 4 (9.8)                  | 2 (13.3)                      |
| <b>Patient-reported outcomes</b>  |  |                          |                               |
| 5D-Pruritus score, mean (SD)  | 14.9 (4.4)                             | 15.4 (4.4)               | 13.3 (4.3)                    |
| POEM, mean (SD)   | 13.3 (7.5)                             | 14.5 (7.7)               | 9.8 (5.9)                     |
| Total ADerm-IS, mean (SD)   | 34.2 (30.0)<br>n=55                    | 39.7 (31.5)              | 17.9 (17.8)<br>n=14           |
| ADerm-IS Sleep domain,  | 10.8 (9.8)                             | 12.2 (10.3)              | 6.9 (7.0)                     |

|   |                    |                    |                    |
|---|--------------------|--------------------|--------------------|
| mean (SD)   | n=55               |                    | n=14               |
| ADerm-SS TSS-7, mean (SD)                           | 23.5 (19.4)        | 27.4 (20.6)        | 13.0 (9.9)         |
| ADerm-SS TSS-11, mean (SD)                          | 35.2 (29.7)        | 40.8 (31.6)        | 19.8 (15.8)        |
| ADerm-SS Skin pain, mean (SD)                       | 2.9 (3.4)          | 3.1 (3.6)          | 2.1 (2.6)          |
| Number of flares in last 6 months, n (%)            |                    |                    |                    |
| 0   | 11 (19.6)          | 8 (19.5)           | 3 (20.0)           |
| 1–2   | 13 (23.2)          | 10 (24.4)          | 3 (20.0)           |
| 3–4   | 14 (25.0)          | 11 (26.8)          | 3 (20.0)           |
| 5–6   | 6 (10.7)           | 6 (14.6)           | 0                  |
| >6  | 9 (16.1)           | 5 (12.2)           | 4 (26.7)           |
| Missing   | 3 (5.4)            | 1 (2.4)            | 2 (13.3)           |
| Number of flares in the last 6 months, mean (range) | 5.0 (0–48)<br>n=53 | 4.2 (0–48)<br>n=40 | 7.3 (0–30)<br>n=13 |
| Average duration of flares in last 6 months, n (%)  |                    |                    |                    |
| ≤2 days   | 16 (28.6)          | 11 (26.8)          | 5 (33.3)           |
| 3–7 days  | 22 (39.3)          | 14 (34.1)          | 8 (53.3)           |
| 8–14 days   | 5 (8.9)            | 5 (12.2)           | 0                  |
| ≥15 days  | 13 (23.2)          | 11 (26.8)          | 2 (13.3)           |
| Inadequately controlled AD, n (%)                   | 11 (19.6)          | 8 (19.5)           | 3 (20.0)           |
| SF-12 PCS, mean (SD)                                | NA                 | 48.8 (8.5)<br>n=40 | NA                 |
| SF-10 PHS, mean (SD)                                | NA                 | NA                 | 39.8 (12.7)        |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 7.3. Psychosocial-Economic Burden of AD in Brazil**

|   | <b>Total population<br/>(n=56)</b> | <b>Adults<br/>(n=41)</b> | <b>Adolescents<br/>(n=15)</b> |
|---|------------------------------------|--------------------------|-------------------------------|
| HADS-A, mean (SD)   | 8.2 (4.2)                          | 8.3 (4.2)                | 8.1 (4.3)                     |
| HADS-A $\geq 8$ , n (%)   | 32 (57.1)                          | 24 (58.5)                | 8 (53.3)                      |
| HADS-D, mean (SD)   | 6.2 (2.8)                          | 6.1 (2.9)                | 6.5 (2.8)                     |
| HADS-D $\geq 8$ , n (%)   | 20 (35.7)                          | 14 (34.1)                | 6 (40.0)                      |
| SF-12 MCS, mean (SD)  | NA                                 | 42.9 (10.7)<br>n=40      | NA                            |
| SF-10 PSS, mean (SD)  | NA                                 | NA                       | 47.0 (8.0)                    |
| ADerm-IS Daily Activities, mean (SD)  | 11.8 (11.9)                        | 14.1 (12.8)              | 5.7 (6.3)                     |
| ADerm-IS Emotional State, mean (SD)   | 11.2 (11.3)                        | 13.5 (11.5)              | 4.9 (8.1)                     |
| WPAI-AD, Employed, n (%)  | 29 (51.8)                          | 25 (61.0)                | 4 (26.7)                      |
| Absenteeism, %, mean (SD)   | 10.0 (17.5)<br>n=27                | 9.3 (17.6)<br>n=23       | 14.2 (18.9)                   |
| Presenteeism, %, mean (SD)  | 32.1 (31.8)                        | 34.8 (32.4)              | 15.0 (23.8)                   |
| Overall work productivity impairment, %, mean (SD)  | 34.9 (31.0)<br>n=27                | 36.4 (31.5)<br>n=23      | 26.1 (30.5)                   |
| Activity impairment, %, mean (SD)   | 33.4 (32.4)                        | 37.3 (33.8)              | 22.7 (26.0)                   |
| Hours missed from work, mean (SD)   | 5.9 (16.0)<br>n=28                 | 6.6 (17.2)<br>n=24       | 1.3 (1.5)                     |
| HCRU  |                                    |                          |                               |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 4.0 (7.5)<br>n=54                  | 3.9 (7.4)<br>n=39        | 4.1 (7.8)                     |
| Out of pocket expenses  |                                    |                          |                               |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 87.0 (88.1)<br>n=53                | 85.2 (97.6)<br>n=39      | 91.9 (56.2)<br>n=14           |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 8.1. Baseline Patient Demographics and Characteristics in Canada**

|  | <b>Total population<br/>(n=212)</b> | <b>Adults<br/>(n=200)</b> | <b>Adolescents<br/>(n=12)</b> |
|--|-------------------------------------|---------------------------|-------------------------------|
| Age, years, mean (SD)  | 45.3 (18.0)                         | 47.1 (16.8)               | 15.2 (1.4)                    |
| Male, n (%)  | 112 (52.8)                          | 107 (53.5)                | 5 (41.7)                      |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 27.0 (5.8)                          | 27.2 (5.7)                | 23.8 (6.8)                    |
| Employed, n (%)  | 124 (58.5)                          | 122 (61.0)                | 2 (16.7)                      |
| Duration of AD, years, mean (SD)                                   | 25.5 (18.5)<br>n=207                | 26.3 (18.8)<br>n=195      | 13.6 (2.9)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 21.5 (19.1)<br>n=29                 | 22.3 (19.5)<br>n=27       | 10.6 (3.6)<br>n=2             |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 21.8 (18.4)<br>n=139                | 22.2 (18.6)<br>n=134      | 10.7 (3.6)<br>n=5             |
| Continuous systemic therapy over previous 12 months, n (%)         | 63 (29.7)                           | 59 (29.5)                 | 4 (33.3)                      |
| Current therapy, n (%)   | 209 (98.6)                          | 197 (98.5)                | 12 (100.0)                    |
| Systemic monotherapy or in combination                             | 123 (58.0)                          | 118 (59.0)                | 5 (41.7)                      |
| Dupilumab  | 93 (75.6)                           | 88 (74.6)                 | 5 (100.0)                     |
| Systemic corticosteroids   | 18 (14.6)                           | 18 (15.3)                 | 0                             |
| Methotrexate   | 21 (17.1)                           | 21 (17.8)                 | 0                             |
| Cyclosporine   | 2 (1.6)                             | 2 (1.7)                   | 0                             |
| Azathioprine   | 0                                   | 0                         | 0                             |
| Mycophenolate  | 0                                   | 0                         | 0                             |
| Systemic monotherapy   | 37 (17.5)                           | 35 (17.5)                 | 2 (16.7)                      |
| Topical monotherapy or in combination                              | 164 (77.4)                          | 154 (77.0)                | 10 (83.3)                     |
| Topical monotherapy  | 39 (18.4)                           | 37 (18.5)                 | 2 (16.7)                      |
| TCS or TCI monotherapy   | 2 (16.7)                            | 27 (13.5)                 | 29 (13.7)                     |
| Previous systemic therapy, n (%)                                   |                                     |                           |                               |
| Systemic monotherapy or in combination                             | 95 (44.8)                           | 95 (47.5)                 | 0                             |
| Systemic monotherapy   | 7 (3.3)                             | 7 (3.5)                   | 0                             |
| Dupilumab, monotherapy or in combination                           | 2 (0.9)                             | 2 (1.0)                   | 0                             |
| Dupilumab monotherapy  | 0                                   | 0                         | 0                             |
| Treatment prior to study enrollment, n (%)                         |                                     |                           |                               |
| Topical therapy received as monotherapy                            | 189 (89.2)                          | 177 (88.5)                | 12 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 179 (84.4)                          | 167 (83.5)                | 12 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 8.2. Physician-Reported and Patient-Reported Clinical Outcomes in Canada**

|  | <b>Total<br/>population<br/>(n=212)</b> | <b>Adults<br/>(n=200)</b> | <b>Adolescents<br/>(n=12)</b> |
|--|---|---------------------------|-------------------------------|
| <b>Physician-reported outcomes</b>   |   |                           |                               |
| EASI, mean (SD)  | 12.4 (12.9)                             | 12.4 (12.9)               | 13.0 (13.4)                   |
| EASI categories, n (%)   |   |                           |                               |
| Clear (0)  | 17 (8.0)                                | 16 (8.0)                  | 1 (8.3)                       |
| Mild (0.1–5.9)   | 70 (33.0)                               | 66 (33.0)                 | 4 (33.3)                      |
| Moderate (6.0–22.9)  | 86 (40.6)                               | 81 (40.5)                 | 5 (41.7)                      |
| Severe (23.0–72.0)   | 39 (18.4)                               | 37 (18.5)                 | 2 (16.7)                      |
| SCORAD, mean (SD)  | 40.2 (21.3)                             | 40.0 (21.2)               | 43.8 (23.9)                   |
| SCORAD categories, n (%)   |   |                           |                               |
| Mild (<25.0)   | 60 (28.3)                               | 57 (28.5)                 | 3 (25.0)                      |
| Moderate (25.0–50.0)   | 78 (36.8)                               | 74 (37.0)                 | 4 (33.3)                      |
| Severe (>50.0)   | 73 (34.4)                               | 68 (34.0)                 | 5 (41.7)                      |
| Missing  | 1 (0.5)                                 | 1 (0.5)                   | 0                             |
| vIGA-AD, mean (SD)   | 2.5 (1.2)                               | 2.5 (1.2)                 | 2.5 (1.4)                     |
| Clear (0)  | 20 (9.4)                                | 19 (9.5)                  | 1 (8.3)                       |
| Almost clear (1)   | 21 (9.9)                                | 18 (9.0)                  | 3 (25.0)                      |
| Mild (2)   | 48 (22.6)                               | 48 (24.0)                 | 0                             |
| Moderate (3)   | 81 (38.2)                               | 76 (38.0)                 | 5 (41.7)                      |
| Severe (4)   | 42 (19.8)                               | 39 (19.5)                 | 3 (25.0)                      |
| BSA, % affected, mean (SD)   | 21.1(23.2)                              | 21.3 (23.5)               | 17.8 (17.9)                   |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.6 (1.5)                               | 6.5 (1.5)                 | 7.1 (0.9)                     |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 35.3 (30.3)                             | 35.5 (30.9)               | 32.1 (15.3)                   |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |   |                           |                               |
| I do not have sleep problems   | 10 (4.7)                                | 10 (5.0)                  | 0                             |
| Not at all   | 71 (33.5)                               | 64 (32.0)                 | 7 (58.3)                      |
| A little   | 47 (22.2)                               | 43 (21.5)                 | 4 (33.3)                      |
| Somewhat   | 41 (19.3)                               | 40 (20.0)                 | 1 (8.3)                       |
| Much   | 19 (9.0)                                | 19 (9.5)                  | 0                             |
| Very much  | 23 (10.8)                               | 23 (11.5)                 | 0                             |
| Missing  | 0                                       | 1 (0.5)                   | 1 (0.5)                       |
| <b>Patient-reported outcomes</b>   |   |                           |                               |
| 5D-Pruritus score, mean (SD)   | 15.1 (4.9)<br>(n=203)                   | 15.2 (4.9)<br>(n=191)     | 13.4 (4.7)                    |
| POEM, mean (SD)  | 15.1 (8.6)                              | 15.2 (8.6)                | 13.8 (8.9)                    |
| Total ADerm-IS, mean (SD)  | 35.6 (29.3)                             | 35.8 (29.3)               | 32.5 (30.5)                   |

|   |                      |                      |                     |
|---|----------------------|----------------------|---------------------|
|   | n=206                | n=194                |                     |
| ADerm-IS Sleep domain, mean (SD)                    | 11.1 (9.6)           | 11.1 (9.7)           | 10.6 (9.9)          |
| ADerm-SS TSS-7, mean (SD)                           | 31.0 (21.9)<br>n=209 | 31.2 (22.0)<br>n=197 | 28.1 (19.7)         |
| ADerm-SS TSS-11, mean (SD)                          | 44.5 (32.4)<br>n=208 | 44.8 (32.6)<br>n=196 | 40.2 (29.5)         |
| ADerm-SS Skin pain, mean (SD)                       | 4.0 (3.5)            | 4.1 (3.5)            | 3.3 (2.8)           |
| Number of flares in last 6 months, n (%)            |                      |                      |                     |
| 0   | 37 (17.5)            | 35 (17.5)            | 2 (16.7)            |
| 1–2   | 45 (21.2)            | 43 (21.5)            | 2 (16.7)            |
| 3–4   | 33 (15.6)            | 33 (16.5)            | 0                   |
| 5–6   | 26 (12.3)            | 24 (12.0)            | 2 (16.7)            |
| >6  | 58 (27.4)            | 52 (26.0)            | 6 (50.0)            |
| Missing   | 13 (6.1)             | 13 (6.5)             | 0                   |
| Number of flares in the last 6 months, mean (range) | 8.8 (0–180)<br>n=199 | 8.8 (0–180)<br>n=187 | 9.1 (0–30)          |
| Average duration of flares in last 6 months, n (%)  |                      |                      |                     |
| ≤2 days   | 50 (23.6)            | 48 (24.0)            | 2 (16.7)            |
| 3–7 days  | 89 (42.0)            | 83 (41.5)            | 6 (50.0)            |
| 8–14 days   | 24 (11.3)            | 23 (11.5)            | 1 (8.3)             |
| ≥15 days  | 34 (16.0)            | 31 (15.5)            | 3 (25.0)            |
| Missing   | 15 (7.1)             | 15 (7.5)             | 0                   |
| Inadequately controlled AD, n (%)                   | 72 (34.0)            | 70 (35.0)            | 2 (16.7)            |
| SF-12 PCS, mean (SD)                                | NA                   | 50.5 (8.4)<br>n=196  | NA                  |
| SF-10 PHS, mean (SD)                                | NA                   | NA                   | 43.0 (13.5)<br>n=11 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 8.3. Psychosocial-Economic Burden of AD in Canada**

|   | <b>Total<br/>population<br/>(n=212)</b> | <b>Adults<br/>(n=200)</b> | <b>Adolescents<br/>(n=12)</b> |
|---|---|---------------------------|-------------------------------|
| HADS-A, mean (SD)   | 7.0 (4.1)<br>n=210                      | 7.0 (4.1)<br>n=198        | 6.3 (4.6)                     |
| HADS-A $\geq 8$ , n (%)   | 81 (38.2)                               | 77 (38.5)                 | 4 (33.3)                      |
| HADS-D, mean (SD)   | 4.1 (3.9)<br>n=210                      | 4.2 (3.9)<br>n=198        | 2.9 (2.6)                     |
| HADS-D $\geq 8$ , n (%)   | 36 (17.0)                               | 35 (17.5)                 | 1 (8.3)                       |
| SF-12 MCS, mean (SD)  | NA                                      | 47.0 (10.7)<br>n=197      | NA                            |
| SF-10 PSS, mean (SD)  | NA                                      | NA                        | 50.4 (8.7)<br>n=11            |
| ADerm-IS Daily Activities, mean (SD)  | 11.9 (11.6)                             | 12.0 (11.7)               | 11.0 (10.6)                   |
| ADerm-IS Emotional State, mean (SD)   | 12.9 (10.7)                             | 13.1 (10.7)               | 10.9 (10.7)                   |
| WPAI-AD, Employed, n (%)  | 124 (58.5)                              | 122 (61.0)                | 2 (16.7)                      |
| Absenteeism, %, mean (SD)   | 4.6 (12.0)<br>n=96                      | 4.6 (12.1)<br>n=95        | 0<br>n=1                      |
| Presenteeism, %, mean (SD)  | 26.8 (27.5)<br>n=113                    | 26.5 (27.4)<br>n=112      | 60.0 (NA)<br>n=1              |
| Overall work productivity impairment, %, mean (SD)  | 31.0 (28.5)<br>n=96                     | 30.7 (28.5)<br>n=95       | 60.0 (NA)<br>n=1              |
| Activity impairment, %, mean (SD)   | 32.9 (30.5)<br>n=209                    | 32.5 (30.6)<br>n=197      | 38.3 (29.5)                   |
| Hours missed from work, mean (SD)   | 1.8 (6.0)<br>n=107                      | 1.9 (6.1)<br>n=105        | 0                             |
| HCRU  |   |                           |                               |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 3.5 (7.9)<br>n=186                      | 3.4 (7.9)<br>n=175        | 4.3 (9.2)<br>n=11             |
| <b>Out of pocket expenses</b>   |   |                           |                               |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 145.3 (279.5)<br>n=187                  | 149.5 (286.8)<br>n=176    | 77.6 (91.1)<br>n=11           |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 9.1. Baseline Patient Demographics and Characteristics in China**

|  | <b>Total population<br/>(n=44)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=5)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 30.7 (15.7)                        | 32.8 (15.4)              | 14.6 (1.5)                   |
| Male, n (%)  | 33 (75.0)                          | 30 (76.9)                | 3 (60.0)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 23.2 (4.1)                         | 23.5 (4.2)               | 20.6 (3.2)                   |
| Employed, n (%)  | 15 (34.1)                          | 15 (38.5)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 13.8 (12.5)<br>n=43                | 14.8 (12.8)<br>n=38      | 5.9 (5.1)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | –                                  | –                        | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 5.5 (8.2)<br>n=13                  | 5.5 (8.2)<br>n=13        | –                            |
| Continuous systemic therapy over previous 12 months, n (%)         | 0                                  | 0                        | 0                            |
| Current therapy, n (%)   | 42 (95.5)                          | 37 (94.9)                | 5 (100.0)                    |
| Systemic monotherapy or in combination                             | 9 (20.5)                           | 9 (23.1)                 | 0                            |
| Dupilumab  | 4 (44.4)                           | 4 (44.4)                 | 0                            |
| Systemic corticosteroids   | 5 (55.6)                           | 5 (55.6)                 | 0                            |
| Methotrexate   | 0                                  | 0                        | 0                            |
| Cyclosporine   | 0                                  | 0                        | 0                            |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 1 (2.3)                            | 1 (2.6)                  | 0                            |
| Topical monotherapy or in combination                              | 33 (75.0)                          | 29 (74.4)                | 4 (80.0)                     |
| Topical monotherapy  | 9 (20.5)                           | 7 (17.9)                 | 2 (40.0)                     |
| TCS or TCI monotherapy   | 5 (11.4)                           | 5 (12.8)                 | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 7 (15.9)                           | 7 (17.9)                 | 0                            |
| Systemic monotherapy   | 2 (4.5)                            | 2 (5.1)                  | 0                            |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 4 (9.1)                            | 3 (7.7)                  | 1 (20.0)                     |
| Suboptimal response to topical monotherapy                         | 3 (6.8)                            | 2 (5.1)                  | 1 (20.0)                     |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 9.2. Physician-Reported and Patient-Reported Clinical Outcomes in China**

|  | <b>Total<br/>population<br/>(n=44)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=5)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 29.8 (13.1)                            | 30.0 (13.4)              | 28.3 (11.8)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Mild (0.1–5.9)   | 0                                      | 0                        | 0                            |
| Moderate (6.0–22.9)  | 12 (27.3)                              | 11 (28.2)                | 1 (20.0)                     |
| Severe (23.0–72.0)   | 32 (72.7)                              | 28 (71.8)                | 4 (80.0)                     |
| SCORAD, mean (SD)  | 62.3 (13.4)<br>n=43                    | 63.1 (12.8)<br>n=38      | 56.6 (17.6)                  |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 0                                      | 0                        | 0                            |
| Moderate (25.0–50.0)   | 9 (20.5)                               | 7 (17.9)                 | 2 (40.0)                     |
| Severe (>50.0)   | 34 (77.3)                              | 31 (79.5)                | 3 (60.0)                     |
| Missing  | 1 (2.3)                                | 1 (2.6)                  | 0                            |
| vIGA-AD, mean (SD)   | 3.4 (0.5)                              | 3.4 (0.5)                | 3.4 (0.5)                    |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Almost clear (1)   | 0                                      | 0                        | 0                            |
| Mild (2)   | 0                                      | 0                        | 0                            |
| Moderate (3)   | 25 (56.8)                              | 22 (56.4)                | 3 (60.0)                     |
| Severe (4)   | 19 (43.2)                              | 17 (43.6)                | 2 (40.0)                     |
| BSA, % affected, mean (SD)   | 44.6 (20.6)                            | 44.6 (21.2)              | 44.4 (17.2)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.5 (1.5)                              | 6.4 (1.5)                | 7.2 (1.6)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 35.7 (33.2)                            | 37.2 (35.0)              | 24.0 (8.2)                   |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 0                                      | 0                        | 0                            |
| Not at all   | 10 (22.7)                              | 8 (20.5)                 | 2 (40.0)                     |
| A little   | 10 (22.7)                              | 9 (23.1)                 | 1 (20.0)                     |
| Somewhat   | 11 (25.0)                              | 10 (25.6)                | 1 (20.0)                     |
| Much   | 11 (25.0)                              | 10 (25.6)                | 1 (20.0)                     |
| Very much  | 2 (4.5)                                | 2 (5.1)                  | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 15.4 (3.9)                             | 15.8 (3.8)               | 12.8 (4.0)                   |
| POEM, mean (SD)  | 15.7 (7.4)                             | 16.1 (7.2)               | 13.2 (9.3)                   |
| Total ADerm-IS, mean (SD)  | 44.3 (26.9)                            | 46.6 (26.4)              | 21.8 (23.2)                  |

|   |                       |                   |                      |
|---|-----------------------|-------------------|----------------------|
|   | (n=43)                |                   | (n=4)                |
| ADerm-IS Sleep domain, mean (SD)                    | 13.6 (9.9)            | 14.5 (9.9)        | 7.0 (6.9)            |
| ADerm-SS TSS-7, mean (SD)                           | 31.3 (16.4)<br>(n=43) | 32.2 (15.6)       | 21.8 (22.9)<br>(n=4) |
| ADerm-SS TSS-11, mean (SD)                          | 45.7 (24.6)           | 47.2 (23.2)       | 30.8 (36.7)          |
| ADerm-SS Skin pain, mean (SD)                       | 3.9 (3.4)             | 4.0 (3.4)         | 3.2 (3.6)            |
| Number of flares in last 6 months, n (%)            |                       |                   |                      |
| 0   | 6 (13.6)              | 5 (12.8)          | 1 (20.0)             |
| 1–2   | 14 (31.8)             | 12 (30.8)         | 2 (40.0)             |
| 3–4   | 16 (36.4)             | 14 (35.9)         | 2 (40.0)             |
| 5–6   | 4 (9.1)               | 4 (10.3)          | 0                    |
| >6  | 2 (4.5)               | 2 (5.1)           | 0                    |
| Missing   | 2 (4.5)               | 2 (5.1)           | 0                    |
| Number of flares in the last 6 months, mean (range) | 2.5 (0–8)<br>n=42     | 2.6 (8–8)<br>n=37 | 1.8 (0–3)            |
| Average duration of flares in last 6 months, n (%)  |                       |                   |                      |
| ≤2 days   | 8 (18.2)              | 7 (17.9)          | 1 (20.0)             |
| 3–7 days  | 13 (29.5)             | 10 (25.6)         | 3 (60.0)             |
| 8–14 days   | 8 (18.2)              | 7 (17.9)          | 1 (20.0)             |
| ≥15 days  | 13 (29.5)             | 13 (33.3)         | 0                    |
| Missing   | 2 (4.5)               | 2 (5.1)           | 0                    |
| Inadequately controlled AD, n (%)                   | 5 (11.4)              | 5 (12.8)          | 0                    |
| SF-12 PCS, mean (SD)                                | NA                    | 48.1 (7.6)        | NA                   |
| SF-10 PHS, mean (SD)                                | NA                    | NA                | 36.0 (22.1)          |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 9.3. Psychosocial-Economic Burden of AD in China**

|   | <b>Total<br/>population<br/>(n=44)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=5)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 6.1 (4.6)                              | 6.4 (4.6)                | 3.2 (4.0)                    |
| HADS-A $\geq 8$ , n (%)   | 14 (31.8)                              | 13 (33.3)                | 1 (20.0)                     |
| HADS-D, mean (SD)   | 5.7 (4.2)                              | 6.3 (4.1)                | 1.2 (0.8)                    |
| HADS-D $\geq 8$ , n (%)   | 16 (36.4)                              | 16 (41.0)                | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 40.2 (12.9)              | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 52.1 (8.1)                   |
| ADerm-IS Daily Activities, mean (SD)  | 14.5 (11.3)<br>n=43                    | 15.2 (11.2)              | 7.3 (10.6)<br>n=4            |
| ADerm-IS Emotional State, mean (SD)   | 16.0 (9.6)                             | 16.9 (9.5)               | 8.8 (8.0)                    |
| WPAI-AD, Employed, n (%)  | 15 (34.1)                              | 15 (38.5)                | 0                            |
| Absenteeism, %, mean (SD)   | 9.2 (26.5)<br>n=14                     | 9.2 (26.5)<br>n=14       | –                            |
| Presenteeism, %, mean (SD)  | 34.6 (22.6)<br>n=13                    | 34.6 (22.6)<br>n=13      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 36.3 (21.9)<br>n=13                    | 36.3 (21.9)<br>n=13      | –                            |
| Activity impairment, %, mean (SD)   | 41.8 (28.1)                            | 42.3 (27.6)              | 38.0 (34.9)                  |
| Hours missed from work, mean (SD)   | 4.2 (12.8)                             | 4.2 (12.8)               | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 5.2 (5.7)<br>n=38                      | 5.4 (5.8)<br>n=34        | 3.8 (5.2)<br>n=4             |
| Out of pocket expenses  |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 385.6 (603.1)<br>n=43                  | 388.7 (620.4)            | 355.1 (465.8)<br>n=4         |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 10.1. Baseline Patient Demographics and Characteristics in the Czech Republic**

|  | <b>Total population<br/>(n=30)</b> | <b>Adults<br/>(n=29)</b> | <b>Adolescents<br/>(n=1)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 33.8 (11.5)                        | 34.6 (10.9)              | 12.0 (NA)                    |
| Male, n (%)  | 19 (63.3)                          | 18 (62.1)                | 1 (100.0)                    |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.2 (4.8)                         | 25.5 (4.5)               | 14.8 (NA)                    |
| Employed, n (%)  | 20 (66.7)                          | 20 (69.0)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 29.0 (11.4)                        | 29.6 (11.1)              | 12.4 (NA)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 33.9 (5.4)<br>n=2                  | 33.9 (5.4)<br>n=2        | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 25.8 (12.3)<br>n=25                | 26.6 (11.8)<br>n=24      | 6.0 (NA)                     |
| Continuous systemic therapy over previous 12 months, n (%)         | 5 (16.7)                           | 4 (13.8)                 | 1 (100.0)                    |
| Current therapy, n (%)   | 30 (100.0)                         | 29 (100.0)               | 1 (100.0)                    |
| Systemic monotherapy or in combination                             | 20 (66.7)                          | 19 (65.5)                | 1 (100.0)                    |
| Dupilumab  | 12 (60.0)                          | 11 (57.9)                | 1 (100.0)                    |
| Systemic corticosteroids   | 4 (20.0)                           | 4 (21.1)                 | 0                            |
| Cyclosporine   | 5 (25.0)                           | 5 (26.3)                 | 0                            |
| Azathioprine   | 1 (5.0)                            | 1 (5.3)                  | 0                            |
| Systemic monotherapy   | 5 (16.7)                           | 5 (17.2)                 | 0                            |
| Topical monotherapy or in combination                              | 25 (83.3)                          | 24 (82.8)                | 1 (100.0)                    |
| Topical monotherapy  | 7 (23.3)                           | 7 (24.1)                 | 0                            |
| TCS or TCI monotherapy   | 5 (16.7)                           | 5 (17.2)                 | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 17 (56.7)                          | 16 (55.2)                | 1 (100.0)                    |
| Systemic monotherapy   | 0                                  | 0                        | 0                            |
| Dupilumab, monotherapy or in combination                           | 1 (3.3)                            | 1 (3.4)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 22 (73.3)                          | 21 (72.4)                | 1 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 21 (70.0)                          | 20 (69.0)                | 1 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 10.2. Physician-Reported and Patient-Reported Clinical Outcomes in the Czech Republic**

|  | <b>Total<br/>population<br/>(n=30)</b> | <b>Adults<br/>(n=29)</b> | <b>Adolescents<br/>(n=1)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 16.9 (12.1)                            | 17.3 (12.1)              | 5.2 (NA)                     |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Mild (0.1–5.9)   | 8 (26.7)                               | 7 (24.1)                 | 1 (100.0)                    |
| Moderate (6.0–22.9)  | 11 (36.7)                              | 11 (37.9)                | 0                            |
| Severe (23.0–72.0)   | 11 (36.7)                              | 11 (37.9)                | 0                            |
| SCORAD, mean (SD)  | 39.9 (15.0)<br>n=29                    | 40.3 (15.1)<br>n=28      | 28.2 (NA)                    |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 6 (20.0)                               | 6 (20.7)                 | 0                            |
| Moderate (25.0–50.0)   | 16 (53.3)                              | 15 (51.7)                | 1 (100.0)                    |
| Severe (>50.0)   | 7 (23.3)                               | 7 (24.1)                 | 0                            |
| Missing  | 1 (3.3)                                | 1 (3.4)                  | 0                            |
| vIGA-AD, mean (SD)   | 2.5 (0.9)                              | 2.5 (0.9)                | 2.0 (NA)                     |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Almost clear (1)   | 6 (20.0)                               | 6 (20.7)                 | 0                            |
| Mild (2)   | 6 (20.0)                               | 5 (17.2)                 | 1 (100.0)                    |
| Moderate (3)   | 15 (50.0)                              | 15 (51.7)                | 0                            |
| Severe (4)   | 3 (10.0)                               | 3 (10.3)                 | 0                            |
| BSA, % affected, mean (SD)   | 30.6 (20.0)                            | 31.4 (19.8)              | 8.0 (NA)                     |
| Average hours of sleep per night in the past week, mean (SD)                   | 5.9 (2.1)                              | 5.9 (2.1)                | 8.0 (NA)                     |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 30.2 (26.8)<br>n=29                    | 29.6 (27.2)<br>n=28      | 45.0 (NA)                    |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 3 (10.0)                               | 3 (10.3)                 | 0                            |
| Not at all   | 2 (6.7)                                | 2 (6.9)                  | 0                            |
| A little   | 10 (33.3)                              | 10 (34.5)                | 0                            |
| Somewhat   | 10 (33.3)                              | 9 (31.0)                 | 1 (100.0)                    |
| Much   | 4 (13.3)                               | 4 (13.8)                 | 0                            |
| Very much  | 1 (3.3)                                | 1 (3.4)                  | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 16.8 (4.1)                             | 16.8 (4.2)               | 15.0 (NA)                    |
| POEM, mean (SD)  | 17.7 (7.0)                             | 17.8 (7.1)               | 17.0 (NA)                    |
| Total ADerm-IS, mean (SD)  | 48.6 (27.9)                            | 49.1 (28.2)              | 32.0 (NA)                    |

|   |             |             |              |
|---|-------------|-------------|--------------|
| ADerm-IS Sleep domain, mean (SD)                    | 14.1 (9.2)  | 14.4 (9.2)  | 5.0 (NA)     |
| ADerm-SS TSS-7, mean (SD)                           | 36.5 (18.1) | 36.6 (18.4) | 33.0 (NA)    |
| ADerm-SS TSS-11, mean (SD)                          | 52.1 (27.7) | 52.6 (28.1) | 39.0 (NA)    |
| ADerm-SS Skin pain, mean (SD)                       | 4.9 (3.4)   | 4.9 (3.5)   | 6.0 (NA)     |
| Number of flares in last 6 months, n (%)            |             |             |              |
| 0   | 3 (10.0)    | 3 (10.3)    | 0            |
| 1–2   | 6 (20.0)    | 6 (20.7)    | 0            |
| 3–4   | 11 (36.7)   | 11 (37.9)   | 0            |
| 5–6   | 2 (6.7)     | 2 (6.9)     | 0            |
| >6  | 8 (26.7)    | 7 (24.1)    | 1 (100.0)    |
| Number of flares in the last 6 months, mean (range) | 6.2 (0–46)  | 5.9 (0–46)  | 15.0 (15–15) |
| Average duration of flares in last 6 months, n (%)  |             |             |              |
| ≤2 days   | 6 (20.0)    | 6 (20.7)    | 0            |
| 3–7 days  | 12 (40.0)   | 11 (37.9)   | 1 (100.0)    |
| 8–14 days   | 7 (23.3)    | 7 (24.1)    | 0            |
| ≥15 days  | 4 (13.3)    | 4 (13.8)    | 0            |
| Inadequately controlled AD, n (%)                   | 13 (43.3)   | 13 (44.8)   | 0            |
| SF-12 PCS, mean (SD)                                | NA          | 47.4 (8.0)  | NA           |
| SF-10 PHS, mean (SD)                                | NA          | NA          | –            |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 10.3. Psychosocial-Economic Burden of AD in the Czech Republic**

|   | <b>Total<br/>population<br/>(n=30)</b> | <b>Adults<br/>(n=29)</b> | <b>Adolescents<br/>(n=1)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 7.2 (4.0)                              | 7.2 (4.1)                | 8.0 (NA)                     |
| HADS-A $\geq 8$ , n (%)   | 15 (50.0)                              | 14 (48.3)                | 1 (100.0)                    |
| HADS-D, mean (SD)   | 6.3 (3.8)                              | 6.4 (3.9)                | 5.0 (NA)                     |
| HADS-D $\geq 8$ , n (%)   | 11 (36.7)                              | 11 (37.9)                | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 39.3 (10.6)              | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | –                            |
| ADerm-IS Daily Activities, mean (SD)  | 19.1 (11.7)                            | 19.2 (11.9)              | 15.0 (NA)                    |
| ADerm-IS Emotional State, mean (SD)   | 15.4 (10.2)                            | 15.5 (10.3)              | 12.0 (NA)                    |
| WPAI-AD, Employed, n (%)  | 20 (66.7)                              | 20 (69.0)                | 0                            |
| Absenteeism, %, mean (SD)   | 26.4 (35.4)<br>n=18                    | 26.4 (35.4)<br>n=18      | –                            |
| Presenteeism, %, mean (SD)  | 42.8 (25.9)<br>n=18                    | 42.8 (25.9)<br>n=18      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 50.2 (30.3)<br>n=17                    | 50.2 (30.3)<br>n=17      | –                            |
| Activity impairment, %, mean (SD)   | 49.3 (33.9)                            | 49.7 (34.5)              | 40.0 (NA)                    |
| Hours missed from work, mean (SD)   | 18.5 (38.6)<br>n=19                    | 18.5 (38.6)<br>n=19      | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 5.3 (7.2)<br>n=26                      | 5.3 (7.4)<br>n=25        | 5.0 (NA)                     |
| Out of pocket expenses  |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 139.4 (114.2)<br>n=28                  | 138.6 (116.3)<br>n=27    | 161.0 (NA)                   |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 11.1. Baseline Patient Demographics and Characteristics in Germany**

|  | <b>Total population<br/>(n=217)</b> | <b>Adults<br/>(n=210)</b> | <b>Adolescents<br/>(n=7)</b> |
|--|-------------------------------------|---------------------------|------------------------------|
| Age, years, mean (SD)  | 42.2 (17.4)                         | 43.1 (17.0)               | 15.1 (1.6)                   |
| Male, n (%)  | 104 (47.9)                          | 101 (48.1)                | 3 (42.9)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.2 (4.8)<br>n=210                 | 25.4 (4.8)<br>n=203       | 20.0 (3.1)                   |
| Employed, n (%)  | 141 (65.0)                          | 141 (67.1)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 28.8 (16.5)<br>n=187                | 29.3 (16.5)<br>n=181      | 13.9 (1.8)<br>n=6            |
| Time from AD diagnosis to first therapy, years mean (SD)           | 30.0 (14.5)<br>n=26                 | 30.0 (14.5)<br>n=26       | —                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 25.7 (15.8)<br>n=118                | 26.1 (16.0)<br>n=114      | 14.2 (2.2)<br>n=4            |
| Continuous systemic therapy over previous 12 months, n (%)         | 44 (20.3)                           | 44 (21.0)                 | 0                            |
| Current therapy, n (%)   | 215 (99.1)                          | 208 (99.0)                | 7 (100.0)                    |
| Systemic monotherapy or in combination                             | 116 (53.5)                          | 114 (54.3)                | 2 (28.6)                     |
| Dupilumab  | 98 (84.5)                           | 96 (84.2)                 | 2 (100.0)                    |
| Systemic corticosteroids   | 15 (12.9)                           | 15 (13.2)                 | 0                            |
| Methotrexate   | 2 (1.7)                             | 2 (1.8)                   | 0                            |
| Cyclosporine   | 3 (2.6)                             | 3 (2.6)                   | 0                            |
| Systemic monotherapy   | 46 (21.2)                           | 45 (21.4)                 | 1 (14.3)                     |
| Topical monotherapy or in combination                              | 167 (77.0)                          | 161 (76.7)                | 6 (85.7)                     |
| Topical monotherapy  | 61 (28.1)                           | 59 (28.1)                 | 2 (28.6)                     |
| TCS or TCI monotherapy   | 44 (20.3)                           | 43 (20.5)                 | 1 (14.3)                     |
| Previous systemic therapy, n (%)                                   |                                     |                           |                              |
| Systemic monotherapy or in combination                             | 94 (43.3)                           | 92 (43.8)                 | 2 (28.6)                     |
| Systemic monotherapy   | 16 (7.4)                            | 14 (6.7)                  | 2 (28.6)                     |
| Dupilumab, monotherapy or in combination                           | 6 (2.8)                             | 6 (2.9)                   | 0                            |
| Dupilumab monotherapy  | 1 (0.5)                             | 1 (0.5)                   | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                     |                           |                              |
| Topical therapy received as monotherapy                            | 185 (85.3)                          | 178 (84.8)                | 7 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 167 (77.0)                          | 160 (76.2)                | 7 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 11.2. Physician-Reported and Patient-Reported Clinical Outcomes in Germany**

|  | <b>Total<br/>population<br/>(n=217)</b> | <b>Adults<br/>(n=210)</b> | <b>Adolescents<br/>(n=7)</b> |
|--|---|---------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |   |                           |                              |
| EASI, mean (SD)  | 13.0 (11.0)<br>n=214                    | 12.7 (11.1)<br>n=207      | 21.8 (4.8)                   |
| EASI categories, n (%)   |   |                           |                              |
| Clear (0)  | 13 (6.0)                                | 13 (6.2)                  | 0                            |
| Mild (0.1–5.9)   | 63 (29.0)                               | 63 (30.0)                 | 0                            |
| Moderate (6.0–22.9)  | 95 (43.8)                               | 91 (43.3)                 | 4 (57.1)                     |
| Severe (23.0–72.0)   | 43 (19.8)                               | 40 (19.0)                 | 3 (42.9)                     |
| Missing  | 3 (1.4)                                 | 3 (1.4)                   | 0                            |
| SCORAD, mean (SD)  | 41.6 (20.7)<br>n=207                    | 41.2 (20.9)<br>n=200      | 53.2 (9.3)                   |
| SCORAD categories, n (%)   |   |                           |                              |
| Mild (<25.0)   | 47 (21.7)                               | 47 (22.4)                 | 0                            |
| Moderate (25.0–50.0)   | 78 (35.9)                               | 74 (35.2)                 | 4 (57.1)                     |
| Severe (>50.0)   | 82 (37.8)                               | 79 (37.6)                 | 3 (42.9)                     |
| Missing  | 10 (4.6)                                | 10 (4.8)                  | 0                            |
| vIGA-AD, mean (SD)   | 2.5 (1.1)<br>n=216                      | 2.5 (1.1)<br>n=209        | 3.3 (0.5)                    |
| Clear (0)  | 14 (6.5)                                | 14 (6.7)                  | 0                            |
| Almost clear (1)   | 28 (12.9)                               | 28 (13.3)                 | 0                            |
| Mild (2)   | 51 (23.5)                               | 51 (24.3)                 | 0                            |
| Moderate (3)   | 87 (40.1)                               | 82 (39.0)                 | 5 (71.4)                     |
| Severe (4)   | 36 (16.6)                               | 34 (16.2)                 | 2 (28.6)                     |
| Missing  | 1 (0.5)                                 | 1 (0.5)                   | 0                            |
| BSA, % affected, mean (SD)   | 22.4 (20.1)<br>n=212                    | 21.9 (20.0)<br>n=206      | 38.0 (19.3)<br>n=6           |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.7 (1.6)<br>n=212                      | 6.7 (1.5)<br>n=205        | 8.0 (2.5)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 33.1 (45.7)<br>n=210                    | 33.1 (46.0)<br>n=203      | 35.0 (38.6)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |   |                           |                              |
| I do not have sleep problems   | 8 (3.7)                                 | 8 (3.8)                   | 0                            |
| Not at all   | 65 (30.0)                               | 64 (30.5)                 | 1 (14.3)                     |
| A little   | 50 (23.0)                               | 47 (22.4)                 | 3 (42.9)                     |
| Somewhat   | 47 (21.7)                               | 45 (21.4)                 | 2 (28.6)                     |
| Much   | 23 (10.6)                               | 22 (10.5)                 | 1 (14.3)                     |
| Very much  | 19 (8.8)                                | 19 (9.0)                  | 0                            |

|   |                      |                      |                    |
|---|----------------------|----------------------|--------------------|
| Missing   | 5 (2.3)              | 5 (2.4)              | 0                  |
| <b>Patient-reported outcomes</b>                    |                      |                      |                    |
| 5D-Pruritus score, mean (SD)                        | 15.3 (4.5)<br>n=204  | 15.3 (4.5)<br>n=197  | 15.4 (4.1)         |
| POEM, mean (SD)                                     | 14.7 (8.3)<br>n=207  | 14.7 (8.3)<br>n=200  | 16.0 (10.1)        |
| Total ADerm-IS, mean (SD)                           | 36.3 (29.1)<br>n=210 | 36.4 (29.0)<br>n=206 | 33.3 (39.5)<br>n=4 |
| ADerm-IS Sleep domain, mean (SD)                    | 12.1 (10.0)<br>n=215 | 12.0 (9.9)<br>n=208  | 13.9 (12.6)        |
| ADerm-SS TSS-7, mean (SD)                           | 29.6 (19.7)<br>n=211 | 29.5 (19.7)<br>n=204 | 31.6 (19.7)        |
| ADerm-SS TSS-11, mean (SD)                          | 42.1 (29.5)<br>n=209 | 42.0 (29.5)<br>n=202 | 45.4 (29.4)        |
| ADerm-SS Skin pain, mean (SD)                       | 3.8 (3.3)<br>n=212   | 3.8 (3.3)<br>n=205   | 4.4 (3.2)          |
| Number of flares in last 6 months, n (%)            |                      |                      |                    |
| 0   | 35 (16.1)            | 35 (16.7)            | 0                  |
| 1–2   | 68 (31.3)            | 65 (31.0)            | 3 (42.9)           |
| 3–4   | 43 (19.8)            | 43 (20.5)            | 0                  |
| 5–6   | 28 (12.9)            | 26 (12.4)            | 2 (28.6)           |
| >6  | 20 (9.2)             | 20 (9.5)             | 0                  |
| Missing   | 23 (10.6)            | 21 (10.0)            | 2 (28.6)           |
| Number of flares in the last 6 months, mean (range) | 4.0 (0–50)<br>n=194  | 4.0 (0–50)<br>n=189  | 3.2 (1–6)<br>n=5   |
| Average duration of flares in last 6 months, n (%)  |                      |                      |                    |
| ≤2 days   | 46 (21.2)            | 44 (21.0)            | 2 (28.6)           |
| 3–7 days  | 55 (25.3)            | 53 (25.2)            | 2 (28.6)           |
| 8–14 days   | 41 (18.9)            | 41 (19.5)            | 0                  |
| ≥15 days  | 40 (18.4)            | 39 (18.6)            | 1 (14.3)           |
| Missing   | 35 (16.1)            | 33 (15.7)            | 2 (28.6)           |
| Inadequately controlled AD, n (%)                   | 51 (23.5)            | 50 (23.8)            | 1 (14.3)           |
| SF-12 PCS, mean (SD)                                | NA                   | 49.6 (8.2)<br>n=202  | NA                 |
| SF-10 PHS, mean (SD)                                | NA                   | NA                   | 35.3 (18.0)<br>n=6 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 11.3. Psychosocial-Economic Burden of AD in Germany**

|   | <b>Total<br/>population<br/>(n=217)</b> | <b>Adults<br/>(n=210)</b> | <b>Adolescents<br/>(n=7)</b> |
|---|---|---------------------------|------------------------------|
| HADS-A, mean (SD)   | 6.7 (4.8)<br>n=212                      | 6.7 (4.8)<br>n=207        | 6.4 (3.6)<br>n=5             |
| HADS-A $\geq 8$ , n (%)   | 87 (40.1)                               | 85 (40.5)                 | 2 (28.6)                     |
| HADS-D, mean (SD)   | 5.6 (4.7)<br>n=212                      | 5.6 (4.7)<br>n=207        | 5.4 (4.5)<br>n=5             |
| HADS-D $\geq 8$ , n (%)   | 58 (26.7)                               | 57 (27.1)                 | 1 (14.3)                     |
| SF-12 MCS, mean (SD)  | NA                                      | 44.1 (12.3)<br>n=202      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                      | NA                        | 44.3 (17.4)<br>n=6           |
| ADerm-IS Daily Activities, mean (SD)  | 13.3 (11.7)<br>n=212                    | 13.3 (11.7)<br>n=208      | 14.5 (13.5)<br>n=4           |
| ADerm-IS Emotional State, mean (SD)   | 11.0 (10.2)<br>n=216                    | 11.0 (10.1)<br>n=209      | 11.4 (12.1)                  |
| WPAI-AD, Employed, n (%)  | 141 (65.0)                              | 141 (67.1)                | 0                            |
| Absenteeism, %, mean (SD)   | 12.9 (25.4)<br>n=118                    | 12.9 (25.4)<br>n=118      | –                            |
| Presenteeism, %, mean (SD)  | 25.6 (24.9)<br>n=127                    | 25.6 (24.9)<br>n=127      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 31.4 (28.3)<br>n=112                    | 31.4 (28.3)<br>n=112      | –                            |
| Activity impairment, %, mean (SD)   | 32.5 (29.2)<br>n=205                    | 32.4 (29.3)<br>n=200      | 38.0 (25.9)<br>n=5           |
| Hours missed from work, mean (SD)   | 4.4 (9.8)<br>n=124                      | 4.4 (9.8)<br>n=124        | –                            |
| HCRU  |   |                           |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 3.0 (4.9)<br>n=190                      | 3.0 (5.0)<br>n=183        | 1.0 (1.2)                    |
| <b>Out of pocket expenses</b>   |   |                           |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 131.9 (135.8)<br>n=181                  | 133.5 (137.3)<br>n=175    | 86.7 (70.6)<br>n=6           |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 12.1. Baseline Patient Demographics and Characteristics in Greece**

|  | <b>Total population<br/>(n=80)</b> | <b>Adults<br/>(n=69)</b> | <b>Adolescents<br/>(n=11)</b> |
|--|------------------------------------|--------------------------|-------------------------------|
| Age, years, mean (SD)  | 34.9 (16.3)                        | 38.2 (15.0)              | 13.6 (1.8)                    |
| Male, n (%)  | 36 (45.0)                          | 30 (43.5)                | 6 (54.5)                      |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 24.6 (4.9)                         | 25.2 (5.0)               | 21.4 (3.1)                    |
| Employed, n (%)  | 45 (56.3)                          | 45 (65.2)                | 0                             |
| Duration of AD, years, mean (SD)                                   | 18.3 (15.0)                        | 20.3 (15.1)              | 5.7 (5.7)                     |
| Time from AD diagnosis to first therapy, years mean (SD)           | 17.3 (13.4)<br>n=17                | 17.3 (13.4)<br>n=17      | –                             |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 15.6 (15.4)<br>n=46                | 17.0 (15.5)<br>n=42      | 1.5 (0.6)<br>n=4              |
| Continuous systemic therapy over previous 12 months, n (%)         | 3 (3.8)                            | 3 (4.3)                  | 0                             |
| Current therapy, n (%)   | 79 (98.8)                          | 68 (98.6)                | 11 (100.0)                    |
| Systemic monotherapy or in combination                             | 18 (22.5)                          | 14 (20.3)                | 4 (36.4)                      |
| Dupilumab  | 2 (11.1)                           | 2 (14.3)                 | 0                             |
| Systemic corticosteroids   | 13 (72.2)                          | 9 (64.3)                 | 4 (100.0)                     |
| Methotrexate   | 1 (5.6)                            | 1 (7.1)                  | 0                             |
| Cyclosporine   | 4 (22.2)                           | 4 (28.6)                 | 0                             |
| Azathioprine   | 0                                  | 0                        | 0                             |
| Mycophenolate  | 0                                  | 0                        | 0                             |
| Systemic monotherapy   | 1 (1.3)                            | 1 (1.4)                  | 0                             |
| Topical monotherapy or in combination                              | 78 (97.5)                          | 67 (97.1)                | 11 (100.0)                    |
| Topical monotherapy  | 36 (45.0)                          | 31 (44.9)                | 5 (45.5)                      |
| TCS or TCI monotherapy   | 28 (35.0)                          | 26 (37.7)                | 2 (18.2)                      |
| Previous systemic therapy, n (%)                                   |                                    |                          |                               |
| Systemic monotherapy or in combination                             | 39 (48.8)                          | 39 (56.5)                | 0                             |
| Systemic monotherapy   | 3 (3.8)                            | 3 (4.3)                  | 0                             |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                             |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                             |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                               |
| Topical therapy received as monotherapy                            | 71 (88.8)                          | 62 (89.9)                | 9 (81.8)                      |
| Suboptimal response to topical monotherapy                         | 70 (87.5)                          | 61 (88.4)                | 9 (81.8)                      |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 12.2. Physician-Reported and Patient-Reported Clinical Outcomes in Greece**

|  | <b>Total<br/>population<br/>(n=80)</b> | <b>Adults<br/>(n=69)</b> | <b>Adolescents<br/>(n=11)</b> |
|--|--|--------------------------|-------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                               |
| EASI, mean (SD)  | 11.8 (11.6)                            | 11.6 (12.2)              | 12.9 (6.9)                    |
| EASI categories, n (%)   |  |                          |                               |
| Clear (0)  | 3 (3.8)                                | 3 (4.3)                  | 0                             |
| Mild (0.1–5.9)   | 31 (38.8)                              | 28 (40.6)                | 3 (27.3)                      |
| Moderate (6.0–22.9)  | 37 (46.3)                              | 29 (42.0)                | 8 (72.7)                      |
| Severe (23.0–72.0)   | 9 (11.3)                               | 9 (13.0)                 | 0                             |
| SCORAD, mean (SD)  | 40.0 (20.6)                            | 39.2 (21.7)              | 44.7 (11.8)                   |
| SCORAD categories, n (%)   |  |                          |                               |
| Mild (<25.0)   | 23 (28.8)                              | 22 (31.9)                | 1 (9.1)                       |
| Moderate (25.0–50.0)   | 32 (40.0)                              | 26 (37.7)                | 6 (54.5)                      |
| Severe (>50.0)   | 25 (31.3)                              | 21 (30.4)                | 4 (36.4)                      |
| vIGA-AD, mean (SD)   | 2.3 (1.1)                              | 2.3 (1.1)                | 2.6 (0.7)                     |
| Clear (0)  | 3 (3.8)                                | 3 (4.3)                  | 0                             |
| Almost clear (1)   | 18 (22.5)                              | 17 (24.6)                | 1 (9.1)                       |
| Mild (2)   | 17 (21.3)                              | 15 (21.7)                | 2 (18.2)                      |
| Moderate (3)   | 34 (42.5)                              | 26 (37.7)                | 8 (72.7)                      |
| Severe (4)   | 8 (10.0)                               | 8 (11.6)                 | 0                             |
| BSA, % affected, mean (SD)   | 17.5 (16.9)                            | 17.3 (16.8)              | 19.1 (18.3)                   |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.7 (1.8)<br>n=77                      | 6.5 (1.8)<br>n=67        | 8.1 (1.3)<br>n=10             |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 31.9 (28.7)                            | 30.4 (25.7)              | 41.4 (43.5)                   |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                               |
| I do not have sleep problems   | 0                                      | 0                        | 0                             |
| Not at all   | 19 (23.8)                              | 16 (23.2)                | 3 (27.3)                      |
| A little   | 31 (38.8)                              | 29 (42.0)                | 2 (18.2)                      |
| Somewhat   | 15 (18.8)                              | 10 (14.5)                | 5 (45.5)                      |
| Much   | 6 (7.5)                                | 5 (7.2)                  | 1 (9.1)                       |
| Very much  | 9 (11.3)                               | 9 (13.0)                 | 0                             |
| <b>Patient-reported outcomes</b>   |  |                          |                               |
| 5D-Pruritus score, mean (SD)   | 14.0 (4.1)<br>n=67                     | 14.0 (4.1)<br>n=67       | –                             |
| POEM, mean (SD)  | 14.9 (7.8)<br>n=69                     | 14.9 (7.8)               | –                             |
| Total ADerm-IS, mean (SD)  | 34.2 (24.0)<br>n=69                    | 34.2 (24.0)              | –                             |

|   |                     |                    |             |
|---|---------------------|--------------------|-------------|
| ADerm-IS Sleep domain, mean (SD)                    | 11.2 (9.7)<br>n=69  | 11.2 (9.7)         | –           |
| ADerm-SS TSS-7, mean (SD)                           | 30.5 (18.3)<br>n=69 | 30.5 (18.3)        | –           |
| ADerm-SS TSS-11, mean (SD)                          | 45.1 (28.6)<br>n=69 | 45.1 (28.6)        | –           |
| ADerm-SS Skin pain, mean (SD)                       | 3.2 (3.1)<br>n=69   | 3.2 (3.1)          | –           |
| Number of flares in last 6 months, n (%)            |                     |                    |             |
| 0   | 5 (6.3)             | 5 (7.2)            | 0           |
| 1–2   | 24 (30.0)           | 24 (34.8)          | 0           |
| 3–4   | 20 (25.0)           | 20 (29.0)          | 0           |
| 5–6   | 10 (12.5)           | 10 (14.5)          | 0           |
| >6  | 10 (12.5)           | 10 (14.5)          | 0           |
| Missing   | 11 (13.8)           | 0                  | 11 (100)    |
| Number of flares in the last 6 months, mean (range) | 3.9 (0–20)<br>n=69  | 3.9 (0–20)         | –           |
| Average duration of flares in last 6 months, n (%)  |                     |                    |             |
| ≤2 days   | 5 (6.3)             | 5 (7.2)            | 0           |
| 3–7 days  | 18 (22.5)           | 18 (26.1)          | 0           |
| 8–14 days   | 24 (30.0)           | 24 (34.8)          | 0           |
| ≥15 days  | 22 (27.5)           | 22 (31.9)          | 0           |
| Missing   | 11 (13.8)           | 0                  | 11 (100)    |
| Inadequately controlled AD, n (%)                   | 12 (15.0)           | 12 (17.4)          | 0           |
| SF-12 PCS, mean (SD)                                | NA                  | 52.3 (7.4)<br>n=67 | NA          |
| SF-10 PHS, mean (SD)                                | NA                  | NA                 | 39.2 (11.8) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 12.3. Psychosocial-Economic Burden of AD in Greece**

|   | <b>Total<br/>population<br/>(n=80)</b> | <b>Adults<br/>(n=69)</b> | <b>Adolescents<br/>(n=11)</b> |
|---|--|--------------------------|-------------------------------|
| HADS-A, mean (SD)   | 5.9 (3.7)<br>n=69                      | 5.9 (3.7)                | –                             |
| HADS-A $\geq 8$ , n (%)   | 21 (26.3)                              | 21 (30.4)                | –                             |
| HADS-D, mean (SD)   | 5.6 (3.8)<br>n=69                      | 5.6 (3.8)                | –                             |
| HADS-D $\geq 8$ , n (%)   | 21 (26.3)                              | 21 (30.4)                | –                             |
| SF-12 MCS, mean (SD)  | NA                                     | 45.9 (9.7)<br>n=67       | NA                            |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 46.7 (8.9)                    |
| ADerm-IS Daily Activities, mean (SD)  | 12.2 (10.2)<br>n=69                    | 12.2 (10.2)              | –                             |
| ADerm-IS Emotional State, mean (SD)   | 10.7 (8.8)<br>n=69                     | 10.7 (8.8)               | –                             |
| WPAI-AD, Employed, n (%)  | 45 (56.3)                              | 45 (65.2)                | 0                             |
| Absenteeism, %, mean (SD)   | 10.2 (21.8)<br>n=45                    | 10.2 (21.8)<br>n=45      | –                             |
| Presenteeism, %, mean (SD)  | 24.1 (19.4)<br>n=44                    | 24.1 (19.4)<br>n=44      | –                             |
| Overall work productivity impairment, %, mean (SD)  | 30.2 (23.2)<br>n=44                    | 30.2 (23.2)<br>n=44      | –                             |
| Activity impairment, %, mean (SD)   | 30.3 (25.8)<br>n=69                    | 30.3 (25.8)              | –                             |
| Hours missed from work, mean (SD)   | 3.5 (7.9)<br>n=45                      | 3.5 (7.9)<br>n=45        | –                             |
| HCRU  |  |                          |                               |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 1.4 (2.3)<br>n=64                      | 1.4 (2.3)<br>n=64        | –                             |
| <b>Out of pocket expenses</b>   |  |                          |                               |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 80.2 (68.9)<br>n=68                    | 80.2 (68.9)<br>n=68      | –                             |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 13.1. Baseline Patient Demographics and Characteristics in Hungary**

|  | <b>Total population<br/>(n=20)</b> | <b>Adults<br/>(n=19)</b> | <b>Adolescents<br/>(n=1)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 39.9 (17.8)                        | 41.2 (17.3)              | 15 (NA)                      |
| Male, n (%)  | 11 (55.0)                          | 10 (52.6)                | 1 (100.0)                    |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.1 (4.7)                         | 24.9 (4.8)               | 28.7 (NA)                    |
| Employed, n (%)  | 12 (60.0)                          | 12 (63.2)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 23.6 (14.7)                        | 24.1 (15.0)              | 14.0 (NA)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 5.1 (7.0)                          | 5.1 (7.0)                | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 18.2 (13.9)<br>n=14                | 18.5 (14.4)<br>n=13      | 13.7 (NA)                    |
| Continuous systemic therapy over previous 12 months, n (%)         | 7 (35.0)                           | 7 (36.8)                 | 0                            |
| Current therapy, n (%)   | 19 (95.0)                          | 18 (94.7)                | 1 (100.0)                    |
| Systemic monotherapy or in combination                             | 14 (70.0)                          | 13 (68.4)                | 1 (100.0)                    |
| Dupilumab  | 10 (71.4)                          | 10 (76.9)                | 0                            |
| Systemic corticosteroids   | 2 (14.3)                           | 2 (15.4)                 | 0                            |
| Methotrexate   | 2 (14.3)                           | 2 (15.4)                 | 0                            |
| Cyclosporine   | 2 (14.3)                           | 1 (7.7)                  | 1 (100.0)                    |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 4 (20.0)                           | 4 (21.1)                 | 0                            |
| Topical monotherapy or in combination                              | 14 (70.0)                          | 13 (68.4)                | 1 (100)                      |
| Topical monotherapy  | 3 (15.0)                           | 3 (15.8)                 | 0                            |
| TCS or TCI monotherapy   | 3 (15.0)                           | 3 (15.8)                 | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 13 (65.0)                          | 13 (68.4)                | 0                            |
| Systemic monotherapy   | 3 (15.0)                           | 3 (15.8)                 | 0                            |
| Dupilumab, monotherapy or in combination                           | 1 (5.0)                            | 1 (5.3)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 14 (70.0)                          | 13 (68.4)                | 1 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 12 (60.0)                          | 11 (57.9)                | 1 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 13.2. Physician-Reported and Patient-Reported Clinical Outcomes in Hungary**

|   | <b>Total<br/>population<br/>(n=20)</b> | <b>Adults<br/>(n=19)</b> | <b>Adolescents<br/>(n=1)</b> |
|---|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>  |  |                          |                              |
| EASI, mean (SD)   | 11.9 (11.3)                            | 12.0 (11.6)              | 8.8 (NA)                     |
| EASI categories, n (%)  |  |                          |                              |
| Clear (0)   | 2 (10.0)                               | 2 (10.5)                 | 0                            |
| Mild (0.1–5.9)  | 5 (25.0)                               | 5 (26.3)                 | 0                            |
| Moderate (6.0–22.9)   | 10 (50.0)                              | 9 (47.4)                 | 1 (100.0)                    |
| Severe (23.0–72.0)  | 3 (15.0)                               | 3 (15.8)                 | 0                            |
| SCORAD, mean (SD)   | 40.2 (20.8)                            | 40.3 (21.4)              | 37.6 (NA)                    |
| SCORAD categories, n (%)  |  |                          |                              |
| Mild (<25.0)  | 4 (20.0)                               | 4 (21.1)                 | 0                            |
| Moderate (25.0–50.0)  | 9 (45.0)                               | 8 (42.1)                 | 1 (100.0)                    |
| Severe (>50.0)  | 7 (35.0)                               | 7 (36.8)                 | 0                            |
| vIGA-AD, mean (SD)  | 2.4 (1.2)                              | 2.4 (1.3)                | 2.0 (NA)                     |
| Clear (0)   | 2 (10.0)                               | 2 (10.5)                 | 0                            |
| Almost clear (1)  | 1 (5.0)                                | 1 (5.3)                  | 0                            |
| Mild (2)  | 9 (45.0)                               | 8 (42.1)                 | 1 (100.0)                    |
| Moderate (3)  | 3 (15.0)                               | 3 (15.8)                 | 0                            |
| Severe (4)  | 5 (25.0)                               | 5 (26.3)                 | 0                            |
| BSA, % affected, mean (SD)  | 21.9 (19.1)                            | 22.8 (19.3)              | 6.0 (NA)                     |
| Average hours of sleep per night in the past week, mean (SD)                | 6.7 (1.7)                              | 6.6 (1.7)                | 8.0 (NA)                     |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 24.5 (20.8)                            | 25.0 (21.2)              | 15.0 (NA)                    |
| Sleep problems interfered with daily function over the past week, n (%)     |  |                          |                              |
| I do not have sleep problems  | 1 (5.0)                                | 1 (5.3)                  | 0                            |
| Not at all  | 7 (35.0)                               | 6 (31.6)                 | 1 (100.0)                    |
| A little  | 4 (20.0)                               | 4 (21.1)                 | 0                            |
| Somewhat  | 2 (10.0)                               | 2 (10.5)                 | 0                            |
| Much  | 5 (25.0)                               | 5 (26.3)                 | 0                            |
| Very much   | 1 (5.0)                                | 1 (5.3)                  | 0                            |
| <b>Patient-reported outcomes</b>  |  |                          |                              |
| 5D-Pruritus score, mean (SD)  | 13.9 (4.3)<br>n=19                     | 14.3 (4.1)<br>n=18       | 8.0 (NA)                     |
| POEM, mean (SD)   | 14.1 (7.4)                             | 14.5 (7.3)               | 6.0 (NA)                     |
| Total ADerm-IS, mean (SD)   | 27.7 (25.3)                            | 28.7 (25.5)              | 8.0 (NA)                     |
| ADerm-IS Sleep domain   | 8.0 (8.2)                              | 8.4 (8.2)                | 1.0 (NA)                     |
| ADerm-SS TSS-7, mean  | 27.1 (18.8)                            | 28.2 (18.6)              | 6.0 (NA)                     |

|   |                    |                    |           |
|---|--------------------|--------------------|-----------|
| (SD)  |                    |                    |           |
| ADerm-SS TSS-11, mean (SD)                          | 36.1 (25.8)        | 37.6 (25.6)        | 8.0 (NA)  |
| ADerm-SS Skin pain, mean (SD)                       | 3.0 (3.0)          | 3.1 (3.1)          | 1.0 (NA)  |
| Number of flares in last 6 months, n (%)            |                    |                    |           |
| 0   | 3 (15.0)           | 3 (15.8)           | 0         |
| 1–2   | 6 (30.0)           | 5 (26.3)           | 1 (100.0) |
| 3–4   | 2 (10.0)           | 2 (10.5)           | 0         |
| 5–6   | 3 (15.0)           | 3 (15.8)           | 0         |
| >6  | 5 (25.0)           | 5 (26.3)           | 0         |
| Missing   | 1 (5.0)            | 1 (5.3)            | 0         |
| Number of flares in the last 6 months, mean (range) | 5.4 (0–20)<br>n=19 | 5.6 (0–20)<br>n=18 | 2.0 (2–2) |
| Average duration of flares in last 6 months, n (%)  |                    |                    |           |
| ≤2 days   | 4 (20.0)           | 4 (21.1)           | 0         |
| 3–7 days  | 10 (50.0)          | 9 (47.4)           | 1 (100.0) |
| 8–14 days   | 2 (10.0)           | 2 (10.5)           | 0         |
| ≥15 days  | 3 (15.0)           | 3 (15.8)           | 0         |
| Missing   | 1 (5.0)            | 1 (5.3)            | 0         |
| Inadequately controlled AD, n (%)                   | 5 (25.0)           | 5 (26.3)           | 0         |
| SF-12 PCS, mean (SD)                                | NA                 | 51.2 (6.1)         | NA        |
| SF-10 PHS, mean (SD)                                | NA                 | NA                 | 51.1 (NA) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 13.3. Psychosocial-Economic Burden of AD in Hungary**

|   | <b>Total<br/>population<br/>(n=20)</b> | <b>Adults<br/>(n=19)</b> | <b>Adolescents<br/>(n=1)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 6.3 (4.0)<br>n=19                      | 6.1 (4.0)<br>n=18        | 10.0 (NA)                    |
| HADS-A $\geq 8$ , n (%)   | 9 (45.0)                               | 8 (42.1)                 | 1 (100.0)                    |
| HADS-D, mean (SD)   | 4.2 (3.4)<br>n=19                      | 4.1 (3.5)<br>n=18        | 5.0 (NA)                     |
| HADS-D $\geq 8$ , n (%)   | 4 (20.0)                               | 4 (21.1)                 | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 42.7 (13.3)              | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 50.7 (NA)                    |
| ADerm-IS Daily Activities   | 9.5 (9.3)                              | 9.8 (9.5)                | 4.0 (NA)                     |
| ADerm-IS Emotional State  | 10.2 (9.5)                             | 10.5 (9.6)               | 3.0 (NA)                     |
| WPAI-AD, Employed, n (%)  | 12 (60.0)                              | 12 (63.2)                | 0                            |
| Absenteeism, %, mean (SD)   | 4.8 (10.1)<br>n=11                     | 4.8 (10.1)<br>n=11       | –                            |
| Presenteeism, %, mean (SD)  | 18.2 (22.7)<br>n=11                    | 18.2 (22.7)<br>n=11      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 20.7 (23.5)<br>n=11                    | 20.7 (23.5)<br>n=11      | –                            |
| Activity impairment, %, mean (SD)   | 28.4 (25.0)<br>n=19                    | 28.4 (25.0)              | –                            |
| Hours missed from work, mean (SD)   | 2.3 (5.4)<br>n=12                      | 2.3 (5.4)<br>n=12        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 2.4 (3.3)<br>n=17                      | 2.4 (3.4)<br>n=16        | 1.0 (NA)                     |
| Out of pocket expenses  |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 62.2 (36.3)<br>n=19                    | 62.2 (36.3)              | –                            |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 14.1. Baseline Patient Demographics and Characteristics in Ireland**

|  | <b>Total population<br/>(n=37)</b> | <b>Adults<br/>(n=25)</b> | <b>Adolescents<br/>(n=12)</b> |
|--|------------------------------------|--------------------------|-------------------------------|
| Age, years, mean (SD)  | 31.3 (15.3)                        | 39.0 (12.7)              | 15.3 (2.0)                    |
| Male, n (%)  | 24 (64.9)                          | 19 (76.0)                | 5 (41.7)                      |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 26.7 (6.0)                         | 27.7 (6.0)               | 24.5 (5.5)                    |
| Employed, n (%)  | 21 (56.8)                          | 20 (80.0)                | 1 (8.3)                       |
| Duration of AD, years, mean (SD)                                   | 24.8 (12.9)                        | 29.7 (13.0)              | 14.6 (2.8)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 20.2 (12.1)<br>n=3                 | 24.5 (13.5)<br>n=2       | 11.5 (NA)<br>n=1              |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 19.2 (13.4)<br>n=25                | 24.9 (15.7)<br>n=14      | 11.9 (2.5)<br>n=11            |
| Continuous systemic therapy over previous 12 months, n (%)         | 10 (27.0)                          | 5 (20.0)                 | 5 (41.7)                      |
| Current therapy, n (%)   | 37 (100.0)                         | 25 (100.0)               | 12 (100.0)                    |
| Systemic monotherapy or in combination                             | 20 (54.1)                          | 12 (48.0)                | 8 (66.7)                      |
| Dupilumab  | 7 (35.0)                           | 3 (25.0)                 | 4 (50.0)                      |
| Systemic corticosteroids   | 3 (15.0)                           | 3 (25.0)                 | 0                             |
| Methotrexate   | 10 (50.0)                          | 6 (50.0)                 | 4 (50.0)                      |
| Cyclosporine   | 2 (10.0)                           | 1 (8.3)                  | 1 (12.5)                      |
| Azathioprine   | 0                                  | 0                        | 0                             |
| Mycophenolate  | 0                                  | 0                        | 0                             |
| Systemic monotherapy   | 1 (2.7)                            | 1 (4.0)                  | 0                             |
| Topical monotherapy or in combination                              | 35 (94.6)                          | 23 (92.0)                | 12 (100.0)                    |
| Topical monotherapy  | 6 (16.2)                           | 3 (12.0)                 | 3 (25.0)                      |
| TCS or TCI monotherapy   | 3 (8.1)                            | 2 (8.0)                  | 1 (8.3)                       |
| Previous systemic therapy, n (%)                                   |                                    |                          |                               |
| Systemic monotherapy or in combination                             | 17 (45.9)                          | 10 (40.0)                | 7 (58.3)                      |
| Systemic monotherapy   | 1 (2.7)                            | 1 (4.0)                  | 0                             |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                             |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                             |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                               |
| Topical therapy received as monotherapy                            | 36 (97.3)                          | 24 (96.0)                | 12 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 36 (97.3)                          | 24 (96.0)                | 12 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 14.2. Physician-Reported and Patient-Reported Clinical Outcomes in Ireland**

|  | <b>Total<br/>population<br/>(n=37)</b> | <b>Adults<br/>(n=25)</b> | <b>Adolescents<br/>(n=12)</b> |
|--|--|--------------------------|-------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                               |
| EASI, mean (SD)  | 14.0 (15.2)                            | 14.4 (14.7)              | 13.2 (17.0)                   |
| EASI categories, n (%)   |  |                          |                               |
| Clear (0)  | 2 (5.4)                                | 1 (4.0)                  | 1 (8.3)                       |
| Mild (0.1–5.9)   | 15 (40.5)                              | 10 (40.0)                | 5 (41.7)                      |
| Moderate (6.0–22.9)  | 12 (32.4)                              | 9 (36.0)                 | 3 (25.0)                      |
| Severe (23.0–72.0)   | 8 (21.6)                               | 5 (20.0)                 | 3 (25.0)                      |
| SCORAD, mean (SD)  | 37.3 (23.2)                            | 41.4 (23.2)              | 29.2 (21.8)                   |
| SCORAD categories, n (%)   |  |                          |                               |
| Mild (<25.0)   | 13 (35.1)                              | 7 (28.0)                 | 6 (50.0)                      |
| Moderate (25.0–50.0)   | 14 (37.8)                              | 9 (36.0)                 | 5 (41.7)                      |
| Severe (>50.0)   | 9 (24.3)                               | 8 (32.0)                 | 1 (8.3)                       |
| Missing  | 1 (2.7)                                | 1 (4.0)                  | 0                             |
| vIGA-AD, mean (SD)   | 2.4 (1.3)                              | 2.5 (1.2)                | 2.3 (1.4)                     |
| Clear (0)  | 3 (8.1)                                | 2 (8.0)                  | 1 (8.3)                       |
| Almost clear (1)   | 6 (16.2)                               | 3 (12.0)                 | 3 (25.0)                      |
| Mild (2)   | 9 (24.3)                               | 7 (28.0)                 | 2 (16.7)                      |
| Moderate (3)   | 10 (27.0)                              | 7 (28.0)                 | 3 (25.0)                      |
| Severe (4)   | 9 (24.3)                               | 6 (24.0)                 | 3 (25.0)                      |
| BSA, % affected, mean (SD)   | 19.7 (22.4)                            | 18.5 (19.0)              | 22.3 (29.0)                   |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.5 (1.7)                              | 6.1 (1.7)                | 7.4 (1.4)                     |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 38.0 (43.1)                            | 40.6 (48.6)              | 32.5 (29.4)                   |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                               |
| I do not have sleep problems   | 0                                      | 0                        | 0                             |
| Not at all   | 16 (43.2)                              | 7 (28.0)                 | 9 (75.0)                      |
| A little   | 8 (21.6)                               | 7 (28.0)                 | 1 (8.3)                       |
| Somewhat   | 5 (13.5)                               | 4 (16.0)                 | 1 (8.3)                       |
| Much   | 3 (8.1)                                | 3 (12.0)                 | 0                             |
| Very much  | 5 (13.5)                               | 4 (16.0)                 | 1 (8.3)                       |
| <b>Patient-reported outcomes</b>   |  |                          |                               |
| 5D-Pruritus score, mean (SD)   | 13.4 (4.9)<br>n=36                     | 14.5 (4.8)               | 10.8 (4.1)<br>n=11            |
| POEM, mean (SD)  | 12.6 (8.7)                             | 15.1 (8.2)               | 7.5 (7.5)                     |
| Total ADerm-IS, mean (SD)  | 27.3 (24.8)<br>n=36                    | 33.3 (25.8)<br>n=24      | 15.3 (17.9)                   |

|   |                     |                     |             |
|---|---------------------|---------------------|-------------|
| ADerm-IS Sleep domain, mean (SD)                    | 9.2 (9.6)           | 12.1 (10.1)         | 3.2 (4.6)   |
| ADerm-SS TSS-7, mean (SD)                           | 22.1 (18.9)         | 28.2 (19.4)         | 9.2 (8.8)   |
| ADerm-SS TSS-11, mean (SD)                          | 30.4 (27.9)<br>n=36 | 39.2 (29.5)<br>n=24 | 12.8 (12.2) |
| ADerm-SS Skin pain, mean (SD)                       | 3.0 (3.0)           | 3.7 (3.1)           | 1.6 (2.5)   |
| Number of flares in last 6 months, n (%)            |                     |                     |             |
| 0   | 5 (13.5)            | 1 (4.0)             | 4 (33.3)    |
| 1–2   | 9 (24.3)            | 7 (28.0)            | 2 (16.7)    |
| 3–4   | 11 (29.7)           | 8 (32.0)            | 3 (25.0)    |
| 5–6   | 4 (10.8)            | 2 (8.0)             | 2 (16.7)    |
| >6  | 5 (13.5)            | 4 (16.0)            | 1 (8.3)     |
| Missing   | 3 (8.1)             | 3 (12.0)            | 0           |
| Number of flares in the last 6 months, mean (range) | 3.9 (0–24)<br>n=34  | 4.3 (0–24)<br>n=22  | 3.3 (0–14)  |
| Average duration of flares in last 6 months, n (%)  |                     |                     |             |
| ≤2 days   | 7 (18.9)            | 4 (16.0)            | 3 (25.0)    |
| 3–7 days  | 18 (48.6)           | 13 (52.0)           | 5 (41.7)    |
| 8–14 days   | 6 (16.2)            | 3 (12.0)            | 3 (25.0)    |
| ≥15 days  | 3 (8.1)             | 2 (8.0)             | 1 (8.3)     |
| Missing   | 3 (8.1)             | 3 (12.0)            | 0           |
| Inadequately controlled AD, n (%)                   | 4 (10.8)            | 4 (16.0)            | 0           |
| SF-12 PCS, mean (SD)                                | NA                  | 52.3 (6.7)          | NA          |
| SF-10 PHS, mean (SD)                                | NA                  | NA                  | 43.4 (13.7) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 14.3. Psychosocial-Economic Burden of AD in Ireland**

|   | <b>Total<br/>population<br/>(n=37)</b> | <b>Adults<br/>(n=25)</b> | <b>Adolescents<br/>(n=12)</b> |
|---|--|--------------------------|-------------------------------|
| HADS-A, mean (SD)   | 8.2 (4.5)                              | 9.0 (4.8)                | 6.7 (3.7)                     |
| HADS-A $\geq 8$ , n (%)   | 21 (56.8)                              | 16 (64.0)                | 5 (41.7)                      |
| HADS-D, mean (SD)   | 5.0 (4.3)                              | 5.8 (4.2)                | 3.4 (4.0)                     |
| HADS-D $\geq 8$ , n (%)   | 11 (29.7)                              | 9 (36.0)                 | 2 (16.7)                      |
| SF-12 MCS, mean (SD)  | NA                                     | 41.0 (11.3)<br>n=22      | NA                            |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 52.2 (12.0)<br>n=9            |
| ADerm-IS Daily Activities, mean (SD)  | 7.6 (9.0)<br>n=36                      | 8.6 (9.3)<br>n=24        | 5.6 (8.4)                     |
| ADerm-IS Emotional State, mean (SD)   | 11.4 (10.8)                            | 13.8 (11.0)              | 6.5 (8.8)                     |
| WPAI-AD, Employed, n (%)  | 21 (56.8)                              | 20 (80.0)                | 1 (8.3)                       |
| Absenteeism, %, mean (SD)   | 9.1 (25.1)<br>n=16                     | 9.1 (25.1)<br>n=16       | –                             |
| Presenteeism, %, mean (SD)  | 24.4 (25.3)<br>n=16                    | 24.4 (25.3)<br>n=16      | –                             |
| Overall work productivity impairment, %, mean (SD)  | 26.1 (26.7)<br>n=15                    | 26.1 (26.7)<br>n=15      | –                             |
| Activity impairment, %, mean (SD)   | 23.1 (25.1)<br>n=36                    | 27.2 (26.2)              | 13.6 (20.1)<br>n=11           |
| Hours missed from work, mean (SD)   | 10.1 (38.4)<br>n=19                    | 10.7 (39.4)<br>n=18      | 0.0 (NA)<br>n=1               |
| HCRU  |  |                          |                               |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 2.2 (4.9)<br>n=33                      | 3.0 (5.6)<br>n=24        | 0.3 (0.7)<br>n=9              |
| Out of pocket expenses  |  |                          |                               |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 177.1 (110.6)<br>n=31                  | 171.5 (105.5)<br>n=21    | 188.8 (125.9)<br>n=10         |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 15.1. Baseline Patient Demographics and Characteristics in Israel.**

|  | <b>Total population<br/>(n=38)</b> | <b>Adults<br/>(n=33)</b> | <b>Adolescents<br/>(n=5)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 34.8 (18.6)                        | 38.0 (18.0)              | 14.2 (1.8)                   |
| Male, n (%)  | 23 (60.5)                          | 23 (69.7)                | 0                            |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 24.8 (4.6)<br>n=36                 | 25.1 (4.6)<br>n=31       | 23.3 (4.1)                   |
| Employed, n (%)  | 24 (63.2)                          | 23 (69.7)                | 1 (20.0)                     |
| Duration of AD, years, mean (SD)                                   | 18.8 (13.4)                        | 19.9 (14.1)              | 11.8 (2.9)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 21.5 (NA)<br>n=1                   | 21.5 (NA)<br>n=1         | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 16.3 (13.1)<br>n=21                | 16.3 (13.4)<br>n=20      | 15.4 (NA)<br>n=1             |
| Continuous systemic therapy over previous 12 months, n (%)         | 1 (2.6)                            | 1 (3.0)                  | 0                            |
| Current therapy, n (%)   | 37 (97.4)                          | 32 (97.0)                | 5 (100.0)                    |
| Systemic monotherapy or in combination                             | 15 (39.5)                          | 14 (42.4)                | 1 (20.0)                     |
| Dupilumab  | 6 (40.0)                           | 6 (42.9)                 | 0                            |
| Systemic corticosteroids   | 2 (13.3)                           | 2 (14.3)                 | 0                            |
| Methotrexate   | 7 (46.7)                           | 6 (42.9)                 | 1 (100.0)                    |
| Cyclosporine   | 1 (6.7)                            | 1 (7.1)                  | 0                            |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 2 (5.3)                            | 1 (3.0)                  | 1 (20.0)                     |
| Topical monotherapy or in combination                              | 32 (84.2)                          | 29 (87.9)                | 3 (60.0)                     |
| Topical monotherapy  | 6 (15.8)                           | 5 (15.2)                 | 1 (20.0)                     |
| TCS or TCI monotherapy   | 5 (13.2)                           | 4 (12.1)                 | 1 (20.0)                     |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 18 (47.4)                          | 18 (54.5)                | 0                            |
| Systemic monotherapy   | 1 (2.6)                            | 1 (3.0)                  | 0                            |
| Dupilumab, monotherapy or in combination                           | 4 (10.5)                           | 4 (12.1)                 | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 28 (73.7)                          | 24 (72.7)                | 4 (80.0)                     |
| Suboptimal response to topical monotherapy                         | 30 (78.9)                          | 26 (78.8)                | 4 (80.0)                     |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 15.2. Physician-Reported and Patient-Reported Clinical Outcomes in Israel**

|  | <b>Total<br/>population<br/>(n=38)</b> | <b>Adults<br/>(n=33)</b> | <b>Adolescents<br/>(n=5)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 20.3 (14.6)<br>n=36                    | 20.7 (15.2)<br>n=31      | 17.4 (11.1)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Mild (0.1–5.9)   | 8 (21.1)                               | 7 (21.2)                 | 1 (20.0)                     |
| Moderate (6.0–22.9)  | 13 (34.2)                              | 10 (30.3)                | 3 (60.0)                     |
| Severe (23.0–72.0)   | 15 (39.5)                              | 14 (42.4)                | 1 (20.0)                     |
| Missing  | 2 (5.3)                                | 2 (6.1)                  | 0                            |
| SCORAD, mean (SD)  | 53.5 (20.0)<br>n=37                    | 53.5 (20.4)<br>n=32      | 53.5 (19.8)                  |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 5 (13.2)                               | 4 (12.1)                 | 1 (20.0)                     |
| Moderate (25.0–50.0)   | 9 (23.7)                               | 9 (27.3)                 | 0                            |
| Severe (>50.0)   | 23 (60.5)                              | 19 (57.6)                | 4 (80.0)                     |
| Missing  | 1 (2.6)                                | 1 (3.0)                  | 0                            |
| vIGA-AD, mean (SD)   | 3.0 (0.9)                              | 3.1 (0.8)                | 2.4 (0.9)                    |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Almost clear (1)   | 2 (5.3)                                | 1 (3.0)                  | 1 (20.0)                     |
| Mild (2)   | 8 (21.1)                               | 7 (21.2)                 | 1 (20.0)                     |
| Moderate (3)   | 16 (42.1)                              | 13 (39.4)                | 3 (60.0)                     |
| Severe (4)   | 12 (31.6)                              | 12 (36.4)                | 0                            |
| BSA, % affected, mean (SD)   | 36.2 (25.7)<br>n=36                    | 38.5 (26.7)<br>n=31      | 22.2 (12.1)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 5.6 (1.9)<br>n=36                      | 5.5 (1.9)<br>n=31        | 6.0 (2.2)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 47.6 (51.4)<br>n=36                    | 51.8 (54.3)<br>n=31      | 22.0 (7.6)                   |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 2 (5.3)                                | 2 (6.1)                  | 0                            |
| Not at all   | 11 (28.9)                              | 10 (30.3)                | 1 (20.0)                     |
| A little   | 3 (7.9)                                | 3 (9.1)                  | 0                            |
| Somewhat   | 8 (21.1)                               | 6 (18.2)                 | 2 (40.0)                     |
| Much   | 7 (18.4)                               | 5 (15.2)                 | 2 (40.0)                     |
| Very much  | 6 (15.8)                               | 6 (18.2)                 | 0                            |
| Missing  | 1 (2.6)                                | 1 (3.0)                  | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |

|   |                      |                      |                   |
|---|----------------------|----------------------|-------------------|
| 5D-Pruritus score, mean (SD)                        | 17.3 (4.2)<br>n=35   | 17.5 (3.9)<br>n=30   | 16.0 (6.0)        |
| POEM, mean (SD)                                     | 18.4 (8.4)<br>n=37   | 18.6 (8.2)<br>n=32   | 17.0 (10.1)       |
| Total ADerm-IS, mean (SD)                           | 53.0 (29.9)          | 51.7 (29.5)          | 61.4 (34.2)       |
| ADerm-IS Sleep domain, mean (SD)                    | 15.0 (10.7)          | 14.3 (10.7)          | 19.2 (10.4)       |
| ADerm-SS TSS-7, mean (SD)                           | 36.6 (20.8)          | 36.2 (20.3)          | 39.4 (26.3)       |
| ADerm-SS TSS-11, mean (SD)                          | 55.5 (31.4)          | 54.5 (30.4)          | 61.6 (40.9)       |
| ADerm-SS Skin pain, mean (SD)                       | 4.6 (3.7)            | 4.4 (3.6)            | 5.8 (4.6)         |
| Number of flares in last 6 months, n (%)            |                      |                      |                   |
| 0   | 3 (7.9)              | 2 (6.1)              | 1 (20.0)          |
| 1–2   | 8 (21.1)             | 8 (24.2)             | 0                 |
| 3–4   | 9 (23.7)             | 8 (24.2)             | 1 (20.0)          |
| 5–6   | 1 (2.6)              | 1 (3.0)              | 0                 |
| >6  | 11 (28.9)            | 9 (27.3)             | 2 (40.0)          |
| Missing   | 6 (15.8)             | 5 (15.2)             | 1 (20.0)          |
| Number of flares in the last 6 months, mean (range) | 12.0 (0–100)<br>n=32 | 12.6 (0–100)<br>n=28 | 7.5 (0–20)<br>n=4 |
| Average duration of flares in last 6 months, n (%)  |                      |                      |                   |
| ≤2 days   | 4 (10.5)             | 4 (12.1)             | 0                 |
| 3–7 days  | 8 (21.2)             | 7 (21.2)             | 1 (20.0)          |
| 8–14 days   | 5 (13.2)             | 3 (9.1)              | 2 (40.0)          |
| ≥15 days  | 14 (36.8)            | 14 (42.4)            | 0                 |
| Missing   | 7 (18.4)             | 5 (15.2)             | 2 (40.0)          |
| Inadequately controlled AD, n (%)                   | 11 (28.9)            | 10 (30.3)            | 1 (20.0)          |
| SF-12 PCS, mean (SD)                                | NA                   | 47.0 (10.5)<br>n=33  | NA                |
| SF-10 PHS, mean (SD)                                | NA                   | NA                   | 48.0 (8.2)<br>n=2 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 15.3. Psychosocial-Economic Burden of AD in Israel**

|   | <b>Total<br/>population<br/>(n=38)</b> | <b>Adults<br/>(n=33)</b> | <b>Adolescents<br/>(n=5)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 7.3 (5.0)<br>n=37                      | 7.4 (5.2)<br>n=33        | 6.8 (4.1)<br>n=4             |
| HADS-A $\geq 8$ , n (%)   | 20 (52.6)                              | 18 (54.5)                | 2 (40.0)                     |
| HADS-D, mean (SD)   | 6.3 (5.6)<br>n=36                      | 6.2 (5.7)<br>n=32        | 7.0 (5.3)<br>n=4             |
| HADS-D $\geq 8$ , n (%)   | 12 (31.6)                              | 10 (30.3)                | 2 (40.0)                     |
| SF-12 MCS, mean (SD)  | NA                                     | 42.8 (10.7)<br>n=33      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 51.1 (15.8)<br>n=2           |
| ADerm-IS Daily Activities, mean (SD)  | 19.0 (13.5)                            | 18.6 (13.6)              | 21.8 (14.0)                  |
| ADerm-IS Emotional State, mean (SD)   | 19.0 (9.5)                             | 18.8 (9.4)               | 20.4 (11.2)                  |
| WPAI-AD, Employed, n (%)  | 24 (63.2)                              | 23 (69.7)                | 1 (20.0)                     |
| Absenteeism, %, mean (SD)   | 29.9 (36.6)<br>n=23                    | 31.3 (36.8)<br>n=22      | 0 (NA)<br>n=1                |
| Presenteeism, %, mean (SD)  | 66.8 (30.9)<br>n=22                    | 65.7 (31.2)<br>n=21      | 90.0 (NA)<br>n=1             |
| Overall work productivity impairment, %, mean (SD)  | 79.3 (23.4)<br>n=21                    | 78.8 (23.9)<br>n=20      | 90.0 (NA)<br>n=1             |
| Activity impairment, %, mean (SD)   | 61.4 (31.5)<br>n=36                    | 62.2 (32.5)<br>n=32      | 55.0 (23.8)<br>n=4           |
| Hours missed from work, mean (SD)   | 14.3 (20.8)<br>n=23                    | 14.9 (21.0)<br>n=22      | 0 (NA)<br>n=1                |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 5.6 (9.5)<br>n=30                      | 6.2 (9.9)<br>n=27        | 0 (0.0)<br>n=3               |
| <b>Out of pocket expenses</b>   |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 267.0 (302.2)<br>n=33                  | 229.2 (217.0)<br>n=28    | 478.2 (589.1)                |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 16.1. Baseline Patient Demographics and Characteristics in Italy**

|  | <b>Total population<br/>(n=121)</b> | <b>Adults<br/>(n=118)</b> | <b>Adolescents<br/>(n=3)</b> |
|--|-------------------------------------|---------------------------|------------------------------|
| Age, years, mean (SD)  | 37.1 (15.7)                         | 37.7 (15.4)               | 15.0 (2.7)                   |
| Male, n (%)  | 65 (53.7)                           | 63 (53.4)                 | 2 (66.7)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 23.7 (3.6)                          | 23.8 (3.6)                | 22.5 (3.1)                   |
| Employed, n (%)  | 62 (51.2)                           | 62 (52.5)                 | 0                            |
| Duration of AD, years, mean (SD)                                   | 24.1 (15.3)<br>n=109                | 24.4 (15.4)<br>n=106      | 12.7 (2.1)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 11.1 (14.6)<br>n=20                 | 11.6 (14.8)<br>n=19       | 0.9 (NA)<br>n=1              |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 19.0 (14.2)<br>n=76                 | 19.3 (14.1)<br>n=75       | 0.9 (NA)<br>n=1              |
| Continuous systemic therapy over previous 12 months, n (%)         | 23 (19.0)                           | 23 (19.5)                 | 0                            |
| Current therapy, n (%)   | 117 (96.7)                          | 114 (96.6)                | 3 (100.0)                    |
| Systemic monotherapy or in combination                             | 91 (75.2)                           | 91 (77.1)                 | 0                            |
| Dupilumab  | 67 (73.6)                           | 67 (73.6)                 | –                            |
| Systemic corticosteroids   | 4 (4.4)                             | 4 (4.4)                   | –                            |
| Methotrexate   | 4 (4.4)                             | 4 (4.4)                   | –                            |
| Cyclosporine   | 19 (20.9)                           | 19 (20.9)                 | –                            |
| Azathioprine   | 0                                   | 0                         | –                            |
| Mycophenolate  | 0                                   | 0                         | –                            |
| Systemic monotherapy   | 52 (43.0)                           | 52 (44.1)                 | 0                            |
| Topical monotherapy or in combination                              | 56 (46.3)                           | 53 (44.9)                 | 3 (100.0)                    |
| Topical monotherapy  | 4 (3.3)                             | 4 (3.4)                   | 0                            |
| TCS or TCI monotherapy   | 4 (3.3)                             | 4 (3.4)                   | 0                            |
| Previous systemic therapy, n (%)                                   |                                     |                           |                              |
| Systemic monotherapy or in combination                             | 69 (57.0)                           | 68 (57.6)                 | 1 (33.3)                     |
| Systemic monotherapy   | 7 (5.8)                             | 7 (5.9)                   | 0                            |
| Dupilumab, monotherapy or in combination                           | 0                                   | 0                         | 0                            |
| Dupilumab monotherapy  | 0                                   | 0                         | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                     |                           |                              |
| Topical therapy received as monotherapy                            | 109 (90.1)                          | 106 (89.8)                | 3 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 88 (72.7)                           | 87 (73.7)                 | 1 (33.3)                     |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 16.2. Physician-Reported and Patient-Reported Clinical Outcomes in Italy**

|  | <b>Total<br/>population<br/>(n=121)</b> | <b>Adults<br/>(n=118)</b> | <b>Adolescents<br/>(n=3)</b> |
|--|---|---------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |   |                           |                              |
| EASI, mean (SD)  | 12.1 (12.9)                             | 11.2 (11.5)               | 50.5 (6.6)                   |
| EASI categories, n (%)   |   |                           |                              |
| Clear (0)  | 12 (9.9)                                | 12 (10.2)                 | 0                            |
| Mild (0.1–5.9)   | 38 (31.4)                               | 38 (32.2)                 | 0                            |
| Moderate (6.0–22.9)  | 46 (38.0)                               | 46 (39.0)                 | 0                            |
| Severe (23.0–72.0)   | 25 (20.7)                               | 22 (18.6)                 | 3 (100.0)                    |
| SCORAD, mean (SD)  | 38.6 (24.3)                             | 38.0 (24.2)               | 65.2 (10.7)                  |
| SCORAD categories, n (%)   |   |                           |                              |
| Mild (<25.0)   | 40 (33.1)                               | 40 (33.9)                 | 0                            |
| Moderate (25.0–50.0)   | 39 (32.2)                               | 39 (33.1)                 | 0                            |
| Severe (>50.0)   | 42 (34.7)                               | 39 (33.1)                 | 3 (100.0)                    |
| vIGA-AD, mean (SD)   | 2.1 (1.3)                               | 2.1 (1.3)                 | 3.7 (0.6)                    |
| Clear (0)  | 14 (11.6)                               | 14 (11.9)                 | 0                            |
| Almost clear (1)   | 29 (24.0)                               | 29 (24.6)                 | 0                            |
| Mild (2)   | 29 (24.0)                               | 29 (24.6)                 | 0                            |
| Moderate (3)   | 28 (23.1)                               | 27 (22.9)                 | 1 (33.3)                     |
| Severe (4)   | 21 (17.4)                               | 19 (16.1)                 | 2 (66.7)                     |
| BSA, % affected, mean (SD)   | 20.0 (21.8)                             | 18.7 (20.3)               | 71.7 (18.6)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.5 (1.7)                               | 6.5 (1.7)                 | 6.7 (1.5)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 31.1 (31.4)                             | 31.1 (31.7)               | 33.3 (25.2)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |   |                           |                              |
| I do not have sleep problems   | 7 (5.8)                                 | 7 (5.9)                   | 0                            |
| Not at all   | 42 (34.7)                               | 42 (35.6)                 | 0                            |
| A little   | 32 (26.4)                               | 30 (25.4)                 | 2 (66.7)                     |
| Somewhat   | 17 (14.0)                               | 17 (14.4)                 | 0                            |
| Much   | 13 (10.7)                               | 12 (10.2)                 | 1 (33.3)                     |
| Very much  | 10 (8.3)                                | 10 (8.5)                  | 0                            |
| <b>Patient-reported outcomes</b>   |   |                           |                              |
| 5D-Pruritus score, mean (SD)   | 14.0 (4.6)<br>n=115                     | 13.9 (4.6)<br>n=112       | 15.3 (2.9)                   |
| POEM, mean (SD)  | 13.2 (8.3)                              | 13.1 (8.3)                | 19.7 (3.8)                   |
| Total ADerm-IS, mean (SD)  | 37.5 (30.1)<br>n=120                    | 37.5 (30.4)<br>n=117      | 34.7 (20.6)                  |
| ADerm-IS Sleep domain,   | 11.8 (10.2)                             | 11.9 (10.2)               | 7.7 (10.8)                   |

|   |                      |                      |             |
|---|----------------------|----------------------|-------------|
| mean (SD)   |                      |                      |             |
| ADerm-SS TSS-7, mean (SD)                           | 32.5 (21.6)<br>n=119 | 32.4 (21.9)<br>n=116 | 36.0 (6.2)  |
| ADerm-SS TSS-11, mean (SD)                          | 47.8 (33.1)<br>n=117 | 47.8 (33.5)<br>n=114 | 50.7 (12.2) |
| ADerm-SS Skin pain, mean (SD)                       | 4.2 (3.5)            | 4.1 (3.5)            | 5.7 (5.1)   |
| Number of flares in last 6 months, n (%)            |                      |                      |             |
| 0   | 28 (23.1)            | 28 (23.7)            | 0           |
| 1–2   | 44 (36.4)            | 42 (35.6)            | 2 (66.7)    |
| 3–4   | 18 (14.9)            | 17 (14.4)            | 1 (33.3)    |
| 5–6   | 9 (7.4)              | 9 (7.6)              | 0           |
| >6  | 18 (14.9)            | 18 (15.3)            | 0           |
| Missing   | 4 (3.3)              | 4 (3.4)              | 0           |
| Number of flares in the last 6 months, mean (range) | 3.5 (0–30)<br>n=117  | 3.5 (0–30)<br>n=114  | 2.0 (1–3)   |
| Average duration of flares in last 6 months, n (%)  |                      |                      |             |
| ≤2 days   | 30 (24.8)            | 30 (25.4)            | 0           |
| 3–7 days  | 33 (27.3)            | 31 (26.3)            | 2 (66.7)    |
| 8–14 days   | 10 (8.3)             | 9 (7.6)              | 1 (33.3)    |
| ≥15 days  | 41 (33.9)            | 41 (34.7)            | 0           |
| Missing   | 7 (5.8)              | 7 (5.9)              | 0           |
| Inadequately controlled AD, n (%)                   | 31 (25.6)            | 31 (26.3)            | 0 (0.0)     |
| SF-12 PCS, mean (SD)                                | NA                   | 50.8 (7.7)<br>n=115  | NA          |
| SF-10 PHS, mean (SD)                                | NA                   | NA                   | 37.9 (20.2) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 16.3. Psychosocial-Economic Burden of AD in Italy**

|   | <b>Total<br/>population<br/>(n=121)</b> | <b>Adults<br/>(n=118)</b> | <b>Adolescents<br/>(n=3)</b> |
|---|---|---------------------------|------------------------------|
| HADS-A, mean (SD)   | 6.3 (4.1)<br>n=120                      | 6.3 (4.1)<br>n=117        | 7.7 (4.9)                    |
| HADS-A $\geq 8$ , n (%)   | 44 (36.4)                               | 42 (35.6)                 | 2 (66.7)                     |
| HADS-D, mean (SD)   | 5.1 (4.0)<br>n=120                      | 5.1 (4.0)<br>n=117        | 3.0 (2.0)                    |
| HADS-D $\geq 8$ , n (%)   | 37 (30.6)                               | 37 (31.4)                 | 0                            |
| SF-12 MCS, mean (SD)  | NA                                      | 44.0 (9.7)<br>n=115       | NA                           |
| SF-10 PSS, mean (SD)  | NA                                      | NA                        | 39.7 (8.9)                   |
| ADerm-IS Daily Activities, mean (SD)  | 13.9 (12.2)<br>n=120                    | 13.9 (12.3)<br>n=117      | 13.7 (6.4)                   |
| ADerm-IS Emotional State, mean (SD)   | 11.9 (10.2)                             | 11.8 (10.3)               | 13.3 (11.1)                  |
| WPAI-AD, Employed, n (%)  | 62 (51.2)                               | 62 (52.5)                 | 0                            |
| Absenteeism, %, mean (SD)   | 7.1 (18.1)<br>n=52                      | 7.1 (18.1)<br>n=52        | –                            |
| Presenteeism, %, mean (SD)  | 32.8 (29.6)<br>n=57                     | 32.8 (29.6)<br>n=57       | –                            |
| Overall work productivity impairment, %, mean (SD)  | 36.1 (30.9)<br>n=51                     | 36.1 (30.9)<br>n=51       | –                            |
| Activity impairment, %, mean (SD)   | 38.8 (31.4)<br>n=120                    | 38.6 (31.7)<br>n=117      | 50.0 (17.3)                  |
| Hours missed from work, mean (SD)   | 1.7 (5.6)<br>n=55                       | 1.7 (5.6)<br>n=55         | –                            |
| HCRU  |   |                           |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 2.7 (3.3)<br>n=114                      | 2.6 (3.2)<br>n=111        | 6.3 (5.1)                    |
| <b>Out of pocket expenses</b>   |   |                           |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 179.4 (160.8)<br>n=111                  | 179.8 (162.9)<br>n=108    | 165.4 (38.9)                 |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 17.1. Baseline Patient Demographics and Characteristics in Kuwait**

|  | <b>Adults*<br/>(n=7)</b> |
|--|--------------------------|
| Age, years, mean (SD)  | 32.9 (14.3)              |
| Male, n (%)  | 3 (42.9)                 |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 28.0 (6.8)               |
| Employed, n (%)  | 3 (42.9)                 |
| Duration of AD, years, mean (SD)                                   | 23.2 (7.2)               |
| Time from AD diagnosis to first therapy, years mean (SD)           | –                        |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 13.6 (7.0)<br>n=6        |
| Continuous systemic therapy over previous 12 months, n (%)         | 1 (14.3)                 |
| Current therapy, n (%)   | 7 (100.0)                |
| Systemic monotherapy or in combination                             | 4 (57.1)                 |
| Dupilumab  | 4 (100.0)                |
| Systemic corticosteroids   | 0                        |
| Methotrexate   | 0                        |
| Cyclosporine   | 0                        |
| Azathioprine   | 0                        |
| Mycophenolate  | 0                        |
| Systemic monotherapy   | 1 (14.3)                 |
| Topical monotherapy or in combination                              | 6 (85.7)                 |
| Topical monotherapy  | 2 (28.6)                 |
| TCS or TCI monotherapy   | 1 (14.3)                 |
| Previous systemic therapy, n (%)                                   |                          |
| Systemic monotherapy or in combination                             | 6 (85.7)                 |
| Systemic monotherapy   | 0                        |
| Dupilumab, monotherapy or in combination                           | 1 (14.3)                 |
| Dupilumab monotherapy  | 0                        |
| Treatment prior to study enrollment, n (%)                         |                          |
| Topical therapy received as monotherapy                            | 7 (100.0)                |
| Suboptimal response to topical monotherapy                         | 5 (71.4)                 |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

\*Only adult patients were included from Kuwait.

**Supplementary Table 17.2. Physician-Reported and Patient-Reported Clinical Outcomes in Kuwait**

|   | <b>Adults*<br/>(n=7)</b> |
|---|--------------------------|
| <b>Physician-reported outcomes</b>  |                          |
| EASI, mean (SD)   | 7.8 (5.5)                |
| EASI categories, n (%)  |                          |
| Clear (0)   | 0                        |
| Mild (0.1–5.9)  | 3 (42.9)                 |
| Moderate (6.0–22.9)   | 4 (57.1)                 |
| Severe (23.0–72.0)  | 0                        |
| SCORAD, mean (SD)   | 40.6 (7.4)               |
| SCORAD categories, n (%)  |                          |
| Mild (<25.0)  | 0                        |
| Moderate (25.0–50.0)  | 6 (85.7)                 |
| Severe (>50.0)  | 1 (14.3)                 |
| vIGA-AD, mean (SD)  | 1.7 (0.8)                |
| Clear (0)   | 0                        |
| Almost clear (1)  | 3 (42.9)                 |
| Mild (2)  | 3 (42.9)                 |
| Moderate (3)  | 1 (14.3)                 |
| Severe (4)  | 0                        |
| BSA, % affected, mean (SD)  | 14.8 (13.5)              |
| Average hours of sleep per night in the past week, mean (SD)                | 6.6 (1.5)                |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 55.7 (27.0)              |
| Sleep problems interfered with daily function over the past week, n (%)     |                          |
| I do not have sleep problems  | 1 (14.3)                 |
| Not at all  | 2 (28.6)                 |
| A little  | 2 (28.6)                 |
| Somewhat  | 1 (14.3)                 |
| Much  | 1 (14.3)                 |
| Very much   | 0                        |
| <b>Patient-reported outcomes</b>  |                          |
| 5D-Pruritus score, mean (SD)  | 13.3 (5.0)<br>n=6        |
| POEM, mean (SD)   | 10.6 (6.5)               |
| Total ADerm-IS, mean (SD)   | 35.0 (29.1)              |
| ADerm-IS Sleep domain, mean (SD)  | 9.9 (10.7)               |
| ADerm-SS TSS-7, mean (SD)   | 27.9 (19.2)              |
| ADerm-SS TSS-11, mean (SD)  | 37.4 (27.2)              |
| ADerm-SS Skin pain, mean (SD)   | 3.4 (2.9)                |
| Number of flares in last 6 months, n (%)                                    |                          |
| 0   | 0                        |
| 1–2   | 2 (28.6)                 |

|   |            |
|---|------------|
| 3–4   | 2 (28.6)   |
| 5–6   | 0          |
| >6  | 3 (42.9)   |
| Number of flares in the last 6 months, mean (range) | 6.6 (6.4)  |
| Average duration of flares in last 6 months, n (%)  |            |
| ≤2 days   | 1 (14.3)   |
| 3–7 days  | 3 (42.9)   |
| 8–14 days   | 2 (28.6)   |
| ≥15 days  | 1 (14.3)   |
| Inadequately controlled AD, n (%)                   | 0          |
| SF-12 PCS, mean (SD)                                | 48.9 (8.4) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

\*Only adult patients were included from Kuwait.

**Supplementary Table 17.3. Psychosocial-Economic Burden of AD in Kuwait**

|   | <b>Adults*<br/>(n=7)</b> |
|---|--------------------------|
| HADS-A, mean (SD)   | 8.0 (3.4)                |
| HADS-A $\geq 8$ , n (%)   | 4 (57.1)                 |
| HADS-D, mean (SD)   | 5.1 (3.6)                |
| HADS-D $\geq 8$ , n (%)   | 2 (28.6)                 |
| SF-12 MCS, mean (SD)  | 49.4 (12.0)              |
| ADerm-IS Daily Activities, mean (SD)  | 13.9 (14.4)              |
| ADerm-IS Emotional State, mean (SD)   | 11.3 (10.3)              |
| WPAI-AD, Employed, n (%)  | 3 (42.9)                 |
| Absenteeism, %, mean (SD)   | 19.8 (18.8)<br>n=3       |
| Presenteeism, %, mean (SD)  | 60.0 (17.3)<br>n=3       |
| Overall work productivity impairment, %, mean (SD)  | 67.7 (17.2)<br>n=3       |
| Activity impairment, %, mean (SD)   | 42.9 (35.9)              |
| Hours missed from work, mean (SD)   | 7.3 (6.4)<br>n=3         |
| HCRU  |                          |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 4.7 (4.1)<br>n=6         |
| Out of pocket expenses  |                          |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 1127.0 (824.8)<br>n=6    |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care resource utilization; SF-12 MCS, Short Form-12 Health Survey mental component summary (adults); USD, United States dollars (2021); WPAI-AD, work activity; Work Productivity and Activity Impairment Atopic Dermatitis.

\*Only adult patients were included from Kuwait.

**Supplementary Table 18.1. Baseline Patient Demographics and Characteristics in Mexico**

|  | <b>Total population<br/>(n=72)</b> | <b>Adults<br/>(n=64)</b> | <b>Adolescents<br/>(n=8)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 38.3 (19.3)                        | 41.2 (18.5)              | 15.1 (1.5)                   |
| Male, n (%)  | 34 (47.2)                          | 32 (50.0)                | 2 (25.0)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.3 (4.1)                         | 25.9 (3.8)               | 20.7 (3.3)                   |
| Employed, n (%)  | 28 (38.9)                          | 28 (43.8)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 13.9 (13.8)                        | 14.3 (14.5)              | 10.9 (4.8)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 9.0 (11.7)<br>n=24                 | 9.1 (12.4)<br>n=21       | 8.2 (5.0)<br>n=3             |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 8.3 (9.9)<br>n=59                  | 8.1 (10.4)<br>n=52       | 9.1 (5.3)<br>n=7             |
| Continuous systemic therapy over previous 12 months, n (%)         | 7 (9.7)                            | 7 (10.9)                 | 0                            |
| Current therapy, n (%)   | 72 (100.0)                         | 64 (100.0)               | 8 (100.0)                    |
| Systemic monotherapy or in combination                             | 47 (65.3)                          | 41 (64.1)                | 6 (75.0)                     |
| Dupilumab  | 10 (21.3)                          | 8 (19.5)                 | 2 (33.3)                     |
| Systemic corticosteroids   | 27 (57.4)                          | 24 (58.5)                | 3 (50.0)                     |
| Methotrexate   | 4 (8.5)                            | 4 (9.8)                  | 0                            |
| Cyclosporine   | 8 (17.0)                           | 8 (19.5)                 | 0                            |
| Azathioprine   | 1 (2.1)                            | 0                        | 1 (16.7)                     |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 4 (5.6)                            | 3 (4.7)                  | 1 (12.5)                     |
| Topical monotherapy or in combination                              | 51 (70.8)                          | 46 (71.9)                | 5 (62.5)                     |
| Topical monotherapy  | 2 (2.8)                            | 2 (3.1)                  | 0                            |
| TCS or TCI monotherapy   | 2 (2.8)                            | 2 (3.1)                  | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 36 (50.0)                          | 33 (51.6)                | 3 (37.5)                     |
| Systemic monotherapy   | 7 (9.7)                            | 6 (9.4)                  | 1 (12.5)                     |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 7 (9.7)                            | 7 (10.9)                 | 0                            |
| Suboptimal response to topical monotherapy                         | 5 (6.9)                            | 5 (7.8)                  | 0                            |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 18.2. Physician-Reported and Patient-Reported Clinical Outcomes in Mexico**

|  | <b>Total<br/>population<br/>(n=72)</b> | <b>Adults<br/>(n=64)</b> | <b>Adolescents<br/>(n=8)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 20.1 (11.3)                            | 21.2 (11.0)              | 11.4 (10.5)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 1 (1.4)                                | 0                        | 1 (12.5)                     |
| Mild (0.1–5.9)   | 0                                      | 0                        | 0                            |
| Moderate (6.0–22.9)  | 43 (59.7)                              | 37 (57.8)                | 6 (75.0)                     |
| Severe (23.0–72.0)   | 28 (38.9)                              | 27 (42.2)                | 1 (12.5)                     |
| SCORAD, mean (SD)  | 61.1 (16.4)<br>n=71                    | 63.1 (14.7)<br>n=63      | 45.4 (21.7)                  |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 1 (1.4)                                | 0                        | 1 (12.5)                     |
| Moderate (25.0–50.0)   | 15 (20.8)                              | 12 (18.8)                | 3 (37.5)                     |
| Severe (>50.0)   | 55 (76.4)                              | 51 (79.7)                | 4 (50.0)                     |
| Missing  | 1 (1.4)                                | 1 (1.6)                  | 0                            |
| vIGA-AD, mean (SD)   | 3.4 (0.6)                              | 3.4 (0.5)                | 2.8 (1.2)                    |
| Clear (0)  | 1 (1.4)                                | 0                        | 1 (12.5)                     |
| Almost clear (1)   | 0                                      | 0                        | 0                            |
| Mild (2)   | 0                                      | 0                        | 0                            |
| Moderate (3)   | 43 (59.7)                              | 37 (57.8)                | 6 (75.0)                     |
| Severe (4)   | 28 (38.9)                              | 27 (42.2)                | 1 (12.5)                     |
| BSA, % affected, mean (SD)   | 25.0 (20.1)                            | 27.0 (20.4)              | 8.6 (5.6)                    |
| Average hours of sleep per night in the past week, mean (SD)                   | 5.7 (1.6)                              | 5.5 (1.5)                | 7.5 (1.1)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 40.8 (36.2)                            | 43.3 (36.4)              | 21.3 (28.9)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 8 (11.1)                               | 6 (9.4)                  | 2 (25.0)                     |
| Not at all   | 13 (18.1)                              | 10 (15.6)                | 3 (37.5)                     |
| A little   | 5 (6.9)                                | 4 (6.3)                  | 1 (12.5)                     |
| Somewhat   | 10 (13.9)                              | 10 (15.6)                | 0                            |
| Much   | 19 (26.4)                              | 18 (28.1)                | 1 (12.5)                     |
| Very much  | 17 (23.6)                              | 16 (25.0)                | 1 (12.5)                     |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 17.4 (4.4)<br>n=71                     | 17.6 (4.3)               | 15.3 (5.4)<br>n=7            |
| POEM, mean (SD)  | 17.2 (6.7)                             | 17.5 (6.5)               | 14.4 (8.2)                   |
| Total ADerm-IS, mean (SD)  | 51.0 (31.3)                            | 53.2 (30.1)              | 33.4 (37.2)                  |

|   | n=71               | n=63               |                  |
|---|--------------------|--------------------|------------------|
| ADerm-IS Sleep domain, mean (SD)                    | 16.5 (11.3)        | 17.3 (11.0)        | 10.0 (12.6)      |
| ADerm-SS TSS-7, mean (SD)                           | 40.5 (20.6)        | 41.3 (20.1)        | 34.1 (24.3)      |
| ADerm-SS TSS-11, mean (SD)                          | 59.1 (31.2)        | 59.9 (30.7)        | 53.0 (37.0)      |
| ADerm-SS Skin pain, mean (SD)                       | 5.2 (3.8)          | 5.3 (3.8)          | 4.3 (3.5)        |
| Number of flares in last 6 months, n (%)            |                    |                    |                  |
| 0   | 2 (2.8)            | 2 (3.1)            | 0                |
| 1–2   | 27 (37.5)          | 25 (39.1)          | 2 (25.0)         |
| 3–4   | 28 (38.9)          | 23 (35.9)          | 5 (62.5)         |
| 5–6   | 4 (5.6)            | 3 (4.7)            | 1 (12.5)         |
| >6  | 10 (13.9)          | 10 (15.6)          | 0                |
| Missing   | 1 (1.4)            | 1 (1.6)            | 0                |
| Number of flares in the last 6 months, mean (range) | 4.0 (0–30)<br>n=71 | 4.1 (0–30)<br>n=63 | 3.4 (2–5)<br>n=8 |
| Average duration of flares in last 6 months, n (%)  |                    |                    |                  |
| ≤2 days   | 5 (6.9)            | 5 (7.8)            | 0                |
| 3–7 days  | 24 (33.3)          | 20 (31.3)          | 4 (50.0)         |
| 8–14 days   | 13 (18.1)          | 11 (17.2)          | 2 (25.0)         |
| ≥15 days  | 30 (41.7)          | 28 (43.8)          | 2 (25.0)         |
| Inadequately controlled AD, n (%)                   | 18 (25.0)          | 18 (28.1)          | 0                |
| SF-12 PCS, mean (SD)                                | NA                 | 45.8 (9.2)<br>n=62 | NA               |
| SF-10 PHS, mean (SD)                                | NA                 | NA                 | 34.5 (17.7)      |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 18.3. Psychosocial-Economic Burden of AD in Mexico**

|   | <b>Total<br/>population<br/>(n=72)</b> | <b>Adults<br/>(n=64)</b> | <b>Adolescents<br/>(n=8)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 9.6 (5.1)                              | 9.5 (5.2)                | 10.5 (4.4)                   |
| HADS-A $\geq 8$ , n (%)   | 47 (65.3)                              | 40 (62.5)                | 7 (87.5)                     |
| HADS-D, mean (SD)   | 6.6 (4.0)                              | 6.7 (4.0)                | 5.5 (4.7)                    |
| HADS-D $\geq 8$ , n (%)   | 29 (40.3)                              | 27 (42.2)                | 2 (25.0)                     |
| SF-12 MCS, mean (SD)  | NA                                     | 39.5 (11.3)<br>n=62      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 40.0 (10.1)                  |
| ADerm-IS Daily Activities, mean (SD)  | 18.0 (12.9)<br>n=71                    | 18.7 (12.5)<br>n=63      | 12.3 (15.3)                  |
| ADerm-IS Emotional State, mean (SD)   | 16.9 (10.4)                            | 17.6 (10.3)              | 11.1 (10.5)                  |
| WPAI-AD, Employed, n (%)  | 28 (38.9)                              | 28 (43.8)                | 0                            |
| Absenteeism, %, mean (SD)   | 18.4 (29.6)<br>n=27                    | 18.4 (29.6)<br>n=27      | –                            |
| Presenteeism, %, mean (SD)  | 33.6 (30.1)<br>n=25                    | 33.6 (30.1)<br>n=25      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 37.9 (31.5)<br>n=25                    | 37.9 (31.5)<br>n=25      | –                            |
| Activity impairment, %, mean (SD)   | 49.2 (36.7)                            | 52.0 (36.6)              | 26.3 (30.2)                  |
| Hours missed from work, mean (SD)   | 12.3 (33.0)<br>n=28                    | 12.3 (33.0)<br>n=28      | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 4.8 (4.5)<br>n=71                      | 4.7 (4.6)<br>n=63        | 5.6 (3.7)                    |
| Out of pocket expenses  |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 127.2 (174.7)<br>n=71                  | 124.2 (180.9)<br>n=63    | 151.0 (120.8)                |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 19.1. Baseline Patient Demographics and Characteristics in the Netherlands**

|  | <b>Adults*<br/>(n=14)</b> |
|--|---------------------------|
| Age, years, mean (SD)  | 36.5 (15.3)               |
| Male, n (%)  | 8 (57.1)                  |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.4 (5.5)                |
| Employed, n (%)  | 12 (85.7)                 |
| Duration of AD, years, mean (SD)                                   | 33.0 (14.6)               |
| Time from AD diagnosis to first therapy, years mean (SD)           | 33.7 (14.1)<br>n=5        |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 28.2 (15.9)               |
| Continuous systemic therapy over previous 12 months, n (%)         | 8 (57.1)                  |
| Current therapy, n (%)   | 14 (100.0)                |
| Systemic monotherapy or in combination                             | 12 (85.7)                 |
| Dupilumab  | 5 (41.7)                  |
| Systemic corticosteroids   | 0                         |
| Methotrexate   | 1 (8.3)                   |
| Cyclosporine   | 6 (50.0)                  |
| Azathioprine   | 0                         |
| Mycophenolate  | 0                         |
| Systemic monotherapy   | 0                         |
| Topical monotherapy or in combination                              | 14 (100.0)                |
| Topical monotherapy  | 1 (7.1)                   |
| TCS or TCI monotherapy   | 0                         |
| Previous systemic therapy, n (%)                                   |                           |
| Systemic monotherapy or in combination                             | 2 (14.3)                  |
| Systemic monotherapy   | 1 (7.1)                   |
| Dupilumab, monotherapy or in combination                           | 0                         |
| Dupilumab monotherapy  | 0                         |
| Treatment prior to study enrollment, n (%)                         |                           |
| Topical therapy received as monotherapy                            | 14 (100.0)                |
| Suboptimal response to topical monotherapy                         | 14 (100.0)                |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

\*Only adult patients were included from the Netherlands.

**Supplementary Table 19.2. Physician-Reported and Patient-Reported Clinical Outcomes in the Netherlands**

|   | <b>Adults*<br/>(n=14)</b> |
|---|---------------------------|
| <b>Physician-reported outcomes</b>  |                           |
| EASI, mean (SD)   | 6.0 (5.2)                 |
| EASI categories, n (%)  |                           |
| Clear (0)   | 0                         |
| Mild (0.1–5.9)  | 9 (64.3)                  |
| Moderate (6.0–22.9)   | 5 (35.7)                  |
| Severe (23.0–72.0)  | 0                         |
| SCORAD, mean (SD)   | 27.1 (11.0)               |
| SCORAD categories, n (%)  |                           |
| Mild (<25.0)  | 6 (42.9)                  |
| Moderate (25.0–50.0)  | 8 (57.1)                  |
| Severe (>50.0)  | 0                         |
| vIGA-AD, mean (SD)  | 1.9 (0.8)                 |
| Clear (0)   | 0                         |
| Almost clear (1)  | 5 (35.7)                  |
| Mild (2)  | 6 (42.9)                  |
| Moderate (3)  | 3 (21.4)                  |
| Severe (4)  | 0                         |
| BSA, % affected, mean (SD)  | 15.9 (13.1)               |
| Average hours of sleep per night in the past week, mean (SD)                | 7.2 (1.1)                 |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 35.7 (30.9)               |
| Sleep problems interfered with daily function over the past week, n (%)     |                           |
| I do not have sleep problems  | 2 (14.3)                  |
| Not at all  | 5 (35.7)                  |
| A little  | 3 (21.4)                  |
| Somewhat  | 3 (21.4)                  |
| Much  | 1 (7.1)                   |
| Very much   | 0                         |
| <b>Patient-reported outcomes</b>  |                           |
| 5D-Pruritus score, mean (SD)  | 14.5 (4.3)                |
| POEM, mean (SD)   | 17.9 (5.8)                |
| Total ADerm-IS, mean (SD)   | 33.8 (23.9)<br>n=13       |
| ADerm-IS Sleep domain, mean (SD)  | 9.6 (9.5)<br>n=13         |
| ADerm-SS TSS-7, mean (SD)   | 29.3 (16.5)               |
| ADerm-SS TSS-11, mean (SD)  | 40.9 (27.6)               |
| ADerm-SS Skin pain, mean (SD)   | 2.8 (3.2)                 |
| Number of flares in last 6 months, n (%)                                    |                           |
| 0   | 3 (21.4)                  |

|   |            |
|---|------------|
| 1–2   | 2 (14.3)   |
| 3–4   | 2 (14.3)   |
| 5–6   | 4 (28.6)   |
| >6  | 3 (21.4)   |
| Number of flares in the last 6 months, mean (range) | 4.9 (0–15) |
| Average duration of flares in last 6 months, n (%)  |            |
| ≤2 days   | 3 (21.4)   |
| 3–7 days  | 7 (50.0)   |
| 8–14 days   | 2 (14.3)   |
| ≥15 days  | 1 (7.1)    |
| Missing   | 1 (7.1)    |
| Inadequately controlled AD, n (%)                   | 1 (7.1)    |
| SF-12 PCS, mean (SD)                                | 50.3 (7.0) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

\*Only adult patients were included from the Netherlands.

**Supplementary Table 19.3. Psychosocial-Economic Burden of AD in the Netherlands**

|   | <b>Adults*<br/>(n=14)</b> |
|---|---------------------------|
| HADS-A, mean (SD)   | 6.9 (2.6)                 |
| HADS-A $\geq 8$ , n (%)   | 7 (50.0)                  |
| HADS-D, mean (SD)   | 3.9 (2.8)                 |
| HADS-D $\geq 8$ , n (%)   | 2 (14.3)                  |
| SF-12 MCS, mean (SD)  | 47.4 (9.7)                |
| ADerm-IS Daily Activities, mean (SD)  | 12.6 (11.6)               |
| ADerm-IS Emotional State, mean (SD)   | 10.5 (7.9)                |
| WPAI-AD, Employed, n (%)  | 12 (85.7)                 |
| Absenteeism, %, mean (SD)   | 0.27 (0.8)<br>n=10        |
| Presenteeism, %, mean (SD)  | 26.4 (35.9)<br>n=11       |
| Overall work productivity impairment, %, mean (SD)  | 21.1 (32.9)<br>n=10       |
| Activity impairment, %, mean (SD)   | 33.6 (29.8)               |
| Hours missed from work, mean (SD)   | 0.1 (0.3)<br>n=11         |
| HCRU  |                           |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 1.4 (1.6)<br>n=12         |
| Out of pocket expenses  |                           |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 137.8 (209.0)<br>n=12     |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care resource utilization; SF-12 MCS, Short Form-12 Health Survey mental component summary (adults); USD, United States dollars (2021); WPAI-AD, work activity; Work Productivity and Activity Impairment Atopic Dermatitis.

\*Only adult patients were included from the Netherlands.

**Supplementary Table 20.1. Baseline Patient Demographics and Characteristics in New Zealand**

|  | <b>Total population<br/>(n=40)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=1)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 37.7 (12.9)                        | 38.2 (12.7)              | 17.0 (NA)                    |
| Male, n (%)  | 24 (60.0)                          | 24 (61.5)                | 0                            |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 28.0 (5.7)                         | 28.2 (5.6)               | 20.5 (NA)                    |
| Employed, n (%)  | 28 (70.0)                          | 28 (71.8)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 31.5 (14.5)                        | 31.9 (14.5)              | 17.6 (NA)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 15.1 (13.6)<br>n=11                | 16.5 (13.5)<br>n=10      | 1.2 (NA)                     |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 20.5 (16.1)<br>n=36                | 21.1 (16.0)<br>n=35      | 1.2 (NA)                     |
| Continuous systemic therapy over previous 12 months, n (%)         | 17 (42.5)                          | 16 (41.0)                | 1 (100.0)                    |
| Current therapy, n (%)   | 40 (100.0)                         | 39 (100.0)               | 1 (100.0)                    |
| Systemic monotherapy or in combination                             | 26 (65.0)                          | 25 (64.1)                | 1 (100.0)                    |
| Dupilumab  | 0                                  | 0                        | 0                            |
| Systemic corticosteroids   | 8 (30.8)                           | 8 (32.0)                 | 0                            |
| Methotrexate   | 17 (65.4)                          | 16 (64.0)                | 1 (100.0)                    |
| Cyclosporine   | 6 (23.1)                           | 6 (24.0)                 | 0                            |
| Azathioprine   | 1 (3.8)                            | 1 (4.0)                  | 0                            |
| Mycophenolate  | 1 (3.8)                            | 1 (4.0)                  | 0                            |
| Systemic monotherapy   | 2 (5.0)                            | 2 (5.1)                  | 0                            |
| Topical monotherapy or in combination                              | 38 (95.0)                          | 37 (94.9)                | 1 (100.0)                    |
| Topical monotherapy  | 9 (22.5)                           | 9 (23.1)                 | 0                            |
| TCS or TCI monotherapy   | 3 (7.5)                            | 3 (7.7)                  | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 29 (72.5)                          | 28 (71.8)                | 1 (100.0)                    |
| Systemic monotherapy   | 9 (22.5)                           | 9 (23.1)                 | 0                            |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 38 (95.0)                          | 38 (97.4)                | 0                            |
| Suboptimal response to topical monotherapy                         | 38 (95.0)                          | 38 (97.4)                | 0                            |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 20.2. Physician-Reported and Patient-Reported Clinical Outcomes in New Zealand**

|  | <b>Total<br/>population<br/>(n=40)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=1)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 24.1 (15.9)                            | 24.0 (16.1)              | 27.6 (NA)                    |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 1 (2.5)                                | 1 (2.6)                  | 0                            |
| Mild (0.1–5.9)   | 8 (20.0)                               | 8 (20.5)                 | 0                            |
| Moderate (6.0–22.9)  | 9 (22.5)                               | 9 (23.1)                 | 0                            |
| Severe (23.0–72.0)   | 22 (55.0)                              | 21 (53.8)                | 1 (100.0)                    |
| SCORAD, mean (SD)  | 49.3 (21.4)<br>n=34                    | 48.9 (21.6)<br>n=33      | 62.7 (NA)                    |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 3 (7.5)                                | 3 (7.7)                  | 0                            |
| Moderate (25.0–50.0)   | 12 (30.0)                              | 12 (30.8)                | 0                            |
| Severe (>50.0)   | 19 (47.5)                              | 18 (46.2)                | 1 (100.0)                    |
| Missing  | 6 (15.0)                               | 6 (15.4)                 | 0                            |
| vIGA-AD, mean (SD)   | 2.7 (1.0)                              | 2.7 (1.0)                | 4.0 (NA)                     |
| Clear (0)  | 1 (2.5)                                | 1 (2.6)                  | 0                            |
| Almost clear (1)   | 5 (12.5)                               | 5 (12.8)                 | 0                            |
| Mild (2)   | 7 (17.5)                               | 7 (17.9)                 | 0                            |
| Moderate (3)   | 18 (45.0)                              | 18 (46.2)                | 0                            |
| Severe (4)   | 9 (22.5)                               | 8 (20.5)                 | 1 (100.0)                    |
| BSA, % affected, mean (SD)   | 48.9 (28.9)                            | 48.9 (29.3)              | 50.0 (NA)                    |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.1 (2.0)                              | 6.1 (2.0)                | 8.0 (NA)                     |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 49.9 (53.3)                            | 50.0 (54.0)              | 45.0 (NA)                    |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 0                                      | 0                        | 0                            |
| Not at all   | 8 (20.0)                               | 8 (20.5)                 | 0                            |
| A little   | 7 (17.5)                               | 7 (17.9)                 | 0                            |
| Somewhat   | 10 (25.0)                              | 9 (23.1)                 | 1 (100.0)                    |
| Much   | 4 (10.0)                               | 4 (10.3)                 | 0                            |
| Very much  | 10 (25.0)                              | 10 (25.6)                | 0                            |
| Missing  | 1 (2.5)                                | 1 (2.6)                  | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 17.2 (4.1)                             | 17.2 (4.2)               | 19.0 (NA)                    |
| POEM, mean (SD)  | 20.4 (7.1)                             | 20.2 (7.1)               | 26.0 (NA)                    |

|   |                      |                      |           |
|---|----------------------|----------------------|-----------|
| Total ADerm-IS, mean (SD)                           | 59.2 (24.1)          | 58.8 (24.3)          | 74.0 (NA) |
| ADerm-IS Sleep domain, mean (SD)                    | 16.8 (8.6)           | 16.8 (8.7)           | 17.0 (NA) |
| ADerm-SS TSS-7, mean (SD)                           | 42.4 (16.5)          | 42.0 (16.5)          | 57.0 (NA) |
| ADerm-SS TSS-11, mean (SD)                          | 62.6 (25.5)          | 62.1 (25.6)          | 83.0 (NA) |
| ADerm-SS Skin pain, mean (SD)                       | 5.8 (2.8)            | 5.8 (2.8)            | 6.0 (NA)  |
| Number of flares in last 6 months, n (%)            |                      |                      |           |
| 0   | 1 (2.5)              | 1 (2.6)              | 0         |
| 1–2   | 7 (17.5)             | 7 (17.9)             | 0         |
| 3–4   | 10 (25.0)            | 10 (25.6)            | 0         |
| 5–6   | 6 (15.0)             | 6 (15.4)             | 0         |
| >6  | 10 (25.0)            | 10 (25.6)            | 0         |
| Missing   | 6 (15.0)             | 5 (12.8)             | 1 (100.0) |
| Number of flares in the last 6 months, mean (range) | 10.8 (0–100)<br>n=34 | 10.8 (0–100)<br>n=34 | –         |
| Average duration of flares in last 6 months, n (%)  |                      |                      |           |
| ≤2 days   | 3 (7.5)              | 3 (7.7)              | 0         |
| 3–7 days  | 18 (45.0)            | 18 (46.2)            | 0         |
| 8–14 days   | 6 (15.0)             | 6 (15.4)             | 0         |
| ≥15 days  | 8 (20.0)             | 8 (20.5)             | 0         |
| Missing   | 5 (12.5)             | 4 (10.3)             | 1 (100.0) |
| Inadequately controlled AD, n (%)                   | 15 (37.5)            | 14 (35.9)            | 1 (100.0) |
| SF-12 PCS, mean (SD)                                | NA                   | 46.1 (9.5)           | NA        |
| SF-10 PHS, mean (SD)                                | NA                   | NA                   | –         |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 20.3. Psychosocial-Economic Burden of AD in New Zealand**

|   | <b>Total<br/>population<br/>(n=40)</b> | <b>Adults<br/>(n=39)</b> | <b>Adolescents<br/>(n=1)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 9.2 (4.6)                              | 9.3 (4.5)                | 4.0 (NA)                     |
| HADS-A $\geq 8$ , n (%)   | 24 (60.0)                              | 24 (61.5)                | 0                            |
| HADS-D, mean (SD)   | 7.1 (4.0)                              | 7.1 (4.1)                | 6.0 (NA)                     |
| HADS-D $\geq 8$ , n (%)   | 15 (37.5)                              | 15 (38.5)                | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 38.2 (11.4)              | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | –                            |
| ADerm-IS Daily Activities, mean (SD)  | 20.6 (10.3)                            | 20.3 (10.2)              | 32.0 (NA)                    |
| ADerm-IS Emotional State, mean (SD)   | 21.8 (8.0)                             | 21.7 (8.1)               | 25.0 (NA)                    |
| WPAI-AD, Employed, n (%)  | 28 (70.0)                              | 28 (71.8)                | 0                            |
| Absenteeism, %, mean (SD)   | 11.0 (20.6)<br>n=26                    | 11.0 (20.6)<br>n=26      | –                            |
| Presenteeism, %, mean (SD)  | 41.9 (21.7)<br>n=27                    | 41.9 (21.7)<br>n=27      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 45.2 (25.5)<br>n=26                    | 45.2 (25.5)<br>n=26      | –                            |
| Activity impairment, %, mean (SD)   | 49.3 (27.0)                            | 48.7 (27.2)              | 70.0 (NA)                    |
| Hours missed from work, mean (SD)   | 4.0 (6.9)<br>n=26                      | 4.0 (6.9)<br>n=26        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 4.5 (4.9)                              | 4.3 (4.8)                | 12.0 (NA)                    |
| Out of pocket expenses  |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 147.5 (152.0)<br>n=36                  | 143.3 (152.1)<br>n=35    | 292.0 (NA)                   |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 21.1. Baseline Patient Demographics and Characteristics in Poland**

|  | <b>Total population<br/>(n=24)</b> | <b>Adults<br/>(n=23)</b> | <b>Adolescents<br/>(n=1)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 32.5 (11.0)                        | 33.3 (10.6)              | 16.0 (NA)                    |
| Male, n (%)  | 10 (41.7)                          | 9 (39.1)                 | 1 (100.0)                    |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 23.7 (3.4)                         | 24.0 (3.2)               | 16.8 (NA)                    |
| Employed, n (%)  | 21 (87.5)                          | 21 (91.3)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 25.4 (12.0)                        | 25.8 (12.1)              | 16.2 (NA)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 28.2 (10.2)<br>n=5                 | 28.2 (10.2)<br>n=5       | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 24.9 (11.6)<br>n=13                | 24.9 (11.6)<br>n=13      | –                            |
| Continuous systemic therapy over previous 12 months, n (%)         | 2 (8.3)                            | 2 (8.7)                  | 0                            |
| Current therapy, n (%)   | 24 (100.0)                         | 23 (100.0)               | 1 (100.0)                    |
| Systemic monotherapy or in combination                             | 5 (20.8)                           | 5 (21.7)                 | 0                            |
| Dupilumab  | 0                                  | 0                        | –                            |
| Systemic corticosteroids   | 4 (80.0)                           | 4 (80.0)                 | –                            |
| Methotrexate   | 0                                  | 0                        | –                            |
| Cyclosporine   | 2 (40.0)                           | 2 (40.0)                 | –                            |
| Azathioprine   | 0                                  | 0                        | –                            |
| Mycophenolate  | 0                                  | 0                        | –                            |
| Systemic monotherapy   | 0                                  | 0                        | 0                            |
| Topical monotherapy or in combination                              | 22 (91.7)                          | 21 (91.3)                | 1 (100.0)                    |
| Topical monotherapy  | 12 (50.0)                          | 11 (47.8)                | 0                            |
| TCS or TCI monotherapy   | 10 (41.7)                          | 10 (43.5)                | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 10 (41.7)                          | 10 (43.5)                | 0                            |
| Systemic monotherapy   | 0                                  | 0                        | 0                            |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 20 (83.3)                          | 19 (82.6)                | 1 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 19 (79.2)                          | 18 (78.3)                | 1 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 21.2. Physician-Reported and Patient-Reported Clinical Outcomes in Poland**

|  | <b>Total<br/>population<br/>(n=24)</b> | <b>Adults<br/>(n=23)</b> | <b>Adolescents<br/>(n=1)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 22.2 (8.3)                             | 22.2 (8.4)               | 20.5 (NA)                    |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Mild (0.1–5.9)   | 0                                      | 0                        | 0                            |
| Moderate (6.0–22.9)  | 14 (58.3)                              | 13 (56.5)                | 1 (100.0)                    |
| Severe (23.0–72.0)   | 10 (41.7)                              | 10 (43.5)                | 0                            |
| SCORAD, mean (SD)  | 60.5 (9.8)                             | 60.0 (9.7)               | 72.0 (NA)                    |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 0                                      | 0                        | 0                            |
| Moderate (25.0–50.0)   | 3 (12.5)                               | 3 (13.0)                 | 0                            |
| Severe (>50.0)   | 21 (87.5)                              | 20 (87.0)                | 1 (100.0)                    |
| vIGA-AD, mean (SD)   | 3.5 (0.5)                              | 3.6 (0.5)                | 3.0 (NA)                     |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Almost clear (1)   | 0                                      | 0                        | 0                            |
| Mild (2)   | 0                                      | 0                        | 0                            |
| Moderate (3)   | 11 (45.8)                              | 10 (43.5)                | 1 (100.0)                    |
| Severe (4)   | 13 (54.2)                              | 13 (56.5)                | 0                            |
| BSA, % affected, mean (SD)   | 28.2 (15.8)                            | 28.6 (16.0)              | 18.0 (NA)                    |
| Average hours of sleep per night in the past week, mean (SD)                   | 5.7 (1.3)                              | 5.8 (1.3)                | 4.0 (NA)                     |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 43.0 (30.1)                            | 42.2 (30.5)              | 60.0 (NA)                    |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 0                                      | 0                        | 0                            |
| Not at all   | 1 (4.2)                                | 1 (4.3)                  | 0                            |
| A little   | 2 (8.3)                                | 2 (8.7)                  | 0                            |
| Somewhat   | 7 (29.2)                               | 7 (30.4)                 | 0                            |
| Much   | 12 (50.0)                              | 11 (47.8)                | 1 (100.0)                    |
| Very much  | 2 (8.3)                                | 2 (8.7)                  | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 17.0 (3.9)                             | 17.0 (4.0)               | 18.0 (NA)                    |
| POEM, mean (SD)  | 17.8 (6.4)                             | 17.6 (6.5)               | 21.0 (NA)                    |
| Total ADerm-IS, mean (SD)  | 52.0 (29.3)                            | 51.9 (29.9)              | 55.0 (NA)                    |
| ADerm-IS Sleep domain, mean (SD)   | 15.0 (9.2)                             | 14.9 (9.4)               | 17.0 (NA)                    |

|   |             |             |           |
|---|-------------|-------------|-----------|
| ADerm-SS TSS-7, mean (SD)                           | 37.0 (18.5) | 36.5 (18.8) | 49.0 (NA) |
| ADerm-SS TSS-11, mean (SD)                          | 56.3 (29.3) | 55.2 (29.4) | 83.0 (NA) |
| ADerm-SS Skin pain, mean (SD)                       | 5.3 (3.1)   | 5.1 (3.1)   | 8.0 (NA)  |
| Number of flares in last 6 months, n (%)            |             |             |           |
| 0   | 0           | 0           | 0         |
| 1–2   | 5 (20.8)    | 5 (21.7)    | 0         |
| 3–4   | 6 (25.0)    | 5 (21.7)    | 1 (100.0) |
| 5–6   | 3 (12.5)    | 3 (13.0)    | 0         |
| >6  | 10 (41.7)   | 10 (43.5)   | 0         |
| Number of flares in the last 6 months, mean (range) | 10.0 (1–70) | 10.3 (1–70) | 3.0 (3–3) |
| Average duration of flares in last 6 months, n (%)  |             |             |           |
| ≤2 days   | 1 (4.2)     | 1 (4.3)     | 0         |
| 3–7 days  | 3 (12.5)    | 3 (13.0)    | 0         |
| 8–14 days   | 10 (41.7)   | 9 (39.1)    | 1 (100.0) |
| ≥15 days  | 10 (41.7)   | 10 (43.5)   | 0         |
| Inadequately controlled AD, n (%)                   | 9 (37.5)    | 8 (34.8)    | 1 (100.0) |
| SF-12 PCS, mean (SD)                                | NA          | 48.4 (5.7)  | NA        |
| SF-10 PHS, mean (SD)                                | NA          | NA          | 13.4 (NA) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 21.3. Psychosocial-Economic Burden of AD in Poland**

|   | <b>Total<br/>population<br/>(n=24)</b> | <b>Adults<br/>(n=23)</b> | <b>Adolescents<br/>(n=1)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 7.0 (5.0)                              | 6.9 (5.1)                | 8.0 (NA)                     |
| HADS-A $\geq 8$ , n (%)   | 13 (54.2)                              | 12 (52.2)                | 1 (100.0)                    |
| HADS-D, mean (SD)   | 6.5 (4.4)                              | 6.5 (4.5)                | 5.8 (NA)                     |
| HADS-D $\geq 8$ , n (%)   | 10 (41.7)                              | 10 (43.5)                | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 38.7 (11.3)              | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 16.8 (NA)                    |
| ADerm-IS Daily Activities, mean (SD)  | 20.6 (12.0)                            | 20.3 (12.2)              | 27.0 (NA)                    |
| ADerm-IS Emotional State, mean (SD)   | 16.5 (9.9)                             | 16.7 (10.1)              | 11.0 (NA)                    |
| WPAI-AD, Employed, n (%)  | 21 (87.5)                              | 21 (91.3)                | 0                            |
| Absenteeism, %, mean (SD)   | 14.8 (28.9)<br>n=16                    | 14.8 (28.9)<br>n=16      | –                            |
| Presenteeism, %, mean (SD)  | 46.9 (26.3)<br>n=16                    | 46.9 (26.3)<br>n=16      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 47.1 (28.1)<br>n=15                    | 47.1 (28.1)<br>n=15      | –                            |
| Activity impairment, %, mean (SD)   | 48.3 (27.8)                            | 47.8 (28.3)              | 60.0 (NA)                    |
| Hours missed from work, mean (SD)   | 4.4 (9.7)<br>n=21                      | 4.4 (9.7)<br>n=21        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 5.2 (6.6)<br>n=17                      | 5.4 (6.7)<br>n=16        | 2.0 (NA)                     |
| <b>Out of pocket expenses</b>   |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 138.6 (86.1)                           | 142.3 (86.1)             | 54.0 (NA)                    |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 22.1. Baseline Patient Demographics and Characteristics in Portugal**

|  | <b>Total population<br/>(n=59)</b> | <b>Adults<br/>(n=52)</b> | <b>Adolescents<br/>(n=7)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 31.4 (13.5)                        | 33.7 (12.6)              | 14.0 (1.0)                   |
| Male, n (%)  | 34 (57.6)                          | 29 (55.8)                | 5 (71.4)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 23.9 (3.8)                         | 24.4 (3.7)               | 20.5 (2.4)                   |
| Employed, n (%)  | 34 (57.6)                          | 33 (63.5)                | 1 (14.3)                     |
| Duration of AD, years, mean (SD)                                   | 24.7 (12.5)                        | 26.4 (12.4)              | 12.5 (1.5)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 8.8 (11.3)<br>n=16                 | 9.6 (12.4)<br>n=13       | 5.5 (4.7)<br>n=3             |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 12.8 (11.6)<br>n=50                | 13.8 (11.9)<br>n=44      | 5.6 (3.4)<br>n=6             |
| Continuous systemic therapy over previous 12 months, n (%)         | 21 (35.6)                          | 19 (36.5)                | 2 (28.6)                     |
| Current therapy, n (%)   | 59 (100.0)                         | 52 (100.0)               | 7 (100.0)                    |
| Systemic monotherapy or in combination                             | 43 (72.9)                          | 39 (75.0)                | 4 (57.1)                     |
| Dupilumab  | 21 (48.8)                          | 20 (51.3)                | 1 (25.0)                     |
| Systemic corticosteroids   | 8 (18.6)                           | 7 (17.9)                 | 1 (25.0)                     |
| Methotrexate   | 8 (18.6)                           | 7 (17.9)                 | 1 (25.0)                     |
| Cyclosporine   | 9 (20.9)                           | 8 (20.5)                 | 1 (25.0)                     |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 15 (25.4)                          | 14 (26.9)                | 1 (14.3)                     |
| Topical monotherapy or in combination                              | 43 (72.9)                          | 37 (71.2)                | 6 (85.7)                     |
| Topical monotherapy  | 7 (11.9)                           | 6 (11.5)                 | 1 (14.3)                     |
| TCS or TCI monotherapy   | 6 (10.2)                           | 5 (9.6)                  | 1 (14.3)                     |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 51 (86.4)                          | 44 (84.6)                | 7 (100.0)                    |
| Systemic monotherapy   | 11 (18.6)                          | 7 (13.5)                 | 4 (57.1)                     |
| Dupilumab, monotherapy or in combination                           | 1 (1.7)                            | 1 (1.9)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 52 (88.1)                          | 48 (92.3)                | 4 (57.1)                     |
| Suboptimal response to topical monotherapy                         | 54 (91.5)                          | 49 (94.2)                | 5 (71.4)                     |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 22.2. Physician-Reported and Patient-Reported Clinical Outcomes in Portugal**

|  | <b>Total<br/>population<br/>(n=59)</b> | <b>Adults<br/>(n=52)</b> | <b>Adolescents<br/>(n=7)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 14.3 (13.4)<br>n=58                    | 13.3 (13.0)<br>n=51      | 21.6 (15.4)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 3 (5.1)                                | 3 (5.8)                  | 0                            |
| Mild (0.1–5.9)   | 23 (39.0)                              | 21 (40.4)                | 2 (28.6)                     |
| Moderate (6.0–22.9)  | 18 (30.5)                              | 17 (32.7)                | 1 (14.3)                     |
| Severe (23.0–72.0)   | 14 (23.7)                              | 10 (19.2)                | 4 (57.1)                     |
| Missing  | 1 (1.7)                                | 1 (1.9)                  | 0                            |
| SCORAD, mean (SD)  | 39.6 (20.6)<br>n=58                    | 39.3 (20.0)              | 41.4 (27.4)<br>n=6           |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 16 (27.1)                              | 14 (26.9)                | 2 (28.6)                     |
| Moderate (25.0–50.0)   | 22 (37.3)                              | 21 (40.4)                | 1 (14.3)                     |
| Severe (>50.0)   | 20 (33.9)                              | 17 (32.7)                | 3 (42.9)                     |
| Missing  | 1 (1.7)                                | 0                        | 1 (14.3)                     |
| vIGA-AD, mean (SD)   | 2.6 (1.2)<br>n=58                      | 2.6 (1.2)                | 3.0 (1.3)<br>n=6             |
| Clear (0)  | 3 (5.1)                                | 3 (5.8)                  | 0                            |
| Almost clear (1)   | 8 (13.6)                               | 7 (13.5)                 | 1 (14.3)                     |
| Mild (2)   | 14 (23.7)                              | 13 (25.0)                | 1 (14.3)                     |
| Moderate (3)   | 16 (27.1)                              | 15 (28.8)                | 1 (14.3)                     |
| Severe (4)   | 17 (28.8)                              | 14 (26.9)                | 3 (42.9)                     |
| Missing  | 1 (1.7)                                | 0                        | 1 (14.3)                     |
| BSA, % affected, mean (SD)   | 23.0 (21.7)                            | 21.3 (21.2)              | 35.4 (22.9)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.8 (1.7)                              | 6.8 (1.7)                | 7.4 (1.0)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 30.0 (30.6)                            | 28.1 (29.5)              | 44.3 (37.5)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 6 (10.2)                               | 5 (9.6)                  | 1 (14.3)                     |
| Not at all   | 18 (30.5)                              | 17 (32.7)                | 1 (14.3)                     |
| A little   | 9 (15.3)                               | 8 (15.4)                 | 1 (14.3)                     |
| Somewhat   | 9 (15.3)                               | 8 (15.4)                 | 1 (14.3)                     |
| Much   | 11 (18.6)                              | 9 (17.3)                 | 2 (28.6)                     |
| Very much  | 4 (6.8)                                | 4 (7.7)                  | 0                            |
| Missing  | 2 (3.4)                                | 1 (1.9)                  | 1 (14.3)                     |

| <b>Patient-reported outcomes</b>                    |                     |                     |                    |
|---|---------------------|---------------------|--------------------|
| 5D-Pruritus score, mean (SD)                        | 14.9 (4.1)<br>n=58  | 14.7 (4.0)<br>n=51  | 16.3 (4.6)         |
| POEM, mean (SD)                                     | 14.3 (7.5)<br>n=58  | 14.1 (7.5)<br>n=51  | 15.6 (7.3)         |
| Total ADerm-IS, mean (SD)                           | 35.9 (27.3)<br>n=57 | 36.1 (27.5)<br>n=51 | 34.3 (28.4)<br>n=6 |
| ADerm-IS Sleep domain, mean (SD)                    | 11.5 (9.1)<br>n=58  | 11.5 (8.7)<br>n=51  | 12.0 (12.7)        |
| ADerm-SS TSS-7, mean (SD)                           | 31.0 (19.7)<br>n=57 | 29.1 (18.7)<br>n=50 | 44.4 (22.9)        |
| ADerm-SS TSS-11, mean (SD)                          | 45.3 (30.2)<br>n=56 | 42.5 (28.6)<br>n=49 | 65.0 (36.1)        |
| ADerm-SS Skin pain, mean (SD)                       | 3.8 (3.1)<br>n=58   | 3.5 (3.0)<br>n=51   | 6.1 (3.5)          |
| Number of flares in last 6 months, n (%)            |                     |                     |                    |
| 0   | 15 (25.4)           | 14 (26.9)           | 1 (14.3)           |
| 1–2   | 18 (30.5)           | 16 (30.8)           | 2 (28.6)           |
| 3–4   | 5 (8.5)             | 5 (9.6)             | 0                  |
| 5–6   | 8 (13.6)            | 6 (11.5)            | 2 (28.6)           |
| >6  | 12 (20.3)           | 10 (19.2)           | 2 (28.6)           |
| Missing   | 1 (1.7)             | 1 (1.9)             | 0                  |
| Number of flares in the last 6 months, mean (range) | 4.6 (0–24)<br>n=58  | 4.2 (0–24)<br>n=51  | 7.1 (0–24)         |
| Average duration of flares in last 6 months, n (%)  |                     |                     |                    |
| ≤2 days   | 15 (25.4)           | 13 (25.0)           | 2 (28.6)           |
| 3–7 days  | 16 (27.1)           | 14 (26.9)           | 2 (28.6)           |
| 8–14 days   | 8 (13.6)            | 6 (11.5)            | 2 (28.6)           |
| ≥15 days  | 15 (25.4)           | 14 (26.9)           | 1 (14.3)           |
| Missing   | 5 (8.5)             | 5 (9.6)             | 0                  |
| Inadequately controlled AD, n (%)                   | 15 (25.4)           | 14 (26.9)           | 1 (14.3)           |
| SF-12 PCS, mean (SD)                                | NA                  | 50.3 (7.4)<br>n=49  | NA                 |
| SF-10 PHS, mean (SD)                                | NA                  | NA                  | 29.9 (20.9)<br>n=4 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 22.3. Psychosocial-Economic Burden of AD in Portugal**

|   | <b>Total<br/>population<br/>(n=59)</b> | <b>Adults<br/>(n=52)</b> | <b>Adolescents<br/>(n=7)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 6.6 (4.0)<br>n=57                      | 6.3 (3.7)<br>n=50        | 8.7 (5.4)                    |
| HADS-A $\geq 8$ , n (%)   | 20 (33.9)                              | 17 (32.7)                | 3 (42.9)                     |
| HADS-D, mean (SD)   | 4.6 (3.2)<br>n=57                      | 4.6 (3.4)<br>n=50        | 4.4 (1.6)                    |
| HADS-D $\geq 8$ , n (%)   | 9 (15.3)                               | 9 (17.3)                 | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 47.5 (10.9)<br>n=49      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 38.2 (21.4)<br>n=4           |
| ADerm-IS Daily Activities, mean (SD)  | 12.2 (11.5)<br>n=57                    | 12.5 (11.8)<br>n=51      | 9.3 (8.2)<br>n=6             |
| ADerm-IS Emotional State, mean (SD)   | 12.8 (10.4)<br>n=58                    | 12.1 (9.9)<br>n=51       | 17.9 (12.9)                  |
| WPAI-AD, Employed, n (%)  | 34 (57.6)                              | 33 (63.5)                | 1 (14.3)                     |
| Absenteeism, %, mean (SD)   | 3.0 (7.0)<br>n=26                      | 1.8 (3.4)<br>n=25        | 33.3 (NA)<br>n=1             |
| Presenteeism, %, mean (SD)  | 27.2 (31.7)<br>n=29                    | 24.6 (29.0)<br>n=28      | 100.0 (NA)<br>n=1            |
| Overall work productivity impairment, %, mean (SD)  | 29.2 (32.9)<br>n=26                    | 26.3 (30.2)<br>n=25      | 100.0 (NA)<br>n=1            |
| Activity impairment, %, mean (SD)   | 35.0 (29.8)<br>n=56                    | 33.4 (29.0)<br>n=50      | 48.3 (36.0)<br>n=6           |
| Hours missed from work, mean (SD)   | 0.8 (1.6)<br>n=31                      | 0.7 (1.6)<br>n=30        | 3.0 (NA)<br>n=1              |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 3.1 (4.2)<br>n=47                      | 2.9 (3.2)<br>n=41        | 4.5 (8.6)<br>n=6             |
| <b>Out of pocket expenses</b>   |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 145.9 (102.3)<br>n=52                  | 141.7 (104.8)<br>n=45    | 172.9 (85.8)                 |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 23.1. Baseline Patient Demographics and Characteristics in Romania**

|  | <b>Total population<br/>(n=23)</b> | <b>Adults<br/>(n=19)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 37.6 (17.6)                        | 42.2 (15.8)              | 15.5 (1.9)                   |
| Male, n (%)  | 5 (21.7)                           | 5 (26.3)                 | 0                            |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 24.2 (6.6)                         | 25.4 (6.5)               | 18.8 (3.6)                   |
| Employed, n (%)  | 14 (60.9)                          | 14 (73.7)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 11.3 (6.7)                         | 10.6 (7.2)               | 14.6 (2.0)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 0.75 (NA)<br>n=1                   | 0.75 (NA)<br>n=1         | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 3.1 (7.5)<br>n=6                   | 3.1 (7.5)<br>n=6         | –                            |
| Continuous systemic therapy over previous 12 months, n (%)         | 1 (4.3)                            | 1 (5.3)                  | 0                            |
| Current therapy, n (%)   | 22 (95.7)                          | 19 (100.0)               | 3 (75.0)                     |
| Systemic monotherapy or in combination                             | 2 (8.7)                            | 2 (10.5)                 | 0                            |
| Dupilumab  | 0                                  | 0                        | –                            |
| Systemic corticosteroids   | 1 (50.0)                           | 1 (50.0)                 | –                            |
| Methotrexate   | 1 (50.0)                           | 1 (50.0)                 | –                            |
| Cyclosporine   | 0                                  | 0                        | –                            |
| Azathioprine   | 0                                  | 0                        | –                            |
| Mycophenolate  | 0                                  | 0                        | –                            |
| Systemic monotherapy   | 0                                  | 0                        | 0                            |
| Topical monotherapy or in combination                              | 22 (95.7)                          | 19 (100.0)               | 3 (75.0)                     |
| Topical monotherapy  | 8 (34.8)                           | 7 (36.8)                 | 1 (25.0)                     |
| TCS or TCI monotherapy   | 7 (30.4)                           | 7 (36.8)                 | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 5 (21.7)                           | 5 (26.3)                 | 0                            |
| Systemic monotherapy   | 1 (4.3)                            | 1 (5.3)                  | 0                            |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 16 (69.6)                          | 13 (68.4)                | 3 (75.0)                     |
| Suboptimal response to topical monotherapy                         | 16 (69.6)                          | 13 (68.4)                | 3 (75.0)                     |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 23.2. Physician-Reported and Patient-Reported Clinical Outcomes in Romania**

|  | <b>Total<br/>population<br/>(n=23)</b> | <b>Adults<br/>(n=19)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 13.0 (4.7)                             | 12.6 (4.2)               | 15.0 (6.9)                   |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Mild (0.1–5.9)   | 1 (4.3)                                | 1 (5.3)                  | 0                            |
| Moderate (6.0–22.9)  | 22 (95.7)                              | 18 (94.7)                | 4 (100.0)                    |
| Severe (23.0–72.0)   | 0                                      | 0                        | 0                            |
| SCORAD, mean (SD)  | 48.0 (9.2)                             | 47.3 (9.6)               | 51.5 (6.7)                   |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 0                                      | 0                        | 0                            |
| Moderate (25.0–50.0)   | 14 (60.9)                              | 12 (63.2)                | 2 (50.0)                     |
| Severe (>50.0)   | 9 (39.1)                               | 7 (36.8)                 | 2 (50.0)                     |
| vIGA-AD, mean (SD)   | 2.7 (0.6)                              | 2.7 (0.7)                | 3.0 (0.0)                    |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Almost clear (1)   | 0                                      | 0                        | 0                            |
| Mild (2)   | 8 (34.8)                               | 8 (42.1)                 | 0                            |
| Moderate (3)   | 13 (56.5)                              | 9 (47.4)                 | 4 (100.0)                    |
| Severe (4)   | 2 (8.7)                                | 2 (10.5)                 | 0                            |
| BSA, % affected, mean (SD)   | 18.7 (23.5)                            | 17.0 (22.6)              | 26.8 (29.5)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 5.7 (1.9)                              | 5.7 (1.5)                | 6.0 (3.4)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 34.8 (29.0)                            | 38.4 (30.2)              | 18.0 (14.2)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 2 (8.7)                                | 1 (5.3)                  | 1 (25.0)                     |
| Not at all   | 3 (13.0)                               | 2 (10.5)                 | 1 (25.0)                     |
| A little   | 5 (21.7)                               | 4 (21.1)                 | 1 (25.0)                     |
| Somewhat   | 8 (34.8)                               | 7 (36.8)                 | 1 (25.0)                     |
| Much   | 2 (8.7)                                | 2 (10.5)                 | 0                            |
| Very much  | 3 (13.0)                               | 3 (15.8)                 | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 13.8 (3.0)                             | 13.8 (3.2)               | 13.5 (1.7)                   |
| POEM, mean (SD)  | 15.3 (4.2)                             | 15.5 (4.4)               | 14.3 (3.0)                   |
| Total ADerm-IS, mean (SD)  | 49.5 (21.5)                            | 51.4 (22.5)              | 40.5 (14.5)                  |
| ADerm-IS Sleep domain, mean (SD)   | 11.6 (7.4)                             | 12.2 (7.8)               | 8.5 (5.1)                    |

|   |                    |                    |                   |
|---|--------------------|--------------------|-------------------|
| ADerm-SS TSS-7, mean (SD)                           | 37.9 (14.9)        | 38.9 (15.2)        | 33.0 (14.1)       |
| ADerm-SS TSS-11, mean (SD)                          | 51.6 (24.4)        | 53.7 (24.8)        | 41.5 (22.2)       |
| ADerm-SS Skin pain, mean (SD)                       | 4.6 (2.7)          | 4.5 (2.7)          | 4.8 (3.2)         |
| Number of flares in last 6 months, n (%)            |                    |                    |                   |
| 0   | 1 (4.3)            | 1 (5.3)            | 0                 |
| 1–2   | 10 (43.5)          | 8 (42.1)           | 2 (50.0)          |
| 3–4   | 7 (30.4)           | 7 (36.8)           | 0                 |
| 5–6   | 1 (4.3)            | 0                  | 1 (25.0)          |
| >6  | 3 (13.0)           | 2 (10.5)           | 1 (25.0)          |
| Missing   | 1 (4.3)            | 1 (5.3)            | 0                 |
| Number of flares in the last 6 months, mean (range) | 4.4 (0–26)<br>n=22 | 3.8 (0–26)<br>n=18 | 7.3 (1–20)        |
| Average duration of flares in last 6 months, n (%)  |                    |                    |                   |
| ≤2 days   | 3 (13.0)           | 2 (10.5)           | 1 (25.0)          |
| 3–7 days  | 9 (39.1)           | 8 (42.1)           | 1 (25.0)          |
| 8–14 days   | 2 (8.7)            | 2 (10.5)           | 0                 |
| ≥15 days  | 7 (30.4)           | 5 (26.3)           | 2 (50.0)          |
| Missing   | 2 (8.7)            | 2 (10.5)           | 0                 |
| Inadequately controlled AD, n (%)                   | 11 (47.8)          | 10 (52.6)          | 1 (25.0)          |
| SF-12 PCS, mean (SD)                                | NA                 | 42.6 (10.5)        | NA                |
| SF-10 PHS, mean (SD)                                | NA                 | NA                 | 49.9 (3.7)<br>n=3 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 23.3. Psychosocial-Economic Burden of AD in Romania**

|   | <b>Total<br/>population<br/>(n=23)</b> | <b>Adults<br/>(n=19)</b> | <b>Adolescents<br/>(n=4)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 9.6 (3.8)                              | 10.3 (3.6)               | 6.0 (2.9)                    |
| HADS-A $\geq 8$ , n (%)   | 17 (73.9)                              | 16 (84.2)                | 1 (25.0)                     |
| HADS-D, mean (SD)   | 7.7 (5.0)                              | 9.0 (4.6)                | 1.8 (0.5)                    |
| HADS-D $\geq 8$ , n (%)   | 13 (56.5)                              | 13 (68.4)                | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 38.9 (9.6)<br>n=19       | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 51.0 (2.7)<br>n=3            |
| ADerm-IS Daily Activities, mean (SD)  | 18.5 (9.9)                             | 19.5 (10.4)              | 13.5 (5.8)                   |
| ADerm-IS Emotional State, mean (SD)   | 19.4 (7.5)                             | 19.6 (7.5)               | 18.5 (8.4)                   |
| WPAI-AD, Employed, n (%)  | 14 (60.9)                              | 14 (73.7)                | 0                            |
| Absenteeism, %, mean (SD)   | 12.8 (15.1)<br>n=11                    | 12.8 (15.1)<br>n=11      | –                            |
| Presenteeism, %, mean (SD)  | 40.0 (25.2)<br>n=13                    | 40.0 (25.2)<br>n=13      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 43.6 (21.8)<br>n=11                    | 43.6 (21.8)<br>n=11      | –                            |
| Activity impairment, %, mean (SD)   | 51.7 (26.7)                            | 52.6 (26.6)              | 47.5 (31.0)                  |
| Hours missed from work, mean (SD)   | 3.6 (3.1)<br>n=12                      | 3.6 (3.1)<br>n=12        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 1.1 (2.1)<br>n=19                      | 1.2 (2.2)<br>n=17        | 0.0 (0.0)<br>n=2             |
| Out of pocket expenses  |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 106.9 (99.7)<br>n=20                   | 93.0 (64.7)<br>n=16      | 162.5 (192.0)                |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 24.1. Baseline Patient Demographics and Characteristics in Saudi Arabia**

|  | <b>Total population<br/>(n=32)</b> | <b>Adults<br/>(n=28)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 31.6 (13.6)                        | 34.0 (12.9)              | 15.3 (1.0)                   |
| Male, n (%)  | 12 (37.5)                          | 10 (35.7)                | 2 (50.0)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.8 (5.6)                         | 25.7 (5.5)               | 26.2 (7.6)                   |
| Employed, n (%)  | 11 (34.4)                          | 11 (39.3)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 15.2 (10.1)                        | 16.2 (10.4)              | 8.4 (2.5)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | 10.8 (14.4)<br>n=5                 | 10.8 (14.4)<br>n=5       | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 11.6 (9.4)<br>n=26                 | 12.4 (9.7)<br>n=23       | 5.5 (1.3)<br>n=3             |
| Continuous systemic therapy over previous 12 months, n (%)         | 7 (21.9)                           | 7 (25.0)                 | 0                            |
| Current therapy, n (%)   | 32 (100.0)                         | 28 (100.0)               | 4 (100.0)                    |
| Systemic monotherapy or in combination                             | 19 (59.4)                          | 17 (60.7)                | 2 (50.0)                     |
| Dupilumab  | 16 (84.2)                          | 15 (88.2)                | 1 (50.0)                     |
| Systemic corticosteroids   | 2 (10.5)                           | 2 (11.8)                 | 0                            |
| Methotrexate   | 3 (15.8)                           | 3 (17.6)                 | 0                            |
| Cyclosporine   | 1 (5.3)                            | 0                        | 1 (50.0)                     |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 1 (5.3)                            | 1 (5.9)                  | 0                            |
| Systemic monotherapy   | 1 (3.1)                            | 0                        | 1 (25.0)                     |
| Topical monotherapy or in combination                              | 30 (93.8)                          | 27 (96.4)                | 3 (75.0)                     |
| Topical monotherapy  | 3 (9.4)                            | 3 (10.7)                 | 0                            |
| TCS or TCI monotherapy   | 2 (6.3)                            | 2 (7.1)                  | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 25 (78.1)                          | 22 (78.6)                | 3 (75.0)                     |
| Systemic monotherapy   | 3 (9.4)                            | 3 (10.7)                 | 0                            |
| Dupilumab, monotherapy or in combination                           | 0                                  | 0                        | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 24 (75.0)                          | 20 (71.4)                | 4 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 23 (71.9)                          | 19 (67.9)                | 4 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 24.2. Physician-Reported and Patient-Reported Clinical Outcomes in Saudi Arabia**

|  | <b>Total<br/>population<br/>(n=32)</b> | <b>Adults<br/>(n=28)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 15.5 (11.1)                            | 14.9 (10.6)              | 20.1 (14.8)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Mild (0.1–5.9)   | 5 (15.6)                               | 4 (14.3)                 | 1 (25.0)                     |
| Moderate (6.0–22.9)  | 18 (56.3)                              | 17 (60.7)                | 1 (25.0)                     |
| Severe (23.0–72.0)   | 9 (28.1)                               | 7 (25.0)                 | 2 (50.0)                     |
| SCORAD, mean (SD)  | 43.1 (15.5)                            | 42.8 (14.1)              | 45.7 (26.2)                  |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 4 (12.5)                               | 3 (10.7)                 | 1 (25.0)                     |
| Moderate (25.0–50.0)   | 16 (50.0)                              | 15 (53.6)                | 1 (25.0)                     |
| Severe (>50.0)   | 12 (37.5)                              | 10 (35.7)                | 2 (50.0)                     |
| vIGA-AD, mean (SD)   | 2.6 (0.7)                              | 2.6 (0.6)                | 2.5 (1.3)                    |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Almost clear (1)   | 2 (6.3)                                | 1 (3.6)                  | 1 (25.0)                     |
| Mild (2)   | 10 (31.3)                              | 9 (32.1)                 | 1 (25.0)                     |
| Moderate (3)   | 19 (59.4)                              | 18 (64.3)                | 1 (25.0)                     |
| Severe (4)   | 1 (3.1)                                | 0                        | 1 (25.0)                     |
| BSA, % affected, mean (SD)   | 14.1 (19.1)                            | 13.8 (18.0)              | 16.4 (29.2)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 5.8 (1.8)                              | 5.7 (1.8)                | 6.0 (2.2)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 52.3 (42.1)                            | 54.3 (43.8)              | 38.3 (27.4)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 0                                      | 0                        | 0                            |
| Not at all   | 10 (31.3)                              | 9 (32.1)                 | 1 (25.0)                     |
| A little   | 7 (21.9)                               | 7 (25.0)                 | 0                            |
| Somewhat   | 9 (28.1)                               | 7 (25.0)                 | 2 (50.0)                     |
| Much   | 5 (15.6)                               | 4 (14.3)                 | 1 (25.0)                     |
| Very much  | 1 (3.1)                                | 1 (3.6)                  | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 14.9 (4.1)<br>n=30                     | 14.9 (4.1)<br>n=26       | 14.5 (4.8)                   |
| POEM, mean (SD)  | 12.6 (7.3)<br>n=31                     | 12.6 (6.9)<br>n=27       | 13.3 (10.9)                  |
| Total ADerm-IS, mean (SD)  | 44.8 (28.7)<br>n=31                    | 45.0 (26.7)<br>n=27      | 43.3 (33.2)                  |

|   |                     |                     |                    |
|---|---------------------|---------------------|--------------------|
| ADerm-IS Sleep domain, mean (SD)                    | 11.6 (10.3)<br>n=31 | 11.6 (10.3)<br>n=27 | 11.5 (12.0)        |
| ADerm-SS TSS-7, mean (SD)                           | 32.1 (16.7)<br>n=31 | 32.6 (15.9)<br>n=27 | 28.8 (23.9)        |
| ADerm-SS TSS-11, mean (SD)                          | 46.0 (25.1)<br>n=31 | 46.8 (23.8)<br>n=27 | 40.3 (36.6)        |
| ADerm-SS Skin pain, mean (SD)                       | 3.8 (3.1)<br>n=31   | 3.8 (3.1)<br>n=27   | 4.0 (3.4)          |
| Number of flares in last 6 months, n (%)            |                     |                     |                    |
| 0   | 1 (3.1)             | 1 (3.6)             | 0                  |
| 1–2   | 5 (15.6)            | 4 (14.3)            | 1 (25.0)           |
| 3–4   | 3 (9.4)             | 3 (10.7)            | 0                  |
| 5–6   | 3 (9.4)             | 2 (7.1)             | 1 (25.0)           |
| >6  | 17 (53.1)           | 15 (53.6)           | 2 (50.0)           |
| Missing   | 3 (9.4)             | 3 (10.7)            | 0                  |
| Number of flares in the last 6 months, mean (range) | 11.6 (0–36)<br>n=29 | 11.7 (0–36)<br>n=25 | 11.0 (2–24)        |
| Average duration of flares in last 6 months, n (%)  |                     |                     |                    |
| ≤2 days   | 9 (28.1)            | 9 (32.1)            | 0                  |
| 3–7 days  | 15 (46.9)           | 11 (39.3)           | 4 (100.0)          |
| 8–14 days   | 4 (12.5)            | 4 (14.3)            | 0                  |
| ≥15 days  | 2 (6.3)             | 2 (7.1)             | 0                  |
| Missing   | 2 (6.3)             | 2 (7.1)             | 0                  |
| Inadequately controlled AD, n (%)                   | 4 (12.5)            | 4 (14.3)            | 0                  |
| SF-12 PCS, mean (SD)                                | NA                  | 49.5 (8.4)<br>n=27  | NA                 |
| SF-10 PHS, mean (SD)                                | NA                  | NA                  | 45.9 (13.2)<br>n=3 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 24.3. Psychosocial-Economic Burden of AD in Saudi Arabia**

|   | <b>Total<br/>population<br/>(n=32)</b> | <b>Adults<br/>(n=28)</b> | <b>Adolescents<br/>(n=4)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 8.8 (2.4)<br>n=29                      | 8.7 (2.5)<br>n=26        | 9.0 (0.0)<br>n=3             |
| HADS-A $\geq 8$ , n (%)   | 20 (62.5)                              | 17 (60.7)                | 3 (75.0)                     |
| HADS-D, mean (SD)   | 8.8 (3.0)<br>n=29                      | 8.9 (3.1)<br>n=26        | 7.7 (1.5)<br>n=3             |
| HADS-D $\geq 8$ , n (%)   | 17 (53.1)                              | 15 (53.6)                | 2 (50.0)                     |
| SF-12 MCS, mean (SD)  | NA                                     | 44.2 (12.9)<br>n=27      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 52.2 (8.7)<br>n=3            |
| ADerm-IS Daily Activities, mean (SD)  | 16.5 (12.4)<br>n=31                    | 17.0 (12.1)<br>n=27      | 13.0 (15.6)                  |
| ADerm-IS Emotional State, mean (SD)   | 16.7 (10.4)<br>n=31                    | 16.4 (10.8)<br>n=27      | 18.8 (7.5)                   |
| WPAI-AD, Employed, n (%)  | 11 (34.4)                              | 11 (39.3)                | 0                            |
| Absenteeism, %, mean (SD)   | 13.2 (23.0)<br>n=11                    | 13.2 (23.0)<br>n=11      | –                            |
| Presenteeism, %, mean (SD)  | 15.5 (19.7)<br>n=11                    | 15.5 (19.7)<br>n=11      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 26.9 (27.5)<br>n=11                    | 26.9 (27.5)<br>n=11      | –                            |
| Activity impairment, %, mean (SD)   | 35.4 (31.2)<br>n=28                    | 35.8 (31.5)<br>n=24      | 32.5 (34.0)                  |
| Hours missed from work, mean (SD)   | 3.0 (4.0)<br>n=11                      | 3.0 (4.0)<br>n=11        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 2.9 (3.8)<br>n=28                      | 2.8 (3.9)<br>n=24        | 3.5 (3.9)                    |
| <b>Out of pocket expenses</b>   |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 236.9 (346.1)<br>n=26                  | 186.1 (189.3)<br>n=22    | 516.4 (790.1)                |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 25.1. Baseline Patient Demographics and Characteristics in Slovakia**

|  | <b>Adults*<br/>(n=13)</b> |
|--|---------------------------|
| Age, years, mean (SD)  | 34.8 (12.2)               |
| Male, n (%)  | 3 (23.1)                  |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 23.4 (2.8)                |
| Employed, n (%)  | 9 (69.2)                  |
| Duration of AD, years, mean (SD)                                   | 23.9 (16.7)               |
| Time from AD diagnosis to first therapy, years mean (SD)           | 13.0 (NA)<br>n=1          |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 20.6 (9.0)<br>n=4         |
| Continuous systemic therapy over previous 12 months, n (%)         | 1 (7.7)                   |
| Current therapy, n (%)   | 13 (100.0)                |
| Systemic monotherapy or in combination                             | 2 (15.4)                  |
| Dupilumab  | 0                         |
| Systemic corticosteroids   | 1 (50.0)                  |
| Methotrexate   | 0                         |
| Cyclosporine   | 1 (50.0)                  |
| Azathioprine   | 0                         |
| Mycophenolate  | 0                         |
| Systemic monotherapy   | 0                         |
| Topical monotherapy or in combination                              | 13 (100.0)                |
| Topical monotherapy  | 0                         |
| TCS or TCI monotherapy   | 0                         |
| Previous systemic therapy, n (%)                                   |                           |
| Systemic monotherapy or in combination                             | 4 (30.8)                  |
| Systemic monotherapy   | 0                         |
| Dupilumab, monotherapy or in combination                           | 0                         |
| Dupilumab monotherapy  | 0                         |
| Treatment prior to study enrollment, n (%)                         |                           |
| Topical therapy received as monotherapy                            | 2 (15.4)                  |
| Suboptimal response to topical monotherapy                         | 0                         |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

\*Only adult patients were included from Slovakia.

**Supplementary Table 25.2. Physician-Reported and Patient-Reported Clinical Outcomes in Slovakia**

|   | <b>Adults*<br/>(n=13)</b> |
|---|---------------------------|
| <b>Physician-reported outcomes</b>  |                           |
| EASI, mean (SD)   | 25.6 (10.7)               |
| EASI categories, n (%)  |                           |
| Clear (0)   | 0                         |
| Mild (0.1–5.9)  | 1 (7.7)                   |
| Moderate (6.0–22.9)   | 2 (15.4)                  |
| Severe (23.0–72.0)  | 10 (76.9)                 |
| SCORAD, mean (SD)   | 66.7 (15.1)               |
| SCORAD categories, n (%)  |                           |
| Mild (<25.0)  | 0                         |
| Moderate (25.0–50.0)  | 2 (15.4)                  |
| Severe (>50.0)  | 11 (84.6)                 |
| vIGA-AD, mean (SD)  | 3.3 (0.6)                 |
| Clear (0)   | 0                         |
| Almost clear (1)  | 0                         |
| Mild (2)  | 1 (7.7)                   |
| Moderate (3)  | 7 (53.8)                  |
| Severe (4)  | 5 (38.5)                  |
| BSA, % affected, mean (SD)  | 52.2 (17.9)               |
| Average hours of sleep per night in the past week, mean (SD)                | 6.1 (1.6)<br>n=12         |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 75.1 (96.1)<br>n=12       |
| Sleep problems interfered with daily function over the past week, n (%)     |                           |
| I do not have sleep problems  | 0                         |
| Not at all  | 2 (15.4)                  |
| A little  | 1 (7.7)                   |
| Somewhat  | 3 (23.1)                  |
| Much  | 5 (38.5)                  |
| Very much   | 1 (7.7)                   |
| Missing   | 1 (7.7)                   |
| <b>Patient-reported outcomes</b>  |                           |
| 5D-Pruritus score, mean (SD)  | 19.8 (2.6)                |
| POEM, mean (SD)   | 21.8 (5.6)                |
| Total ADerm-IS, mean (SD)   | 64.5 (15.6)               |
| ADerm-IS Sleep domain, mean (SD)  | 18.5 (8.8)                |
| ADerm-SS TSS-7, mean (SD)   | 49.1 (18.2)               |
| ADerm-SS TSS-11, mean (SD)  | 71.4 (27.6)               |
| ADerm-SS Skin pain, mean (SD)   | 6.7 (3.4)                 |
| Number of flares in last 6 months, n (%)                                    |                           |
| 0   | 0                         |

|   |                    |
|---|--------------------|
| 1–2   | 4 (30.8)           |
| 3–4   | 3 (23.1)           |
| 5–6   | 2 (15.4)           |
| >6  | 3 (23.1)           |
| Missing   | 1 (7.7)            |
| Number of flares in the last 6 months, mean (range) | 8.9 (1–56)<br>n=12 |
| Average duration of flares in last 6 months, n (%)  |                    |
| ≤2 days   | 0                  |
| 3–7 days  | 4 (30.8)           |
| 8–14 days   | 3 (23.1)           |
| ≥15 days  | 5 (38.5)           |
| Missing   | 1 (7.7)            |
| Inadequately controlled AD, n (%)                   | 2 (15.4)           |
| SF-12 PCS, mean (SD)                                | 41.9 (8.3)         |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

\*Only adult patients were included from Slovakia.

**Supplementary Table 25.3. Psychosocial-Economic Burden of AD in Slovakia**

|   | <b>Adults*<br/>(n=13)</b> |
|---|---------------------------|
| HADS-A, mean (SD)   | 10.3 (5.0)                |
| HADS-A $\geq 8$ , n (%)   | 9 (69.2)                  |
| HADS-D, mean (SD)   | 9.6 (5.7)                 |
| HADS-D $\geq 8$ , n (%)   | 8 (61.5)                  |
| SF-12 MCS, mean (SD)  | 33.9 (9.3)                |
| ADerm-IS Daily Activities, mean (SD)  | 28.7 (7.4)                |
| ADerm-IS Emotional State, mean (SD)   | 17.3 (4.8)                |
| WPAI-AD, Employed, n (%)  | 9 (69.2)                  |
| Absenteeism, %, mean (SD)   | 38.3 (45.1)<br>n=8        |
| Presenteeism, %, mean (SD)  | 38.3 (28.6)<br>n=6        |
| Overall work productivity impairment, %, mean (SD)  | 44.1 (35.9)<br>n=6        |
| Activity impairment, %, mean (SD)   | 64.6 (29.3)               |
| Hours missed from work, mean (SD)   | 18.7 (19.1)<br>n=9        |
| HCRU  |                           |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 5.9 (7.1)<br>n=11         |
| Out of pocket expenses  |                           |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 144.0 (114.6)<br>n=12     |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care resource utilization; SF-12 MCS, Short Form-12 Health Survey mental component summary (adults); United States dollars (2021); WPAI-AD, work activity; Work Productivity and Activity Impairment Atopic Dermatitis.

\*Only adult patients were included in Slovakia.

**Supplementary Table 26.1. Baseline Patient Demographics and Characteristics in Spain**

|  | <b>Total population<br/>(n=95)</b> | <b>Adults<br/>(n=91)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 32.9 (12.2)                        | 33.7 (11.9)              | 16.0 (0.8)                   |
| Male, n (%)  | 48 (50.5)                          | 46 (50.5)                | 2 (50.0)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 24.9 (4.1)<br>n=92                 | 25.0 (4.1)<br>n=88       | 21.0 (3.8)                   |
| Employed, n (%)  | 53 (55.8)                          | 53 (58.2)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 21.9 (11.7)<br>n=79                | 22.2 (11.9)<br>n=75      | 15.3 (0.6)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 13.9 (13.3)<br>n=29                | 13.9 (13.3)<br>n=29      | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 13.2 (12.3)<br>n=64                | 13.2 (12.6)<br>n=61      | 13.3 (1.1)<br>n=3            |
| Continuous systemic therapy over previous 12 months, n (%)         | 33 (34.7)                          | 32 (35.2)                | 1 (25.0)                     |
| Current therapy, n (%)   | 95 (100.0)                         | 91 (100.0)               | 4 (100.0)                    |
| Systemic monotherapy or in combination                             | 81 (85.3)                          | 77 (84.6)                | 4 (100.0)                    |
| Dupilumab  | 40 (49.4)                          | 38 (49.4)                | 2 (50.0)                     |
| Systemic corticosteroids   | 5 (6.2)                            | 5 (6.5)                  | 0                            |
| Methotrexate   | 9 (11.1)                           | 8 (10.4)                 | 1 (25.0)                     |
| Cyclosporine   | 23 (28.4)                          | 22 (28.6)                | 1 (25.0)                     |
| Azathioprine   | 8 (9.9)                            | 8 (10.4)                 | 0                            |
| Mycophenolate  | 2 (2.5)                            | 2 (2.6)                  | 0                            |
| Systemic monotherapy   | 29 (30.5)                          | 28 (30.8)                | 1 (25.0)                     |
| Topical monotherapy or in combination                              | 64 (67.4)                          | 61 (67.0)                | 3 (75.0)                     |
| Topical monotherapy  | 9 (9.5)                            | 9 (9.9)                  | 0                            |
| TCS or TCI monotherapy   | 8 (8.4)                            | 8 (8.8)                  | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 87 (91.6)                          | 83 (91.2)                | 4 (100.0)                    |
| Systemic monotherapy   | 18 (18.9)                          | 18 (19.8)                | 0                            |
| Dupilumab, monotherapy or in combination                           | 2 (2.1)                            | 2 (2.2)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 90 (94.7)                          | 86 (94.5)                | 4 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 90 (94.7)                          | 86 (94.5)                | 4 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 26.2. Physician-Reported and Patient-Reported Clinical Outcomes in Spain**

|  | <b>Total<br/>population<br/>(n=95)</b> | <b>Adults<br/>(n=91)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 11.8 (10.9)                            | 11.9 (11.0)              | 8.3 (7.9)                    |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 10 (10.5)                              | 10 (11.0)                | 0                            |
| Mild (0.1–5.9)   | 26 (27.4)                              | 24 (26.4)                | 2 (50.0)                     |
| Moderate (6.0–22.9)  | 45 (47.4)                              | 43 (47.3)                | 2 (50.0)                     |
| Severe (23.0–72.0)   | 14 (14.7)                              | 14 (15.4)                | 0                            |
| SCORAD, mean (SD)  | 33.9 (20.5)<br>n=94                    | 34.1 (20.7)<br>n=90      | 29.3 (19.0)                  |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 34 (35.8)                              | 32 (35.2)                | 2 (50.0)                     |
| Moderate (25.0–50.0)   | 37 (38.9)                              | 36 (39.6)                | 1 (25.0)                     |
| Severe (>50.0)   | 23 (24.2)                              | 22 (24.2)                | 1 (25.0)                     |
| Missing  | 1 (1.1)                                | 1 (1.1)                  | 0                            |
| vIGA-AD, mean (SD)   | 2.1 (1.3)                              | 2.1 (1.3)                | 2.0 (0.8)                    |
| Clear (0)  | 13 (13.7)                              | 13 (14.3)                | 0                            |
| Almost clear (1)   | 19 (20.0)                              | 18 (19.8)                | 1 (25.0)                     |
| Mild (2)   | 21 (22.1)                              | 19 (20.9)                | 2 (50.0)                     |
| Moderate (3)   | 28 (29.5)                              | 27 (29.7)                | 1 (25.0)                     |
| Severe (4)   | 14 (14.7)                              | 14 (15.4)                | 0                            |
| BSA, % affected, mean (SD)   | 23.2 (21.5)                            | 23.2 (21.6)              | 23.0 (21.4)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.8 (1.4)<br>n=88                      | 6.8 (1.4)<br>n=84        | 7.8 (1.0)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 37.7 (65.2)<br>n=93                    | 38.4 (66.4)<br>n=89      | 21.3 (26.3)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 14 (14.7)                              | 14 (15.4)                | 0                            |
| Not at all   | 32 (33.7)                              | 30 (33.0)                | 2 (50.0)                     |
| A little   | 21 (22.1)                              | 21 (23.1)                | 0                            |
| Somewhat   | 17 (17.9)                              | 16 (17.6)                | 1 (25.0)                     |
| Much   | 5 (5.3)                                | 5 (5.5)                  | 0                            |
| Very much  | 4 (4.2)                                | 3 (3.3)                  | 1 (25.0)                     |
| Missing  | 2 (2.1)                                | 2 (2.2)                  | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 14.9 (4.8)<br>n=84                     | 14.9 (4.8)<br>n=80       | 14.8 (6.1)                   |
| POEM, mean (SD)  | 12.3 (7.7)                             | 12.3 (7.6)               | 13.8 (10.5)                  |

|   | n=94                | n=90                |                    |
|---|---------------------|---------------------|--------------------|
| Total ADerm-IS, mean (SD)                           | 28.9 (28.6)<br>n=94 | 28.5 (28.7)<br>n=90 | 36.3 (30.8)        |
| ADerm-IS Sleep domain, mean (SD)                    | 9.3 (9.7)           | 9.1 (9.6)           | 12.3 (12.7)        |
| ADerm-SS TSS-7, mean (SD)                           | 26.5 (18.1)         | 26.4 (18.1)         | 28.5 (21.7)        |
| ADerm-SS TSS-11, mean (SD)                          | 37.0 (26.1)<br>n=93 | 36.9 (26.1)<br>n=89 | 39.3 (31.4)        |
| ADerm-SS Skin pain, mean (SD)                       | 3.4 (3.1)           | 3.5 (3.2)           | 2.8 (2.5)          |
| Number of flares in last 6 months, n (%)            |                     |                     |                    |
| 0   | 14 (14.7)           | 14 (15.4)           | 0                  |
| 1–2   | 23 (24.2)           | 22 (24.2)           | 1 (25.0)           |
| 3–4   | 33 (34.7)           | 32 (35.2)           | 1 (25.0)           |
| 5–6   | 8 (8.4)             | 8 (8.8)             | 0                  |
| >6  | 15 (15.8)           | 13 (14.3)           | 2 (50.0)           |
| Missing   | 2 (2.1)             | 2 (2.2)             | 0                  |
| Number of flares in the last 6 months, mean (range) | 4.5 (0–50)<br>n=93  | 4.3 (0–50)<br>n=89  | 9.0 (1–20)         |
| Average duration of flares in last 6 months, n (%)  |                     |                     |                    |
| ≤2 days   | 17 (17.9)           | 17 (18.7)           | 0                  |
| 3–7 days  | 39 (41.1)           | 37 (40.7)           | 2 (50.0)           |
| 8–14 days   | 16 (16.8)           | 15 (16.5)           | 1 (25.0)           |
| ≥15 days  | 19 (20.0)           | 18 (19.8)           | 1 (25.0)           |
| Missing   | 4 (4.2)             | 4 (4.4)             | 0                  |
| Inadequately controlled AD, n (%)                   | 25 (26.3)           | 24 (26.4)           | 1 (25.0)           |
| SF-12 PCS, mean (SD)                                | NA                  | 52.7 (7.8)<br>n=90  | NA                 |
| SF-10 PHS, mean (SD)                                | NA                  | NA                  | 31.6 (17.7)<br>n=3 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 26.3. Psychosocial-Economic Burden of AD in Spain**

|   | <b>Total population<br/>(n=95)</b> | <b>Adults<br/>(n=91)</b> | <b>Adolescents<br/>(n=4)</b> |
|---|------------------------------------|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 6.4 (4.8)<br>n=93                  | 6.5 (4.8)<br>n=89        | 4.0 (3.4)                    |
| HADS-A $\geq 8$ , n (%)   | 35 (36.8)                          | 34 (37.4)                | 1 (25.0)                     |
| HADS-D, mean (SD)   | 4.0 (4.1)<br>n=93                  | 4.0 (4.1)<br>n=89        | 4.0 (3.7)                    |
| HADS-D $\geq 8$ , n (%)   | 19 (20.0)                          | 18 (19.8)                | 1 (25.0)                     |
| SF-12 MCS, mean (SD)  | NA                                 | 45.8 (11.0)<br>n=90      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                 | NA                       | 46.2 (7.3)<br>n=3            |
| ADerm-IS Daily Activities, mean (SD)  | 10.5 (11.8)<br>n=94                | 10.3 (11.8)<br>n=90      | 16.0 (12.7)                  |
| ADerm-IS Emotional State, mean (SD)   | 9.0 (9.1)                          | 9.0 (9.2)                | 8.0 (7.1)                    |
| WPAI-AD, Employed, n (%)  | 53 (55.8)                          | 53 (58.2)                | 0                            |
| Absenteeism, %, mean (SD)   | 2.1 (5.9)<br>n=40                  | 2.1 (5.9)<br>n=40        | –                            |
| Presenteeism, %, mean (SD)  | 18.6 (21.9)<br>n=43                | 18.6 (21.9)<br>n=43      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 18.6 (22.6)<br>n=40                | 18.6 (22.6)<br>n=40      | –                            |
| Activity impairment, %, mean (SD)   | 24.7 (27.7)<br>n=91                | 24.2 (27.4)<br>n=88      | 40.0 (40.0)<br>n=3           |
| Hours missed from work, mean (SD)   | 0.7 (2.0)<br>n=51                  | 0.7 (2.0)<br>n=51        | –                            |
| HCRU  |                                    |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 2.2 (3.8)<br>n=77                  | 2.1 (3.8)<br>n=74        | 3.7 (6.4)<br>n=3             |
| <b>Out of pocket expenses</b>   |                                    |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 99.6 (102.4)<br>n=83               | 96.9 (102.4)<br>n=79     | 151.3 (102.8)                |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 27.1. Baseline Patient Demographics and Characteristics in Switzerland**

|  | <b>Total population<br/>(n=57)</b> | <b>Adults<br/>(n=55)</b> | <b>Adolescents<br/>(n=2)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 42.8 (20.6)                        | 43.9 (20.2)              | 13.0 (1.4)                   |
| Male, n (%)  | 30 (52.6)                          | 30 (54.5)                | 0                            |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 25.4 (5.5)                         | 25.6 (5.5)               | 21.9 (0.2)                   |
| Employed, n (%)  | 35 (61.4)                          | 35 (63.6)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 20.0 (15.5)<br>n=55                | 20.1 (15.7)<br>n=54      | 13.7 (NA)<br>n=1             |
| Time from AD diagnosis to first therapy, years mean (SD)           | 14.6 (13.6)<br>n=10                | 14.6 (13.6)<br>n=10      | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 13.4 (14.8)<br>n=45                | 13.7 (14.9)<br>n=44      | 0.0 (NA)<br>n=1              |
| Continuous systemic therapy over previous 12 months, n (%)         | 10 (17.5)                          | 10 (18.2)                | 0                            |
| Current therapy, n (%)   | 57 (100.0)                         | 55 (100.0)               | 2 (100.0)                    |
| Systemic monotherapy or in combination                             | 39 (68.4)                          | 38 (69.1)                | 1 (50.0)                     |
| Dupilumab  | 34 (87.2)                          | 34 (89.5)                | 0                            |
| Methotrexate   | 6 (15.4)                           | 5 (13.2)                 | 1 (100.0)                    |
| Cyclosporine   | 3 (7.7)                            | 3 (7.9)                  | 0                            |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 4 (7.0)                            | 4 (7.3)                  | 0                            |
| Topical monotherapy or in combination                              | 52 (91.2)                          | 50 (90.9)                | 2 (100.0)                    |
| Topical monotherapy  | 5 (8.8)                            | 5 (9.1)                  | 0                            |
| TCS or TCI monotherapy   | 4 (7.0)                            | 4 (7.3)                  | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 43 (75.4)                          | 43 (78.2)                | 0                            |
| Systemic monotherapy   | 10 (17.5)                          | 10 (18.2)                | 0                            |
| Dupilumab, monotherapy or in combination                           | 2 (3.5)                            | 2 (3.6)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 55 (96.5)                          | 53 (96.4)                | 2 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 53 (93.0)                          | 51 (92.7)                | 2 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 27.2. Physician-Reported and Patient-Reported Clinical Outcomes in Switzerland**

|   | <b>Total<br/>population<br/>(n=57)</b> | <b>Adults<br/>(n=55)</b> | <b>Adolescents<br/>(n=2)</b> |
|---|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>  |  |                          |                              |
| EASI, mean (SD)   | 14.3 (14.0)                            | 14.1 (14.0)              | 18.2 (17.5)                  |
| EASI categories, n (%)  |  |                          |                              |
| Clear (0)   | 3 (5.3)                                | 3 (5.5)                  | 0                            |
| Mild (0.1–5.9)  | 19 (33.3)                              | 18 (32.7)                | 1 (50.0)                     |
| Moderate (6.0–22.9)   | 18 (31.6)                              | 18 (32.7)                | 0                            |
| Severe (23.0–72.0)  | 17 (29.8)                              | 16 (29.1)                | 1 (50.0)                     |
| SCORAD, mean (SD)   | 43.1 (24.4)                            | 42.5 (24.5)              | 58.8 (19.6)                  |
| SCORAD categories, n (%)  |  |                          |                              |
| Mild (<25.0)  | 16 (28.1)                              | 16 (29.1)                | 0                            |
| Moderate (25.0–50.0)  | 18 (31.6)                              | 17 (30.9)                | 1 (50.0)                     |
| Severe (>50.0)  | 23 (40.4)                              | 22 (40.0)                | 1 (50.0)                     |
| vIGA-AD, mean (SD)  | 2.4 (1.1)                              | 2.4 (1.1)                | 3.0 (0.0)                    |
| Clear (0)   | 2 (3.5)                                | 2 (3.6)                  | 0                            |
| Almost clear (1)  | 11 (19.3)                              | 11 (20.0)                | 0                            |
| Mild (2)  | 14 (24.6)                              | 14 (25.5)                | 0                            |
| Moderate (3)  | 22 (38.6)                              | 20 (36.4)                | 2 (100.0)                    |
| Severe (4)  | 8 (14.0)                               | 8 (14.5)                 | 0                            |
| BSA, % affected, mean (SD)  | 27.1 (25.3)                            | 27.8 (25.5)              | 7.5 (3.5)                    |
| Average hours of sleep per night in the past week, mean (SD)                | 6.8 (1.5)                              | 6.7 (1.5)                | 8.5 (0.7)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 33.2 (36.1)                            | 33.7 (36.7)              | 20.0 (14.1)                  |
| Sleep problems interfered with daily function over the past week, n (%)     |  |                          |                              |
| I do not have sleep problems  | 2 (3.5)                                | 2 (3.6)                  | 0                            |
| Not at all  | 20 (35.1)                              | 19 (34.5)                | 1 (50.0)                     |
| A little  | 10 (17.5)                              | 9 (16.4)                 | 1 (50.0)                     |
| Somewhat  | 17 (29.8)                              | 17 (30.9)                | 0                            |
| Much  | 5 (8.8)                                | 5 (9.1)                  | 0                            |
| Very much   | 3 (5.3)                                | 3 (5.5)                  | 0                            |
| <b>Patient-reported outcomes</b>  |  |                          |                              |
| 5D-Pruritus score, mean (SD)  | 14.0 (4.4)<br>n=52                     | 14.0 (4.4)<br>n=50       | 15.5 (6.4)                   |
| POEM, mean (SD)   | 12.4 (7.7)                             | 12.4 (7.7)               | 12.5 (9.2)                   |
| Total ADerm-IS, mean (SD)   | 27.6 (26.3)                            | 27.4 (26.2)              | 34.5 (41.7)                  |
| ADerm-IS Sleep domain, mean (SD)  | 10.0 (10.0)                            | 9.9 (10.0)               | 11.5 (14.9)                  |
| ADerm-SS TSS-7, mean (SD)   | 22.4 (18.5)<br>n=56                    | 22.3 (18.6)<br>n=54      | 27.5 (21.9)                  |

|   |                     |                     |             |
|---|---------------------|---------------------|-------------|
| ADerm-SS TSS-11, mean (SD)                          | 31.0 (26.7)<br>n=56 | 30.6 (26.6)<br>n=54 | 42.5 (37.5) |
| ADerm-SS Skin pain, mean (SD)                       | 3.3 (3.2)           | 3.3 (3.2)           | 3.5 (3.5)   |
| Number of flares in last 6 months, n (%)            |                     |                     |             |
| 0   | 10 (17.5)           | 10 (18.2)           | 0           |
| 1–2   | 13 (22.8)           | 13 (23.6)           | 0           |
| 3–4   | 13 (22.8)           | 12 (21.8)           | 1 (50.0)    |
| 5–6   | 7 (12.3)            | 7 (12.7)            | 0           |
| >6  | 13 (22.8)           | 12 (21.8)           | 1 (50.0)    |
| Missing   | 1 (1.8)             | 1 (1.8)             | 0           |
| Number of flares in the last 6 months, mean (range) | 9.0 (0–200)<br>n=56 | 9.1 (0–200)<br>n=54 | 5.0 (3–7)   |
| Average duration of flares in last 6 months, n (%)  |                     |                     |             |
| ≤2 days   | 16 (28.1)           | 16 (29.1)           | 0           |
| 3–7 days  | 23 (40.4)           | 21 (38.2)           | 2 (100.0)   |
| 8–14 days   | 7 (12.3)            | 7 (12.7)            | 0           |
| ≥15 days  | 8 (14.0)            | 8 (14.5)            | 0           |
| Missing   | 3 (5.3)             | 3 (5.5)             | 0           |
| Inadequately controlled AD, n (%)                   | 16 (28.1)           | 16 (29.1)           | 0           |
| SF-12 PCS, mean (SD)                                | NA                  | 51.1 (7.9)<br>n=54  | NA          |
| SF-10 PHS, mean (SD)                                | NA                  | NA                  | 45.2 (3.6)  |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 27.3. Psychosocial-Economic Burden of AD in Switzerland**

|   | <b>Total<br/>population<br/>(n=57)</b> | <b>Adults<br/>(n=55)</b> | <b>Adolescents<br/>(n=2)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 5.6 (3.6)<br>n=56                      | 5.6 (3.6)<br>n=54        | 6.0 (2.8)                    |
| HADS-A $\geq 8$ , n (%)   | 14 (24.6)                              | 13 (23.6)                | 1 (50.0)                     |
| HADS-D, mean (SD)   | 5.0 (4.2)<br>n=56                      | 5.1 (4.3)<br>n=54        | 2.0 (2.8)                    |
| HADS-D $\geq 8$ , n (%)   | 18 (31.6)                              | 18 (32.7)                | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 46.1 (9.3)<br>n=54       | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 54.3 (3.8)                   |
| ADerm-IS Daily Activities, mean (SD)  | 9.1 (10.1)                             | 8.9 (10.0)               | 14.5 (14.9)                  |
| ADerm-IS Emotional State, mean (SD)   | 8.6 (8.9)                              | 8.6 (8.9)                | 8.5 (12.0)                   |
| WPAI-AD, Employed, n (%)  | 35 (61.4)                              | 35 (63.6)                | 0                            |
| Absenteeism, %, mean (SD)   | 3.1 (10.1)<br>n=26                     | 3.1 (10.1)<br>n=26       | –                            |
| Presenteeism, %, mean (SD)  | 21.3 (22.0)<br>n=32                    | 21.3 (22.0)<br>n=32      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 22.8 (25.9)<br>n=25                    | 22.8 (25.9)<br>n=25      | –                            |
| Activity impairment, %, mean (SD)   | 23.5 (26.3)<br>n=54                    | 22.7 (26.0)<br>n=52      | 45.0 (35.4)                  |
| Hours missed from work, mean (SD)   | 1.4 (4.9)<br>n=28                      | 1.4 (4.9)<br>n=28        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 3.6 (6.1)<br>n=50                      | 3.7 (6.2)<br>n=48        | 1.0 (1.4)                    |
| <b>Out of pocket expenses</b>   |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 258.1 (415.2)<br>n=42                  | 268.0 (423.2)<br>n=40    | 60.5 (23.3)                  |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 28.1. Baseline Patient Demographics and Characteristics in Taiwan**

|  | <b>Total population<br/>(n=25)</b> | <b>Adults<br/>(n=21)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 26.1 (11.2)                        | 28.4 (10.8)              | 14.0 (2.2)                   |
| Male, n (%)  | 15 (60.0)                          | 12 (57.1)                | 3 (75.0)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 22.5 (4.3)                         | 23.3 (4.1)               | 18.1 (1.5)                   |
| Employed, n (%)  | 10 (40.0)                          | 10 (47.6)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 17.0 (8.8)                         | 18.3 (9.0)               | 10.2 (2.8)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 22.9 (2.7)<br>n=2                  | 22.9 (2.7)<br>n=2        | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 14.7 (9.1)<br>n=18                 | 15.9 (8.9)<br>n=16       | 5.3 (2.0)<br>n=2             |
| Continuous systemic therapy over previous 12 months, n (%)         | 2 (8.0)                            | 2 (9.5)                  | 0                            |
| Current therapy, n (%)   | 25 (100.0)                         | 21 (100.0)               | 4 (100.0)                    |
| Systemic monotherapy or in combination                             | 14 (56.0)                          | 13 (61.9)                | 1 (25.0)                     |
| Dupilumab  | 3 (21.4)                           | 3 (23.1)                 | 0                            |
| Systemic corticosteroids   | 2 (14.3)                           | 1 (7.7)                  | 1 (100.0)                    |
| Methotrexate   | 3 (21.4)                           | 3 (23.1)                 | 0                            |
| Cyclosporine   | 4 (28.6)                           | 4 (30.8)                 | 0                            |
| Azathioprine   | 2 (14.3)                           | 2 (15.4)                 | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 1 (4.0)                            | 1 (4.8)                  | 0                            |
| Topical monotherapy or in combination                              | 23 (92.0)                          | 20 (95.2)                | 3 (75.0)                     |
| Topical monotherapy  | 1 (4.0)                            | 1 (4.8)                  | 0                            |
| TCS or TCI monotherapy   | 0                                  | 0                        | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 11 (44.0)                          | 9 (42.9)                 | 2 (50.0)                     |
| Systemic monotherapy   | 2 (8.0)                            | 0                        | 2 (50.0)                     |
| Dupilumab, monotherapy or in combination                           | 1 (4.0)                            | 1 (4.8)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 3 (12.0)                           | 3 (14.3)                 | 0                            |
| Suboptimal response to topical monotherapy                         | 13 (52.0)                          | 12 (57.1)                | 1 (25.0)                     |

AD, atopic dermatitis; BMI, body mass index; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 28.2. Physician-Reported and Patient-Reported Clinical Outcomes in Taiwan**

|  | <b>Total<br/>population<br/>(n=25)</b> | <b>Adults<br/>(n=21)</b> | <b>Adolescents<br/>(n=4)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 19.1 (13.5)                            | 17.6 (12.6)              | 26.8 (17.4)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Mild (0.1–5.9)   | 2 (8.0)                                | 2 (9.5)                  | 0                            |
| Moderate (6.0–22.9)  | 15 (60.0)                              | 13 (61.9)                | 2 (50.0)                     |
| Severe (23.0–72.0)   | 8 (32.0)                               | 6 (28.6)                 | 2 (50.0)                     |
| SCORAD, mean (SD)  | 41.2 (14.8)                            | 41.4 (15.2)              | 40.4 (14.9)                  |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 4 (16.0)                               | 3 (14.3)                 | 1 (25.0)                     |
| Moderate (25.0–50.0)   | 14 (56.0)                              | 12 (57.1)                | 2 (50.0)                     |
| Severe (>50.0)   | 7 (28.0)                               | 6 (28.6)                 | 1 (25.0)                     |
| vIGA-AD, mean (SD)   | 3.0 (0.8)                              | 3.0 (0.8)                | 3.0 (0.8)                    |
| Clear (0)  | 0                                      | 0                        | 0                            |
| Almost clear (1)   | 1 (4.0)                                | 1 (4.8)                  | 0                            |
| Mild (2)   | 5 (20.0)                               | 4 (19.0)                 | 1 (25.0)                     |
| Moderate (3)   | 13 (52.0)                              | 11 (52.4)                | 2 (50.0)                     |
| Severe (4)   | 6 (24.0)                               | 5 (23.8)                 | 1 (25.0)                     |
| BSA, % affected, mean (SD)   | 35.6 (22.9)                            | 33.4 (21.4)              | 47.4 (30.4)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 6.3 (1.5)                              | 6.3 (1.2)                | 5.9 (2.7)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 32.2 (28.2)                            | 30.8 (22.6)              | 40.0 (53.5)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 3 (12.0)                               | 2 (9.5)                  | 1 (25.0)                     |
| Not at all   | 6 (24.0)                               | 5 (23.8)                 | 1 (25.0)                     |
| A little   | 3 (12.0)                               | 3 (14.3)                 | 0                            |
| Somewhat   | 6 (24.0)                               | 4 (19.0)                 | 2 (50.0)                     |
| Much   | 4 (16.0)                               | 4 (19.0)                 | 0                            |
| Very much  | 3 (12.0)                               | 3 (14.3)                 | 0                            |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 14.3 (4.1)                             | 14.9 (4.3)               | 11.3 (0.5)                   |
| POEM, mean (SD)  | 14.5 (7.5)                             | 15.2 (7.7)               | 10.8 (5.0)                   |
| Total ADerm-IS, mean (SD)  | 44.0 (26.8)                            | 48.2 (26.3)              | 21.8 (19.5)                  |
| ADerm-IS Sleep domain, mean (SD)   | 12.1 (8.8)                             | 13.8 (8.5)               | 3.3 (4.3)                    |

|   |             |                    |             |
|---|-------------|--------------------|-------------|
| ADerm-SS TSS-7, mean (SD)                           | 31.3 (19.1) | 35.1 (18.2)        | 11.3 (7.5)  |
| ADerm-SS TSS-11, mean (SD)                          | 45.4 (30.0) | 51.3 (29.0)        | 14.3 (7.7)  |
| ADerm-SS Skin pain, mean (SD)                       | 4.3 (3.2)   | 4.9 (3.2)          | 1.3 (1.0)   |
| Number of flares in last 6 months, n (%)            |             |                    |             |
| 0   | 3 (12.0)    | 2 (9.5)            | 1 (25.0)    |
| 1–2   | 4 (16.0)    | 3 (14.3)           | 1 (25.0)    |
| 3–4   | 8 (32.0)    | 6 (28.6)           | 2 (50.0)    |
| 5–6   | 5 (20.0)    | 5 (23.8)           | 0           |
| >6  | 5 (20.0)    | 5 (23.8)           | 0           |
| Number of flares in the last 6 months, mean (range) | 5.8 (0–36)  | 6.6 (0–36)         | 1.8 (0–3)   |
| Average duration of flares in last 6 months, n (%)  |             |                    |             |
| ≤2 days   | 5 (20.0)    | 4 (19.0)           | 1 (25.0)    |
| 3–7 days  | 11 (44.0)   | 10 (47.6)          | 1 (25.0)    |
| 8–14 days   | 7 (28.0)    | 6 (28.6)           | 1 (25.0)    |
| ≥15 days  | 2 (8.0)     | 1 (4.8)            | 1 (25.0)    |
| Inadequately controlled AD, n (%)                   | 4 (16.0)    | 4 (19.0)           | 0           |
| SF-12 PCS, mean (SD)                                | NA          | 47.2 (7.1)<br>n=20 | NA          |
| SF-10 PHS, mean (SD)                                | NA          | NA                 | 27.9 (16.1) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 28.3. Psychosocial-Economic Burden of AD in Taiwan**

|   | <b>Total<br/>population<br/>(n=25)</b> | <b>Adults<br/>(n=21)</b> | <b>Adolescents<br/>(n=4)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 6.3 (4.7)                              | 7.0 (4.8)                | 2.5 (2.1)                    |
| HADS-A $\geq 8$ , n (%)   | 10 (40.0)                              | 10 (47.6)                | 0                            |
| HADS-D, mean (SD)   | 5.0 (3.9)                              | 5.5 (4.1)                | 2.8 (1.3)                    |
| HADS-D $\geq 8$ , n (%)   | 6 (24.0)                               | 6 (28.6)                 | 0                            |
| SF-12 MCS, mean (SD)  | NA                                     | 40.9 (9.9)<br>n=20       | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 46.7 (12.1)                  |
| ADerm-IS Daily Activities, mean (SD)  | 16.6 (10.8)                            | 18.1 (10.9)              | 8.8 (6.6)                    |
| ADerm-IS Emotional State, mean (SD)   | 15.2 (9.5)                             | 16.3 (9.4)               | 9.8 (9.5)                    |
| WPAI-AD, Employed, n (%)  | 10 (40.0)                              | 10 (47.6)                | 0                            |
| Absenteeism, %, mean (SD)   | 9.3 (14.0)<br>n=10                     | 9.3 (14.0)<br>n=10       | –                            |
| Presenteeism, %, mean (SD)  | 42.0 (22.5)<br>n=10                    | 42.0 (22.5)<br>n=10      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 48.4 (18.9)<br>n=10                    | 48.4 (18.9)<br>n=10      | –                            |
| Activity impairment, %, mean (SD)   | 47.2 (28.2)                            | 50.0 (26.1)              | 32.5 (38.6)                  |
| Hours missed from work, mean (SD)   | 2.1 (2.8)<br>n=10                      | 2.1 (2.8)<br>n=10        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 5.5 (7.8)                              | 6.0 (8.4)                | 2.5 (3.0)                    |
| Out of pocket expenses  |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 287.5 (643.1)                          | 321.6 (698.9)            | 108.0 (25.5)                 |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 29.1. Baseline Patient Demographics and Characteristics in Turkey**

|  | <b>Total population<br/>(n=48)</b> | <b>Adults<br/>(n=43)</b> | <b>Adolescents<br/>(n=5)</b> |
|--|------------------------------------|--------------------------|------------------------------|
| Age, years, mean (SD)  | 36.0 (16.8)                        | 38.4 (16.0)              | 14.6 (1.7)                   |
| Male, n (%)  | 21 (43.8)                          | 18 (41.9)                | 3 (60.0)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 24.8 (4.1)                         | 25.3 (4.1)               | 20.6 (1.7)                   |
| Employed, n (%)  | 13 (27.1)                          | 13 (30.2)                | 0                            |
| Duration of AD, years, mean (SD)                                   | 13.8 (10.3)<br>n=47                | 13.7 (10.6)<br>n=42      | 14.8 (8.0)                   |
| Time from AD diagnosis to first therapy, years mean (SD)           | 10.4 (15.0)<br>n=8                 | 11.4 (15.9)<br>n=7       | 3.8 (NA)<br>n=1              |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 6.9 (8.4)<br>n=44                  | 6.8 (8.8)<br>n=40        | 7.5 (3.5)<br>n=4             |
| Continuous systemic therapy over previous 12 months, n (%)         | 4 (8.3)                            | 3 (7.0)                  | 1 (20.0)                     |
| Current therapy, n (%)   | 48 (100.0)                         | 43 (100.0)               | 5 (100.0)                    |
| Systemic monotherapy or in combination                             | 30 (62.5)                          | 20 (60.5)                | 4 (80.0)                     |
| Dupilumab  | 10 (33.3)                          | 10 (38.5)                | 0                            |
| Systemic corticosteroids   | 12 (40.0)                          | 10 (38.5)                | 2 (50.0)                     |
| Methotrexate   | 3 (10.0)                           | 2 (7.7)                  | 1 (25.0)                     |
| Cyclosporine   | 5 (16.7)                           | 4 (15.4)                 | 1 (25.0)                     |
| Azathioprine   | 0                                  | 0                        | 0                            |
| Mycophenolate  | 0                                  | 0                        | 0                            |
| Systemic monotherapy   | 4 (8.3)                            | 4 (9.3)                  | 0                            |
| Topical monotherapy or in combination                              | 40 (83.3)                          | 35 (81.4)                | 5 (100.0)                    |
| Topical monotherapy  | 7 (14.6)                           | 7 (16.3)                 | 0                            |
| TCS or TCI monotherapy   | 5 (10.4)                           | 5 (11.6)                 | 0                            |
| Previous systemic therapy, n (%)                                   |                                    |                          |                              |
| Systemic monotherapy or in combination                             | 31 (64.6)                          | 30 (69.8)                | 1 (20.0)                     |
| Systemic monotherapy   | 5 (10.4)                           | 5 (11.6)                 | 0                            |
| Dupilumab, monotherapy or in combination                           | 2 (4.2)                            | 2 (4.7)                  | 0                            |
| Dupilumab monotherapy  | 0                                  | 0                        | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                    |                          |                              |
| Topical therapy received as monotherapy                            | 45 (93.8)                          | 40 (93.0)                | 5 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 41 (85.4)                          | 36 (83.7)                | 5 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 29.2. Physician-Reported and Patient-Reported Clinical Outcomes in Turkey**

|  | <b>Total<br/>population<br/>(n=48)</b> | <b>Adults<br/>(n=43)</b> | <b>Adolescents<br/>(n=5)</b> |
|--|--|--------------------------|------------------------------|
| <b>Physician-reported outcomes</b>   |  |                          |                              |
| EASI, mean (SD)  | 13.7 (11.9)                            | 13.5 (12.1)              | 15.5 (11.7)                  |
| EASI categories, n (%)   |  |                          |                              |
| Clear (0)  | 1 (2.1)                                | 1 (2.3)                  | 0                            |
| Mild (0.1–5.9)   | 16 (33.3)                              | 15 (34.9)                | 1 (20.0)                     |
| Moderate (6.0–22.9)  | 18 (37.5)                              | 16 (37.2)                | 2 (40.0)                     |
| Severe (23.0–72.0)   | 13 (27.1)                              | 11 (25.6)                | 2 (40.0)                     |
| SCORAD, mean (SD)  | 42.9 (20.0)                            | 42.4 (20.3)              | 47.3 (17.8)                  |
| SCORAD categories, n (%)   |  |                          |                              |
| Mild (<25.0)   | 15 (31.3)                              | 14 (32.6)                | 1 (20.0)                     |
| Moderate (25.0–50.0)   | 12 (25.0)                              | 11 (25.6)                | 1 (20.0)                     |
| Severe (>50.0)   | 21 (43.8)                              | 18 (41.9)                | 3 (60.0)                     |
| vIGA-AD, mean (SD)   | 2.3 (1.1)                              | 2.2 (1.1)                | 2.6 (1.1)                    |
| Clear (0)  | 2 (4.2)                                | 2 (4.7)                  | 0                            |
| Almost clear (1)   | 10 (20.8)                              | 9 (20.9)                 | 1 (20.0)                     |
| Mild (2)   | 17 (35.4)                              | 16 (37.2)                | 1 (20.0)                     |
| Moderate (3)   | 11 (22.9)                              | 9 (20.9)                 | 2 (40.0)                     |
| Severe (4)   | 8 (16.7)                               | 7 (16.3)                 | 1 (20.0)                     |
| BSA, % affected, mean (SD)   | 21.1 (17.4)                            | 21.0 (17.8)              | 22.0 (16.0)                  |
| Average hours of sleep per night in the past week, mean (SD)                   | 7.3 (1.5)                              | 7.3 (1.5)                | 7.2 (1.1)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD)    | 31.9 (25.8)                            | 32.6 (26.4)              | 26.0 (20.4)                  |
| <b>Sleep problems interfered with daily function over the past week, n (%)</b> |  |                          |                              |
| I do not have sleep problems   | 8 (16.7)                               | 7 (16.3)                 | 1 (20.0)                     |
| Not at all   | 10 (20.8)                              | 9 (20.9)                 | 1 (20.0)                     |
| A little   | 7 (14.6)                               | 6 (14.0)                 | 1 (20.0)                     |
| Somewhat   | 10 (20.8)                              | 10 (23.3)                | 0                            |
| Much   | 3 (6.3)                                | 2 (4.7)                  | 1 (20.0)                     |
| Very much  | 10 (20.8)                              | 9 (20.9)                 | 1 (20.0)                     |
| <b>Patient-reported outcomes</b>   |  |                          |                              |
| 5D-Pruritus score, mean (SD)   | 14.0 (4.4)<br>n=43                     | 13.9 (4.5)<br>n=39       | 15.0 (4.2)<br>n=4            |
| POEM, mean (SD)  | 13.5 (7.3)<br>n=44                     | 13.3 (7.6)<br>n=41       | 16.0 (1.0)<br>n=3            |
| Total ADerm-IS, mean (SD)  | 39.6 (27.7)<br>n=43                    | 39.1 (28.5)<br>n=40      | 46.3 (12.3)<br>n=3           |

|   |                     |                     |                    |
|---|---------------------|---------------------|--------------------|
| ADerm-IS Sleep domain, mean (SD)                    | 12.6 (9.6)<br>n=44  | 12.3 (9.8)<br>n=41  | 17.0 (3.5)<br>n=3  |
| ADerm-SS TSS-7, mean (SD)                           | 32.9 (18.3)<br>n=43 | 32.8 (18.9)<br>n=40 | 34.7 (5.5)<br>n=3  |
| ADerm-SS TSS-11, mean (SD)                          | 49.4 (29.5)<br>n=42 | 49.2 (30.6)<br>n=39 | 52.0 (6.0)<br>n=3  |
| ADerm-SS Skin pain, mean (SD)                       | 3.8 (3.4)<br>n=44   | 3.9 (3.4)<br>n=41   | 3.0 (1.7)<br>n=3   |
| Number of flares in last 6 months, n (%)            |                     |                     |                    |
| 0   | 5 (10.4)            | 5 (11.6)            | 0                  |
| 1–2   | 14 (29.2)           | 12 (27.9)           | 2 (40.0)           |
| 3–4   | 17 (35.4)           | 15 (34.9)           | 2 (40.0)           |
| 5–6   | 4 (8.3)             | 4 (9.3)             | 0                  |
| >6  | 5 (10.4)            | 5 (11.6)            | 0                  |
| Missing   | 3 (6.3)             | 2 (4.7)             | 1 (20.0)           |
| Number of flares in the last 6 months, mean (range) | 3.4 (0–12)<br>n=45  | 3.5 (0–12)<br>n=41  | 2.3 (1–3)<br>n=4   |
| Average duration of flares in last 6 months, n (%)  |                     |                     |                    |
| ≤2 days   | 6 (12.5)            | 6 (14.0)            | 0                  |
| 3–7 days  | 11 (22.9)           | 10 (23.3)           | 1 (20.0)           |
| 8–14 days   | 10 (20.8)           | 9 (20.9)            | 1 (20.0)           |
| ≥15 days  | 16 (33.3)           | 14 (32.6)           | 2 (40.0)           |
| Missing   | 5 (10.4)            | 4 (9.3)             | 1 (20.0)           |
| Inadequately controlled AD, n (%)                   | 15 (31.3)           | 14 (32.6)           | 1 (20.0)           |
| SF-12 PCS, mean (SD)                                | NA                  | 51.0 (9.6)<br>n=40  | NA                 |
| SF-10 PHS, mean (SD)                                | NA                  | NA                  | 33.1 (17.9)<br>n=4 |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.

**Supplementary Table 29.3. Psychosocial-Economic Burden of AD in Turkey**

|   | <b>Total<br/>population<br/>(n=48)</b> | <b>Adults<br/>(n=43)</b> | <b>Adolescents<br/>(n=5)</b> |
|---|--|--------------------------|------------------------------|
| HADS-A, mean (SD)   | 8.8 (5.3)<br>n=45                      | 8.7 (5.5)<br>n=42        | 10.0 (2.0)<br>n=3            |
| HADS-A $\geq 8$ , n (%)   | 27 (56.3)                              | 24 (55.8)                | 3 (60.0)                     |
| HADS-D, mean (SD)   | 7.4 (4.7)<br>n=45                      | 7.4 (4.7)<br>n=42        | 7.3 (5.5)<br>n=3             |
| HADS-D $\geq 8$ , n (%)   | 20 (41.7)                              | 18 (41.9)                | 2 (40.0)                     |
| SF-12 MCS, mean (SD)  | NA                                     | 39.6 (11.9)<br>n=40      | NA                           |
| SF-10 PSS, mean (SD)  | NA                                     | NA                       | 38.2 (13.5)<br>n=4           |
| ADerm-IS Daily Activities, mean (SD)  | 14.8 (11.2)<br>n=43                    | 14.5 (11.5)<br>n=40      | 18.0 (5.3)<br>n=3            |
| ADerm-IS Emotional State, mean (SD)   | 11.9 (10.1)<br>n=44                    | 11.9 (10.4)<br>n=41      | 11.3 (4.9)<br>n=3            |
| WPAI-AD, Employed, n (%)  | 13 (27.1)                              | 13 (30.2)                | 0                            |
| Absenteeism, %, mean (SD)   | 9.6 (12.8)<br>n=11                     | 9.6 (12.8)<br>n=11       | –                            |
| Presenteeism, %, mean (SD)  | 31.7 (32.7)<br>n=12                    | 31.7 (32.7)<br>n=12      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 37.7 (35.0)<br>n=11                    | 37.7 (35.0)<br>n=11      | –                            |
| Activity impairment, %, mean (SD)   | 42.2 (28.4)<br>n=41                    | 41.8 (28.6)<br>n=40      | 60.0 (NA)<br>n=1             |
| Hours missed from work, mean (SD)   | 5.5 (7.5)<br>n=11                      | 5.5 (7.5)<br>n=11        | –                            |
| HCRU  |  |                          |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 2.8 (2.7)<br>n=42                      | 2.7 (2.7)<br>n=39        | 3.7 (1.5)<br>n=3             |
| <b>Out of pocket expenses</b>   |  |                          |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 62.4 (37.8)<br>n=40                    | 64.1 (38.4)<br>n=37      | 42.0 (24.2)<br>n=3           |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 30.1. Baseline Patient Demographics and Characteristics in United Arab Emirates**

|  | <b>Total population<br/>(n=9)</b> | <b>Adults<br/>(n=7)</b> | <b>Adolescents<br/>(n=2)</b> |
|--|-----------------------------------|-------------------------|------------------------------|
| Age, years, mean (SD)  | 28.7 (11.8)                       | 32.3 (10.8)             | 16.0 (0.0)                   |
| Male, n (%)  | 5 (55.6)                          | 4 (57.1)                | 1 (50.0)                     |
| BMI, kg/m <sup>2</sup> , mean (SD)                                 | 26.4 (7.6)                        | 28.1 (7.8)              | 20.2 (1.8)                   |
| Employed, n (%)  | 5 (55.6)                          | 4 (57.1)                | 1 (50.0)                     |
| Duration of AD, years, mean (SD)                                   | 14.9 (10.0)<br>n=8                | 17.2 (10.4)<br>n=6      | 8.0 (5.7)                    |
| Time from AD diagnosis to first therapy, years mean (SD)           | –                                 | –                       | –                            |
| Time from AD diagnosis to first systemic therapy, years, mean (SD) | 10.6 (10.9)<br>n=7                | 12.1 (11.1)<br>n=6      | 1.8 (NA)<br>n=1              |
| Continuous systemic therapy over previous 12 months, n (%)         | 2 (22.2)                          | 2 (28.6)                | 0                            |
| Current therapy, n (%)   | 9 (100.0)                         | 7 (100.0)               | 2 (100.0)                    |
| Systemic monotherapy or in combination                             | 8 (88.9)                          | 7 (100.0)               | 1 (50.0)                     |
| Dupilumab  | 8 (100.0)                         | 7 (100.0)               | 1 (100.0)                    |
| Systemic corticosteroids   | 0                                 | 0                       | 0                            |
| Methotrexate   | 0                                 | 0                       | 0                            |
| Cyclosporine   | 0                                 | 0                       | 0                            |
| Azathioprine   | 0                                 | 0                       | 0                            |
| Mycophenolate  | 0                                 | 0                       | 0                            |
| Systemic monotherapy   | 1 (11.1)                          | 1 (14.3)                | 0                            |
| Topical monotherapy or in combination                              | 7 (77.8)                          | 5 (71.4)                | 2 (100.0)                    |
| Topical monotherapy  | 0                                 | 0                       | 0                            |
| TCS or TCI monotherapy   | 0                                 | 0                       | 0                            |
| Previous systemic therapy, n (%)                                   |                                   |                         |                              |
| Systemic monotherapy or in combination                             | 5 (55.6)                          | 4 (57.1)                | 1 (50.0)                     |
| Systemic monotherapy   | 0                                 | 0                       | 0                            |
| Dupilumab, monotherapy or in combination                           | 2 (22.2)                          | 1 (14.3)                | 1 (50.0)                     |
| Dupilumab monotherapy  | 0                                 | 0                       | 0                            |
| Treatment prior to study enrollment, n (%)                         |                                   |                         |                              |
| Topical therapy received as monotherapy                            | 8 (88.9)                          | 6 (85.7)                | 2 (100.0)                    |
| Suboptimal response to topical monotherapy                         | 8 (88.9)                          | 6 (85.7)                | 2 (100.0)                    |

AD, atopic dermatitis; BMI, body mass index; NA, not applicable; TCI, Topical calcineurin inhibitor; TCS, topical corticosteroid.

**Supplementary Table 30.2. Physician-Reported and Patient-Reported Clinical Outcomes in United Arab Emirates**

|   | <b>Total<br/>population<br/>(n=9)</b> | <b>Adults<br/>(n=7)</b> | <b>Adolescents<br/>(n=2)</b> |
|---|---------------------------------------|-------------------------|------------------------------|
| <b>Physician-reported outcomes</b>  |                                       |                         |                              |
| EASI, mean (SD)   | 6.6 (12.1)                            | 6.8 (14.0)              | 5.8 (0.3)                    |
| EASI categories, n (%)  |                                       |                         |                              |
| Clear (0)   | 4 (44.4)                              | 4 (57.1)                | 0                            |
| Mild (0.1–5.9)  | 2 (22.2)                              | 1 (14.3)                | 1 (50.0)                     |
| Moderate (6.0–22.9)   | 2 (22.2)                              | 1 (14.3)                | 1 (50.0)                     |
| Severe (23.0–72.0)  | 1 (11.1)                              | 1 (14.3)                | 0                            |
| SCORAD, mean (SD)   | 24.4 (24.9)                           | 19.3 (25.7)             | 42.1 (12.8)                  |
| SCORAD categories, n (%)  |                                       |                         |                              |
| Mild (<25.0)  | 5 (55.6)                              | 5 (71.4)                | 0                            |
| Moderate (25.0–50.0)  | 2 (22.2)                              | 1 (14.3)                | 1 (50.0)                     |
| Severe (>50.0)  | 2 (22.2)                              | 1 (14.3)                | 1 (50.0)                     |
| vIGA-AD, mean (SD)  | 1.2 (1.3)                             | 0.9 (1.2)               | 2.5 (0.7)                    |
| Clear (0)   | 4 (44.4)                              | 4 (57.1)                | 0                            |
| Almost clear (1)  | 1 (11.1)                              | 1 (14.3)                | 0                            |
| Mild (2)  | 2 (22.2)                              | 1 (14.3)                | 1 (50.0)                     |
| Moderate (3)  | 2 (22.2)                              | 1 (14.3)                | 1 (50.0)                     |
| Severe (4)  | 0                                     | 0                       | 0                            |
| BSA, % affected, mean (SD)  | 16.9 (26.3)                           | 18.9 (29.9)             | 10.0 (5.7)                   |
| Average hours of sleep per night in the past week, mean (SD)                | 6.0 (1.5)                             | 6.4 (1.4)               | 4.5 (0.7)                    |
| Average minutes needed to fall asleep per night in the past week, mean (SD) | 40.0 (38.7)                           | 25.7 (25.1)             | 90.0 (42.4)                  |
| Sleep problems interfered with daily function over the past week, n (%)     |                                       |                         |                              |
| I do not have sleep problems  | 1 (11.1)                              | 1 (14.3)                | 0                            |
| Not at all  | 3 (33.3)                              | 3 (42.9)                | 0                            |
| A little  | 2 (22.2)                              | 2 (28.6)                | 0                            |
| Somewhat  | 0                                     | 0                       | 0                            |
| Much  | 3 (33.3)                              | 1 (14.3)                | 2 (100.0)                    |
| Very much   | 0                                     | 0                       | 0                            |
| <b>Patient-reported outcomes</b>  |                                       |                         |                              |
| 5D-Pruritus score, mean (SD)  | 14.0 (5.5)<br>n=7                     | 13.2 (6.5)<br>n=5       | 16.0 (1.4)                   |
| POEM, mean (SD)   | 12.0 (11.1)                           | 9.6 (11.5)              | 20.5 (2.1)                   |
| Total ADerm-IS, mean (SD)   | 37.9 (37.6)                           | 30.9 (39.9)             | 62.5 (13.4)                  |
| ADerm-IS Sleep domain, mean (SD)  | 10.1 (11.6)                           | 7.4 (11.3)              | 19.5 (9.2)                   |

|   |             |             |            |
|---|-------------|-------------|------------|
| ADerm-SS TSS-7, mean (SD)                           | 24.2 (26.8) | 18.4 (27.9) | 44.5 (3.5) |
| ADerm-SS TSS-11, mean (SD)                          | 35.9 (40.8) | 27.6 (43.1) | 65.0 (2.8) |
| ADerm-SS Skin pain, mean (SD)                       | 3.3 (4.2)   | 2.6 (4.4)   | 6.0 (1.4)  |
| Number of flares in last 6 months, n (%)            |             |             |            |
| 0   | 2 (22.2)    | 2 (28.6)    | 0          |
| 1–2   | 2 (22.2)    | 1 (14.3)    | 1 (50.0)   |
| 3–4   | 2 (22.2)    | 2 (28.6)    | 0          |
| 5–6   | 0           | 0           | 0          |
| >6  | 3 (33.3)    | 2 (28.6)    | 1 (50.0)   |
| Number of flares in the last 6 months, mean (range) | 8.6 (0–48)  | 9.4 (0–48)  | 5.5 (1–10) |
| Average duration of flares in last 6 months, n (%)  |             |             |            |
| ≤2 days   | 5 (55.6)    | 5 (71.4)    | 0          |
| 3–7 days  | 3 (33.3)    | 1 (14.3)    | 2 (100.0)  |
| 8–14 days   | 1 (11.1)    | 1 (14.3)    | 0          |
| ≥15 days  | 0           | 0           | 0          |
| Inadequately controlled AD, n (%)                   | 1 (11.1)    | 1 (14.3)    | 0          |
| SF-12 PCS, mean (SD)                                | NA          | 52.7 (5.5)  | NA         |
| SF-10 PHS, mean (SD)                                | NA          | NA          | 34.6 (2.1) |

ADerm-IS, Atopic Dermatitis Impact Scale; ADerm-SS, Atopic Dermatitis Symptom Scale; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NA, not applicable; POEM, Patient Oriented Eczema Measurement; SCORAD, SCORing Atopic Dermatitis; SF-12 PCS, Short Form-12 Health Survey physical component summary (adults); SF-10 PHS, Short Form-10 Health Survey physical component summary (adolescents); vIGA-AD, Validated Investigator Global Assessment for Atopic Dermatitis.



**Supplementary Table 30.3. Psychosocial-Economic Burden of AD in United Arab Emirates**

|   | <b>Total<br/>population<br/>(n=9)</b> | <b>Adults<br/>(n=7)</b> | <b>Adolescents<br/>(n=2)</b> |
|---|---------------------------------------|-------------------------|------------------------------|
| HADS-A, mean (SD)   | 5.3 (4.6)                             | 4.3 (4.1)               | 9.0 (5.7)                    |
| HADS-A $\geq 8$ , n (%)   | 3 (33.3)                              | 2 (28.6)                | 1 (50.0)                     |
| HADS-D, mean (SD)   | 3.9 (4.1)                             | 2.3 (2.8)               | 9.5 (2.1)                    |
| HADS-D $\geq 8$ , n (%)   | 2 (22.2)                              | 0                       | 2 (100.0)                    |
| SF-12 MCS, mean (SD)  | NA                                    | 46.0 (19.0)             | NA                           |
| SF-10 PSS, mean (SD)  | NA                                    | NA                      | 46.2 (7.6)                   |
| ADerm-IS Daily Activities, mean (SD)  | 14.4 (15.5)                           | 10.7 (15.7)             | 27.5 (3.5)                   |
| ADerm-IS Emotional State, mean (SD)   | 13.3 (13.5)                           | 12.7 (15.6)             | 15.5 (0.7)                   |
| WPAI-AD, Employed, n (%)  | 5 (55.6)                              | 4 (57.1)                | 1 (50.0)                     |
| Absenteeism, %, mean (SD)   | 27.3 (41.7)<br>n=5                    | 9.2 (10.7)<br>n=4       | 100.0 (NA)<br>n=1            |
| Presenteeism, %, mean (SD)  | 27.5 (42.7)<br>n=4                    | 27.5 (42.7)<br>n=4      | –                            |
| Overall work productivity impairment, %, mean (SD)  | 31.9 (43.3)<br>n=4                    | 31.9 (43.3)<br>n=4      | –                            |
| Activity impairment, %, mean (SD)   | 33.3 (36.4)                           | 25.7 (38.2)             | 60.0 (0.0)                   |
| Hours missed from work, mean (SD)   | 3.2 (3.8)<br>n=5                      | 1.8 (2.4)<br>n=4        | 9.0 (NA)<br>n=1              |
| HCRU  |                                       |                         |                              |
| Number of healthcare or acute care visits in previous 6 months, mean (SD)                                 | 6.0 (8.1)                             | 3.4 (4.4)               | 15.0 (14.1)                  |
| Out of pocket expenses  |                                       |                         |                              |
| Total monthly healthcare-related expenses and costs of everyday necessities related to AD, USD, mean (SD) | 226.1 (309.5)<br>n=8                  | 211.5 (358.4)<br>n=6    | 270.0 (152.7)                |

AD, atopic dermatitis; ADerm-IS, Atopic Dermatitis Impact Scale; HADS, Hospital Anxiety and Depression Scale; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; HCRU, health-care research utilization; NA, not applicable; SF-12 MCS, Short Form-12 Health Survey Mental Component Summary (adults); SF-10 PSS, Short Form-10 Health Survey Psychosocial Component Summary (adolescents); USD, United States dollars (2021); WPAI-AD, Work Productivity and Activity Impairment Atopic Dermatitis.

**Supplementary Table 31. Disease Burden in Real-World Studies Among Patients with Moderate to Severe AD**


|  | <b>WP-NRS</b>    | <b>EASI</b>     | <b>SCORAD</b>   | <b>DLQI</b>     |
|--|------------------|-----------------|-----------------|-----------------|
| <b>Mean (SD)</b>   |                  |                 |                 |                 |
| MEASURE AD   | 5.3 (3.1)        | 15.0 (12.9)     | 43.7 (21.7)     | 10.8 (7.8)      |
| EUROSTAD <sup>1</sup>                                    | 5.5 (2.5)        | 16.2 (10.9)     | NR              | 11.8 (6.9)      |
| AD-AWARE <sup>2</sup>                                    | 5.8 (2.5)        | NR              | NR              | 9.2 (NR)        |
| de Bruin-Weller et al<br>study– Moderate AD <sup>3</sup> | 5.3 <sup>a</sup> | 9.5 (8.0)       | 49.2 (16.0)     | 10.2 (6.3)      |
| de Bruin-Weller et al<br>study – Severe AD <sup>3</sup>  | 7.1 <sup>a</sup> | 22.7 (13.9)     | 68.4 (14.9)     | 16.2 (6.9)      |
| <b>Median (range)</b>                                    |                  |                 |                 |                 |
| MEASURE AD   | 6.0 (0.0–10.0)   | 12.1 (0.0–71.7) | 45.6 (0.0–99.4) | 10.0 (0.0–30.0) |
| EUROSTAD <sup>1</sup>                                    | 6.0 (0.0–1.0)    | 14.6 (0.0–55.3) | NR              | 11.0 (0.0–29.0) |
| ADDRESS-J <sup>4</sup>                                   | 7.0 (0.0–10.0)   | 21.7 (3.4–72.0) | NR              | 6.0 (0.0–30.0)  |

AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; NR, not reported; SCORAD, Scoring Atopic Dermatitis; WP-NRS, Worst Pruritus Numeric Rating Scale.


<sup>a</sup>Average overall itch in last 24 hours.

MEASURE-AD and EUROSTAD included patients treated with dupilumab.


**Supplementary Figure 1. Number of Hours Slept per Night in Past 7 Days by (A) Skin Severity (EASI), (B) Itch Severity (WP-NRS), and (C) Skin and Itch Severity (EASI + WP-NRS) in Adults from MEASURE-AD.** EASI, Eczema Area and Severity Index; WP-NRS, Worst Pruritus Numeric Rating Scale.




**Supplementary Figure 2. Mean DLQI Scores and Proportion of Patients with DLQI  $\geq 6$  by (A) Skin Severity (EASI), (B) Itch Severity (WP-NRS), and (C) Skin and Itch Severity (EASI + WP-NRS) in Adults from MEASURE-AD. DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; WP-NRS, Worst Pruritus Numeric Rating Scale.**




**Supplementary Figure 3. Mean Number of AD Flares in the Past 6 Months by (A) Skin Severity (EASI), (B) Itch Severity (WP-NRS), and (C) Skin and Itch Severity (EASI + WP-NRS) in Adults from MEASURE-AD.** AD, atopic dermatitis; EASI, Eczema Area and Severity Index; WP-NRS, Worst Pruritus Numeric Rating Scale.




**Supplementary Figure 4. Number of Healthcare or Acute Care Visits Due to AD in Past 6 Months by (A) Skin Severity (EASI), (B) Itch Severity (WP-NRS), and (C) Skin and Itch Severity (EASI + WP-NRS) in Adults from MEASURE-AD.** AD, atopic dermatitis; EASI, Eczema Area and Severity Index; WP-NRS, Worst Pruritus Numeric Rating Scale.



**Supplementary Figure 5. Total OOPPE Due to AD by (A) Skin Severity (EASI), (B) Itch Severity (WP-NRS), and (C) Skin and Itch Severity (EASI + WP-NRS) in Adults from MEASURE-AD.** AD, atopic dermatitis; EASI, Eczema Area and Severity Index; OOPPE, out-of-pocket expenses; WP-NRS, Worst Pruritus Numeric Rating Scale.




**Supplementary Figure 6. Presenteeism, Absenteeism, and Work Productivity Impairment by (A) Skin Severity (EASI), (B) Itch Severity (WP-NRS), and (C) Skin and Itch Severity (EASI + WP-NRS) in Adults from MEASURE-AD.** AD, atopic dermatitis; EASI, Eczema Area and Severity Index; WPAI, Work Productivity and Activity Impairment; WP-NRS, Worst Pruritus Numeric Rating Scale.







**Supplementary Figure 7. Mean Total Exposure to Topical, Systemic, and Dupilumab Therapy in Adults With AD Across Geographic Clusters.** Analyzed clusters were (1) Canada (n=200), (2) Germany (n=210), (3) Italy (n=118), (4) Spain (n=91), (5) Australia and New Zealand (n=103), (6) China and Taiwan (n=60), (7) Brazil, Argentina, and Mexico (n=157), (8) Netherlands, Belgium, and Ireland (n=59), (9) Switzerland and Austria (n=94), (10) Greece, Israel, Turkey, and Portugal (n=197), (11) Hungary, Romania, the Czech Republic, Poland, and Slovakia (n=1-3), and (12) Saudi Arabia, Kuwait, and United Arab Emirates (n=42). Note: Exposure for each AD treatment entry was calculated as stop date minus start date plus 1; overlapping entries were merged to 1 entry by retaining the earliest start date and the latest stop date. For therapies assessed in the current AD therapy section, the visit date was used as stop date. For the total exposure per category, exposure for all entries within the category was summed up. For therapies assessed in the current AD therapy section, the visit date was used as stop date. AD, atopic dermatitis.




**Supplementary Figure 8. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in Argentina.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. Only adult patients were included from Argentina.




**Supplementary Figure 9. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Australia.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 10. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Austria.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 11. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in Belgium.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. Only adult patients were included from Belgium.




**Supplementary Figure 12. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Brazil.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.



**Supplementary Figure 13. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Canada.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 14. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in China.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.







**Supplementary Figure 15. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in the Czech Republic.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 16. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Germany.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 17. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Greece.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 18. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Hungary.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 19. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Ireland.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 20. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Israel.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.



**Supplementary Figure 21. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Italy.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 22. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in Kuwait.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. Only adult patients were included from Kuwait.







**Supplementary Figure 23. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Mexico.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 24. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in the Netherlands.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. Only adult patients were included from the Netherlands.




**Supplementary Figure 25. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in New Zealand.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30.




**Supplementary Figure 26. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in Poland.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30.



**Supplementary Figure 27. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Portugal.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 28. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Romania.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 29. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Saudi Arabia.**

CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 30. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in Slovakia.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. Only adult patients were included from Slovakia.






**Supplementary Figure 31. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Spain.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 32. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Switzerland.**


CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.




**Supplementary Figure 33. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Taiwan.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/CDLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.



**Supplementary Figure 34. Primary Endpoints Mean WP-NRS and Mean DLQI/CDLQI and Proportion of Patients in WP-NRS and DLQI/CDLQI Categories in Turkey.** CDLQI, children's Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For CDLQI/DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30. CDLQI categories: No to Small Impact, 0–6; Moderate Impact, 7–12; Very Large to Extremely Large Impact, 13–30.



**Supplementary Figure 35. Primary Endpoints Mean WP-NRS and Mean DLQI and Proportion of Patients in WP-NRS and DLQI Categories in United Arab Emirates.** DLQI, Dermatology Life Quality Index; WP-NRS, Worst Pruritus Numeric Rating Scale. For DLQI, no statistical tests regarding adult (Yes/No) were applied because the scores for adults and adolescents cannot be combined. DLQI categories: No to Small Impact, 0–5; Moderate Impact, 6–10; Very Large to Extremely Large Impacts, 11–30.



## REFERENCES

1. Bruin-Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. *J Dermatolog Treat* 2021;**32**:164-173.
2. Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. *JAMA Dermatol* 2018;**154**:903-912.
3. de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. *J Eur Acad Dermatol Venereol* 2020;**34**:1026-1036.
4. Katoh N, Saeki H, Kataoka Y, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden. *J Dermatol* 2019;**46**:290-300.